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As the National Aeronautics and Space Administration (NASA), plans to return to the moon 
and send humans to Mars, crew health and safety concerns need to be examined with a focus 
on longer duration exploratory class missions. One of the transient changes that has been 
observed during the ISS missions is dysregulation of immune system. Latent viral reactivation 
and diminished cellular mediated immunity along with a TH2-cytokine shift being the 
consistently observed effects of spaceflight on immune system. However, most of the changes 
observed in spaceflight are a composite effect of stress, microgravity, radiation, circadian 
disruption, altered nutrition, and sleep disturbances, all of which have an immune-altering 
effect. Discerning precise effects of the various components of spaceflight become crucial to 
devise appropriate countermeasures. Ground-based simulated microgravity systems can be 
used to understand the specific effects of microgravity on human immune system. Rotary cell 
culture system (RCCS) is a NASA validated ground-based model to simulate microgravity. 
Using this quiescent low-shear stress environment, human immune cells can be exposed to 
simulated microgravity (SMG) for brief periods by randomizing the gravity vector and 
facilitating continuous free fall.  
 
In short-term spaceflight, latent viral reactivation along with lowered viral-specific T cell 
function has been recorded. Healthy functioning of viral-specific T cells is a prerequisite to 
controlling viral infections. So, it becomes imperative to examine if microgravity plays a role 
in this reduction of viral-specific T-cell function.  
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There is also a paucity of data on effect of spaceflight and simulated microgravity on γδ-T 
cells. These crucial effector lymphocytes are considered a connecting link between innate and 
adaptive immune system. Their function in spaceflight, especially Vγ9Vδ2 T cell subset, 
becomes important to control hematological malignancies in early stages.  
 
Therefore, this dissertation examined the effect of simulated microgravity on expansion 
potential and function of viral specific T-cells and γδ-T cells. 
 
Exposure to SMG impaired in vitro expansion of CMV-specific T-cells (RM ANOVA, 
F(1.571, 6.283)= 8.367, p=0.0198). 10-million PBMCs at day1 of the expansion in SMG-
exposed condition yielded 17.63±3.75 million (MEAN±SEM, N=5) CMV-specific T-cells at 
the end of the expansion. In comparison, STATIC-1G control cells expanded to 33.8±7.57 
million, while 1G-rotational control exposed cells expanded to 28.32±7.21 million cells. 
However, exposure to SMG did not affect in vitro function of CMV-specific T-cells (RM 
ANOVA, F(1.357,12.21)=0.7434, p=0.4457). Hundred thousand cytotoxic (CD8+) CMV-
specific T-cells exposed to SMG at the end of expansion killed 804.6±166.3 (MEAN±SEM, 
N=10) autologous PHA blasts pulsed with CMV peptides. In comparison, 1G-control and 1G-
rotational control killed 909.2±160.6 and 669.7±125 PHA blasts respectively. 
 
 Exposure to SMG also impaired in vitro expansion of γδ-T cells (Wilcoxon signed ranks test, 
p=0.039). 10 million PBMCs at day 1 of the expansion in SMG-exposed condition yielded 
102.3±23.07 million (MEAN±SEM, N=9) γδ-T cells at the end of the expansion. In 
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comparison, 1G-control PBMCs yielded 113.7±23.91 million γδ-T cells. Γδ-T cells that were 
exposed to SMG and later expanded in 1G showed downregulation of inhibitory receptor 
CD158b (paired t-test, p=0.03) and killed more U266 target cells (paired t-test, p=0.04) 
compared to γδ-T cells that were expanded in 1G. Exposure to SMG upregulated activating 
receptor NKG2D on γδ-T cells that were expanded in 1G (Wilcoxon matched-pairs signed rank 
test, p=0.0078), without concomitant increase in function. Exposure to SMG did not impair 
γδ-T cells’ ability to kill tumor target cells (K562: paired t-test, t(8) =0.5032, p=0.628; U266: 
paired t-test, t(8) =0.1479, p=0.886). 
 
Another limitation of spaceflight data is lack of in vivo functional data. Although we have 
observed decreased in vitro function of various immune cells in several flight and ground-
based simulation studies, how this translates to a more physiologically relevant in vivo model 
remains to be explored.  
 
Ergo, this dissertation also improved upon the current in vitro data by examining how exposure 
to SMG using a RCCS, affects in vivo anti-leukemia activity of human effector lymphocytes. 
A humanized NSG-tg(hu-IL15) mice model, which is used in a pre-clinical setting for 
hematopoietic stem cell transplantation studies, was used to examine the in vivo effect of 
exposure to SMG on PBMCs. Furthermore, we examined the efficacy of Zoledronic acid+IL2 
(ZOL+IL2) therapy as a possible spaceflight countermeasure to revive the in vivo anti-
leukemia activity of SMG exposed PBMCs. ZOL+IL2 is a clinical therapeutic strategy to 
accelerate favorable immune reconstitution. This therapy also improves NK cell and γδ-T cell 
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activity in vivo, after a hematopoietic stem cell transplantation. Therefore, we expected 
administration of ZOL+IL2 to abrogate the effect of exposure to SMG on human PBMCs, by 
stimulating NK cells and γδ-T cells.  
 
Exposure to SMG impaired anti-leukemia activity of human immune cells in vivo. Tumor 
growth control was compared between mice that were injected with PBMCs exposed to SMG 
(TUMOR+SMG PBMCs) or 1G-control (TUMOR+1G PBMCs) to evaluate the effect of SMG 
on anti-leukemia activity of human immune cells in vivo. Mice injected with tumor cells only 
was used as a reference for unrestrained tumor growth. Bioluminescent intensity (BLI) score 
was used as a measure of tumor burden. A mixed effects model was used to analyze BLI scores 
with ‘condition’ (TUMOR control, TUMOR+SMG PBMCs, TUMOR+1G PBMCs) and ‘time’ 
as main effects and an interaction term ‘condition*time’ in the model. This revealed that tumor 
grew differentially over time in different conditions. A pairwise comparison revealed that 1G-
exposed PBMCs controlled tumor growth better than SMG-exposed PBMCs (p<0.001). Peak 
BLI reached during the experiment further understated the inability of SMG-exposed PBMCs 
to control tumor growth (Friedman test, p=0.0018, N=12, TUMOR+SMG 
PBMCs>TUMOR+1G PBMCs). Exposure to SMG did not alter engraftment, survival or graft-
versus-host-disease (GVHD) dynamics.  
 
ZOL+IL2 therapy improved anti-leukemia activity of human immune cells in vivo. Mice that 
received SMG PBMCs and given ZOL+IL2 therapy controlled their tumor better compared to 
mice that received SMG PBMCs without ZOL+IL2 therapy (Mixed effects model, p=0.0004). 
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There were no differences in tumor control between mice that received SMG PBMCs along 
with ZOL+IL2 therapy and mice that received 1G-exposed PBMCs. This showed that 
ZOL+IL2 therapy abrogated the loss of in vivo function after exposure to SMG. ZOL+IL2 
therapy did not alter survival and GVHD dynamics. There were non-significant increases in 
NK cell and γδ-T cell engraftment throughout the experiment in blood of the animals, showing 
that ZOL+IL2 therapy improved anti-leukemia effector immune cell engraftment, which 
helped in tumor control. 
 
In summary, these experiments advance our understanding of the effect of simulated 
microgravity on immune cells. Exposure to SMG detrimentally affects immune cell function 
and expansion potential both in vitro and in vivo. These negative effects could impair crew 
health and performance during an exploratory class missions. These experiments also highlight 
the importance of microgravity as a contributor to the immune dysregulation observed in 
spaceflight. Future studies should explore the sustenance of this detrimental effect in 
confluence with other perturbations of spaceflight. Future investigations should also include 
relevant immunotherapeutic countermeasures to improve crew health and performance during 
long-duration exploration class missions. 
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Space— ‘the final frontier’—has been a challenging arena for humans to conquer. Exploring 
beyond the protective blanket of earth’s atmosphere would involve facing hazardous 
challenges especially in long duration exploratory missions like returning to the moon, 
establishing lunar bases, asteroid exploration and reaching Mars. This would entail humans 
being exposed to multitude of hazardous extraneous factors like radiation, microgravity, partial 
gravities on lunar (0.16G) and Martian (0.37G) surfaces, circadian misalignment, altered 
microbial virulence, high G forces of launching and landing, and celestial dust (B. Crucian & 
Sams, 2009; Guéguinou et al., 2009; Rooney et al., 2019) which are collectively termed ‘space 
exposome’. In addition to these extraneous factors, intrinsic effect of spaceflight on human 
physiology, and its several organ systems, that have evolved for millions of years in 1G 
(9.8m/s2) gravitational force of the earth is a challenge that needs to be overcome before 
humans become multi-planetary.  
 
Immune dysregulation has been reported in both short and long duration spaceflight. Short 
duration space shuttle missions  usually last 14-17 days (B. E. Crucian, Stowe, Pierson, & 
Sams, 2008b; B. Crucian et al., 2013; B. Crucian, Stowe, Quiriarte, Pierson, & Sams, 2011; S. 
K. Mehta et al., 2014), and long duration missions to the International Space Station (ISS) 
usually last 5-6 months (B. Crucian et al., 2015; Satish K. Mehta et al., 2017). Major alterations 
to immune system observed include diminished cell mediated immunity, latent viral 
reactivation and TH-2 cytokine shift. However, limitations of spaceflight data are that the 
observed changes are a composite effect of ‘space exposome’ on human body. It is tough to 
discern the precise effect of each aspect of spaceflight on the human immune system, which 
would facilitate designing countermeasures. Processing time delays of ‘in-flight samples’ and 
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landing stress confounding results in ‘post-flight samples’ are other major limitations (B. 
Crucian et al., 2014b). 
 
Another limitation of spaceflight immunology data is that most of the data was gathered from 
in vitro assays. Although in vitro assays help us to estimate the functional activity, how this 
translates to more physiologically relevant in vivo activities need to be explored. Tumor 
surveillance, homing, extravasation, tumor infiltration, and tumor lysis are some in vivo 
activities that can be evaluated using in vivo models. Humanized mice models can be used to 
estimate in vivo anti-leukemia activity of human immune cells.  
 
Tumor transformation due to radiation exposure and latent viral reactivation due to 
physiological and psychological stress are two of the major concerns in relation to immune 
system during long-duration exploration class missions. Natural killer cells are a crucial set of 
innate immune cells that control early tumor growth (Chiossone, Dumas, Vienne, & Vivier, 
2018). Previous studies have shown reduction in NK cell function during long duration 
spaceflight (Bigley et al., 2019). This reduction in NK cell activity appears to be more 
pronounced in first-time fliers to the ISS hinting at some adaptive response in veteran 
astronauts. We have previously shown that exposure to 12-hour simulated microgravity (SMG) 
also impaired NK cell killing against all the target cells (K562, U266, 721.221, 221.AEH) 
tested (fig. 1a-d) (Mylabathula et al., 2020). NK cells expressed lower perforin and granzymeB 
after exposure to SMG. This exposure also lowered levels of degranulation (CD107a+) and 
effector cytokine (TNFα and IFNγ) production when exposed to target cells (fig. 1e). Exposure 
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to SMG did not suppress K562 susceptibility to NK cell killing showing that cancer cells might 
be more resistant to effects of SMG compared to immune cells (fig. 1f). This might tip the 
balance in the favor of tumor transformation during a long duration mission with continuous 
radiation exposure and latent viral reactivation. These immune hazards further underscore the 
importance of understanding the effects of microgravity on various cell populations that 
control ‘tumor transformation’ and ‘viral reactivation’. Two of them—γδ-T cells and viral-
specific T-cells—are being investigated in this dissertation.  
5  
 
Figure 1. Effect of simulated microgravity on NK cell function. 1a-d. Exposure to SMG 
suppressed NK cell function (specific lysis) against four target cells (k562, U266, 721.221 and 
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221.AEH) 1e. Exposure to SMG suppressed NK cell degranulation and effector cytokine 
production when exposed to target cells later. 1f. Exposure to SMG did not affect K562 
susceptibility to NK cell killing. 
 
 
Immune dysregulation due to extreme environments is not an isolated occurrence in 
spaceflight. Similar immune perturbations occur in several spaceflight analogs, which hint at 
a contributory role that various factors play in contributing to the aggregate dysregulation 
observed in spaceflight. These analogs include isolation and confinement stress seen in winter-
over Antarctica expeditions, Arctic Devon Island expeditions, NASA extreme environment 
mission operations (NEEMO); cephalad fluid shift seen in head-down bed rest (HDBR) studies 
and murine hind-limb unloading studies; short-term weightlessness like parabolic flight, 
sounding rockets, drop towers and simulated microgravity instruments like rotating wall 
vessels (RWV), 3D-clinostats, and random positioning machines. While the financial and 
logistical constrains have limited availability of human data from spaceflight, these analogs 
have been used to make scientific estimates of the effect of spaceflight on the immune system. 
Additionally, they can also be used to test efficacy of possible countermeasures to mitigate the 
risks of spaceflight. For example, vitamin D supplementation during Antarctica winter-over 
expeditions has shown to improve calcium homeostasis, and also reduce stress-induced 
Epstein-Barr virus reactivation (Zwart et al., 2011). Furthermore, these spaceflight analogs can 
also be used to identify the precise effect of each component of spaceflight. For instance, 
exclusive effect of microgravity on immune cells can be detected using SMG machines. 
Rotating wall vessels, when rotated on a horizontal axis, in a low-shear quiescent environment, 
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simulate the weightlessness of space by allowing the cells to experience continuous free fall 
and by randomizing the gravitational vector (Goodwin, Schroeder, Wolf, & Moyer, 1993; 
Klaus, 2001; Cheryl A. Nickerson et al., 2003; Schwarz, Goodwin, & Wolf, 1992). Using this 
NASA-validated RWV called rotary cell culture system (RCCSTM), human immune cells can 
be exposed to SMG.  
Therefore, here we propose an in vivo model to evaluate the effect of exposure to short term 
(12h) SMG on ‘effector lymphocyte killing’. This will be accomplished by using NSG-tg(hu-
IL15) mice that have been genetically manipulated to have an immature immune system. This 
facilitates easier colonization of the mouse body by human immune cells. The indigenously 
produced human IL15 in these mice will help NK cells thrive. Hence, by pre-exposing human 
PBMCs to SMG, we propose to estimate the effects of microgravity exposure on in vivo 
dynamics of NK cells as a measure of immune surveillance as well as cytotoxicity in vivo. We 
will also evaluate the effect of zoledronic acid+IL-2 therapy as a possible countermeasure to 
SMG induced loss-of-function. Additionally, we will use our 12h SMG exposure model to 
evaluate expansion potential, effector cytokine production and cytotoxicity of VSTs that are 
specific to CMV antigens and Vγ9/Vδ2 T cells. Since we see latent viral reactivation during 
spaceflight (B. Crucian et al., 2015; S. K. Mehta et al., 2014; Rooney et al., 2019), optimal 
functioning of viral-specific T-cells (VST) is a requisite. Since there is evidence of suppressed 
VST function (B. Crucian et al., 2013; S. K. Mehta et al., 2013) during short term spaceflight, 
there is a need to see if this translates to short term SMG (12h) exposure. This would help us 
decipher if there is a microgravity component to the loss-of-function in spaceflight.  
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Tumorigenic stimulus like ionizing radiation occurs in multiple forms during spaceflight. 
Radiation in space is composed of galactic cosmic radiation (GCR), solar particle events (SPE) 
and trapped radiation. Solar particle events like solar flares and coronal mass ejections inject 
the interplanetary space with high-energy protons, high-energy charged (HZE) nuclei and 
neutrons travelling at relativistic speeds. Trapped radiation zones like ‘Van Allen belts’ consist 
of radiation dense zones. Venturing beyond low earth orbit (LEO) will involve traversing these 
zones of trapped radiation. This also will contribute to fluctuations in the expected dose-rates 
during a 2-year mission. While definitive solutions to the ‘radiation problem in space’ will be 
a material sciences challenge involving sufficient shielding, other measures like nutritional, 
pharmacological and immunological countermeasures can offer complementary solutions from 
the life sciences branch. In this context, effect of microgravity on γδ T-cells becomes a very 
pertinent question to be answered. γδ T-cells are a sparse but important subset of effector T-
lymphocytes that inhabit the gut lining, mucosa and blood compartments. They have multiple 
activating and effector pathways that mimic both T-cells and NK cells. Therefore, they are 
considered a connecting link between innate and adaptive arms of the immune system. They 
work hand-in-hand with NK cells to suppress tumorigenic growth in its initial stages before 
the adaptive immune system can gear up. There is a lack of γδ T-cell data in the spaceflight 
niche. In this dissertation, we will examine if exposure to short-term SMG will reduce γδ T-
cell ability to expand and later kill cancer cells in an in vitro setting. We will also use systemic 








There are various epistemic uncertainties that confound any projections about the response of 
human body on a mission to Mars that is estimated to last two years. Nevertheless, valuable 
data relating to human spaceflight in low earth orbit (LEO) has been gathered using the national 
laboratory on the International Space Station (ISS) over the last few decades. This literature 
review will discuss the effect of spaceflight on human body, and then more intricately discuss 
the current understanding of the effect of spaceflight on the human immune system, and results 
from various analog modules. 
 
Maintenance of crew health and performance are of paramount importance for the success of 
the mission. Current 6-12-month missions to the International Space Station (ISS) have 
suggested that human body can tolerate the physiological challenge of short-term spaceflight 
with a few permanent and many temporary decrements. Hence, the idea of a ‘space normal’—
a new acceptable state of homeostasis—for spaceflight has been posited. 
 
1. Spaceflight physiology  
Ever since the advent of spaceflight, investigations have been conducted on how spaceflight 
affects human body. In the words of the first human in space, Yuri Gagarin, “The feeling of 
weightlessness was somewhat unfamiliar compared with Earth conditions. Here, you feel as if 
you were hanging in a horizontal position in straps. You feel as if you are 
suspended”(Siddiqi  1966-, 2000). This feeling of suspension is a novel stimulus to a human 
body. This was the dawn of the era of human spaceflight. 
11  
While a 2-lead ECG, pulse, and pneumogram were the only biomedical data collected from 
Gagarin’s flight, current ISS missions contain equipment to measure everything from a 12-
lead ECG to biochemical analysis of blood and urine. Many studies conducted on ISS have 
increased our understanding of alterations in normal biological processes. These data can be 
used to make relevant predictions for a 2-year mission to Mars. 
 
Crucial concerns that can affect mission success for a Mars flyby and landing currently include 
space radiation and intracranial hypertension (ICH). Mission relevant dose exposure to 
simulated galactic cosmic radiation (GCRsim) has shown neurocognitive defects in murine 
models (Acharya et al., 2019; Britten et al., 2014; Parihar et al., 2016). Exposure to GCR will 
also have various long term effects including cancer (Cucinotta, 2014; Cucinotta, To, & Cacao, 
2017), CNS degeneration (Blue et al., 2019; Cekanaviciute, Rosi, & Costes, 2018; Chancellor, 
Scott, & Sutton, 2014), radiation induced cardiovascular disease (RICVD) (Sylvester, Abe, 
Patel, & Grande-Allen, 2018). Intracranial hypertension leads to various structural changes in 
the brain. Recent studies have shown increased lateral and third ventricular volume (Van 
Ombergen et al., 2019), vertical  displacement of the brain, changes in volume of the central 
sulcus, narrowing of cerebrospinal fluid spaces at the vertex (Roberts et al., 2017) and decrease 
of gray matter in orbitofrontal and temporal cortexes (Van Ombergen et al., 2018). Both these 
studies showed significant effect of time on the magnitude of these structural changes. 
Therefore, these structural changes can be expected to progress further during a 2-year mission 
to Mars causing major neurocognitive deficits. Van Ombergen’s study included a long-term 
follow up, which showed sustained volume changes 7-months after a long-term ISS mission 
hinting at consequences that might extend beyond the mission duration. Cephalad fluid shift 
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also causes spaceflight associated neuro-ocular syndrome (SANS or VIIP) (Zhang & Hargens, 
2018), resulting in permanent visual acuity deficits. Other major concerns include renal calculi 
formation due to calcium excretion (Liakopoulos, Leivaditis, Eleftheriadis, & Dombros, 2012; 
Smith et al., 2015), altered immune response (B. Crucian et al., 2015; Rooney et al., 2019), 
altered host-microorganism interactions and microbial virulence (Foster, Wheeler, & 
Pamphile, 2014; Senatore, Mastroleo, Leys, & Mauriello, 2018). Minor concerns include 
perturbations that might not affect mission success but might affect optimal crew performance. 
They include sensorimotor alterations (Mulavara et al., 2018; Wood, Loehr, & Guilliams, 
2011), reduced muscle mass and strength (Maffiuletti, Green, Vaz, & Dirks, 2019; Narici & 
de Boer, 2011), reduced aerobic capacity (Ade, Broxterman, & Barstow, 2015), and decreased 
bone mineral density resulting in fractures (Swaffield, Neviaser, & Lehnhardt, 2018). Other 
concerns include orthostatic intolerance (Shen & Frishman, 2019), sleep loss and circadian 
misalignment (Brainard, Barger, Soler, & Hanifin, 2016; Wu et al., 2018). 
 
2. Spaceflight Immunology:  
While immune suppression might lead to increased infectious diseases, altered wound healing, 
latent viral reactivation, increased tumor transformation potential and disease susceptibility, 
an overactive immune system might lead to allergies, hypersensitivity, autoimmune diseases. 
Therefore, a perfect balance of the immune system is essential for a healthy living. 
Dysregulation of the immune system during spaceflight is especially precarious given the 
limited exploration class medical capabilities that can be expected during a multiple year 
mission to Mars (Antonsen, E, Bayuse, T, 2017; Blue et al., 2019). A simple medical event on 
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earth like a latent CMV reactivation might be threatening mission success during spaceflight. 
A crew member with already weakened/overburdened immune system might progress from 
simple skin lesions to ocular CMV manifestations like endothelitis, which is rarely seen in 
immunocompetent hosts (Joye & Gonzales, 2018). When this is coupled with modified 
pharmacokinetics and pharmacodynamics in microgravity resulting in altered efficacy of drugs 
(Kast, Yu, Seubert, Wotring, & Derendorf, 2017), medical treatments like topical or oral 
ganciclovir might not be sufficient. Additionally, we have to consider that while direct contact 
is necessary for transmission of CMV on earth, in microgravity, there might be increased routes 
of transmission (for example via atmospheric routes through ocular or nasal openings). Several 
factors involved in spaceflight are known modulators of the immune system (figure 2). The 
overall magnitude of each of these factors will depend on the length and the directive of the 
mission.  
 
15 out of 29 Apollo astronauts developed bacterial or viral infections whether during or after 
the 5 to 12-day missions (Johnston et al., 1975). With minimal amount of biomedical data 
collected during these missions, post-flight leukocytosis (mostly driven by neutrophilia) was 
observed but lymphocyte reactivity  results remained inconclusive (Fischer, Daniels, et al., 
1972). Immunoglobulin levels showed an elevation of IgA and α2-globulin while IgM, IgG and 
IgD remained unchanged (Fischer, Gill, et al., 1972). These signs of an ‘acute phase reaction’ 
was a sign of pro-inflammatory status, most probably a result of psychological and 
physiological stress response. While the Apollo astronauts showed no elevation in plasma 
cortisol levels, a 24% increase in urinary cortisol levels was observed in post-flight samples 
(Johnston et al., 1975). Three manned Skylab missions of 28, 59 and 84 days duration showed 
14  
elevated plasma and urinary cortisol levels in the post-flight samples (“BIOMEDICAL 
RESULTS OF SKYLAB,” 2013). Skylab experiments were also the first to hint at reduced 
cellular immunity. Blastoid transformation of lymphocytes in response to PHA was markedly 
decreased in all the missions irrespective of duration and recovered within 7-days of returning 
to earth (“BIOMEDICAL RESULTS OF SKYLAB,” 2013). No in-flight samples were 
collected during Apollo and Skylab missions. 
 
 
Figure 2. Various factors of spaceflight that could affect the immune system. 
 
Shuttle missions also showed reduced cellular immunity, with in-flight and post-flight T-cells 
showing reduced early activation (CD69+) and late activation (CD69+ CD25+) but only when 
stimulated with staphylococcal enterotoxin A and B (SEA and SEB) (B. Crucian et al., 2013). 
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No such reduction in activation was observed when anti-CD3 and anti-CD28 antibodies were 
used to stimulate the T-cells suggesting that while non-specific stimulation with a mitogen 
(PHA) might be affected, T-cells retained the cellular mechanisms to be specifically stimulated 
with stimulants that are more powerful. This suggests that either the ‘activation threshold’ for 
T-cells might be elevated during spaceflight or the antigen presenting cells are necessary for 
activation when stimulated with superantigens (SEA and SEB). Shuttle missions also showed 
that during flight, WBC major subsets did not alter while CD8 T-cell subsets showed 
fluctuations. Expansion of cytotoxic CD8+ T-cells (CD28+/CD244+) was observed 10 days 
prior to and during the mission. This might be in response to the latent viral reactivation and 
stress. The crewmembers are under considerable stress prior to launch and immediately after 
docking with the ISS. 53% (47/89) of the crew members that flew on the shuttle missions shed 
at least one of the three (CMV, VZV and EBV) latent viruses (Rooney et al., 2019). This is 
mostly understood to be a stress response as significant increases in CORTISOL:DHEA molar 
ratio (area under the curve) were observed in saliva of in-flight samples compared to pre- and 
after flight (Rooney et al., 2019). However, Stowe et al. reported elevation of urinary cortisol 
and norepinephrine in post-flight samples but this was not limited to crewmembers with EBV 
reactivation. Interestingly, the urinary cortisol levels did not differ between astronauts with 
and without EBV reactivation but epinephrine and norepinephrine levels were higher in the 
EBV-reactivating group compared to those with reactivation (Stowe, Pierson, & Barrett, 2001). 
This suggests an activation of sympathetic-adrenal-medullary axis while absence of activation 
of hypothalamo-pituitary-adrenal axis. No in-flight samples were collected for this study and 
the reported elevations in stress hormones were from R+0 (day-of-return) samples. Therefore, 
it is necessary to extricate the effect of landing stress from these results. Another important 
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finding from the shuttle crewmembers is reduced function of viral specific T-cells (CMV and 
EBV), seen as reduced intracellular IFNγ production after stimulation with specific peptides. 
This dissertation project involves expanding CMV-specific T-cells and exposing them to SMG 
and later evaluating their IFNγ production and cytotoxicity. This will delineate whether 
microgravity plays a contributory role in this loss of function. Agha et al. reported a correlation 
between pre-flight fitness status and maintaining fitness during a long-term mission with 
reduced incidence of latent viral reactivation (Agha, Mehta, et al., 2020). Another noteworthy 
observation was a widespread reduction in cytokine production (IFNγ, TNFα, IL10, IL4, IL5 
and IL6) when in-flight PBMCs were stimulated with PMA+ ionomycin.  
 
Effect of short-term spaceflight (Shuttle missions) on innate immune system is not so clear. 
Crucian et al. (B. Crucian et al., 2013) reported that monocytes retained their function and that 
in-flight monocytes when stimulated with LPS, not only secreted comparable levels of all 
cytokines measured but higher levels of IL-8 compared to L-180 (180 days prior to launch). 
Kaur et al. (Kaur, Simons, Castro, Ott, & Pierson, 2005) reported reduced phagocytosis, 
oxidative burst capacity and degranulation in monocytes collected on day of return (R+0). 
Studies about neutrophil function with short duration spaceflight seem ambiguous. While Kaur 
et al. (Kaur, Simons, Castro, Mark Ott, & Pierson, 2004) reported reduced neutrophil function 
(oxidative burst capacity) only in 9-11 day missions but not in 5-day missions; Stowe et al. 
showed a 10-fold decrease in chemotaxis (Stowe et al., 1999). 
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Long term spaceflight (usually 6-month) missions to the ISS showed that adaptive immune 
dysregulation continued to persist (B. Crucian et al., 2015). Differential activation responses 
to various stimulants, seen in short-term spaceflight continued with in-flight samples in long-
duration spaceflight. Both CD4+ and CD8+ T-cells showed reduced early (CD69+) and late 
(CD69+/CD25+) activation with SEA and SEB only in early flight (day 14) time point. Similar 
to short-term spaceflight, this reduced activation was not seen with more potent anti-CD3 and 
anti-CD28 stimulation. Furthermore, stimulation with PMA+ ionomycin showed lower 
percentage of CD4+ T-cells producing IL-2 at R+0 (day of return). Interestingly, viral-specific 
T-cell function seems to have recovered from loss-of-function observed during short-term 
spaceflight. PBMCs continued to produce lower amounts of IFNγ, IL4, IL5, IL10, IL17A, 
TNFα and IL6 when stimulated with PMA+ ionomycin. While B-cell homeostasis and function 
were maintained during spaceflight (Spielmann et al., 2019), NK cell function seems to be 
reduced in-flight (Bigley et al., 2018). Natural killer cells are effector lymphocytes that do not 
undergo thymus mediated antigen education and instead use their signaling amplitude on MHC 
ligands as identity checks to eliminate virus-infected cells and malignantly transformed cells. 
Therefore, when both these immune challenges (latent viral reactivations and increased 
carcinogenic exposure via the ‘space exposome’) are exacerbated during long duration 
spaceflight, healthy functioning of NK cells is a prerogative. NK-cells isolated from PBMCs 
collected during mid-flight time point (flight day 90) lysed 50% fewer k562 cancer cells 
compared to age and sex matched controls. This suppression in NK cell function seems to be 
more pronounced in first-time fliers compared to crew members with prior flight experience, 
suggesting some blunting of this effect after acclimatization to spaceflight. Whether this is 
related to different stress levels remains unclear since there was no evidence suggesting lower 
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stress hormone levels in “veteran” crewmembers. Like with all spaceflight data, low subject 
numbers, time delays in processing and scarcity of subjects (one or two subjects every 6 
months) make collection of sufficient data cumbersome.  
 
While reductions in NK cell function might hint at weakened innate immunity during 
spaceflight, Agha et al. recently showed that salivary antimicrobial protein levels increased 
during spaceflight suggesting that innate immunity might be intact if not enhanced (Agha, 
Baker, et al., 2020). However, this might be in response to latent viral reactivation observed in 
the astronauts. While salivary cortisol levels remained normal compared to ground-based 
controls, higher cortisol levels were observed in viral shedders compared to non-shedders. This 
suggests that stress response to spaceflight might not be universal and that there might be a 
personalized component to the perception of the stress of spaceflight.  
 
Elevations in cortisol:DHEA were also observed corroborating the previous data but this 
appears to be driven by reductions in DHEA levels than increase in cortisol levels. While both 
these hormones are produced by the adrenal glands, they are supposed to have an inter-
modulatory effect on each other. High DHEA levels are supposed to reduce cortisol levels and 
antagonize most of the immune-suppressive effects of cortisol. This is another mechanism 
through which medium and short term stress is supposed to be modulated by the psycho-neuro-
immunological network to maintain homeostasis (Kamin & Kertes, 2017). Buchheim et al. 
also reported that diurnal salivary cortisol levels remained steady in Russian cosmonauts (J. 
Buchheim et al., 2019). Interestingly, there were evidences of activation of the 
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endocannabinoid system, represented by elevation of anandamide (N-
arachidonylethanolamine) at late in-flight time point (flight day 150). Elevation of anandamide 
is also considered a stress response, that is supposed to have strong immunomodulatory effects 
(J. I. Buchheim et al., 2018). Therefore, taken together, these studies show an effect of stress 
response from spaceflight affecting the immune system. However, the magnitude of this effect 
seems to vary along with high amount of interpersonal variability.   
 
Understandably, many factors including prior flight experience, training, workload, sleep 
schedules, team cohesion, exercise training regimen, nutritional preferences, and mission goals 
all play a contributory role to how stress is perceived and handled which ultimately affects the 
immune system.   
 
3. Spaceflight analogs 
‘Stress’ can be defined as a physiological response of an organism to an unfavorable stimulus 
from the environment. Human physiology responds to stress by releasing hormones that have 
a profound effect on the immune system. In the initial seconds, the sympathetic nervous system 
activates the adrenal medulla, which releases epinephrine and norepinephrine. This connection 
is termed sympathetic-adrenal-medullary (SAM) axis. Later, hypothalamus releases 
corticotropin-releasing hormone (CRH) that acts on the anterior pituitary to release 
adrenocorticotropic hormone (ACTH) that acts on the adrenal cortex to release cortisol. This 
connection is termed the hypothalamo-pituitary-adrenal (HPA) axis. All these hormones have 
an immuno-modulatory effect. Since stress is thought to play a huge role in immune system 
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dysregulation observed with spaceflight, using terrestrial models that can replicate the stress 
can be used as analogs to study effects of stress on human immune system. Supportive evidence 
for this can be found in early studies conducted by Glaser (Glaser, Kiecolt-Glaser, Speicher, 
& Holliday, 1985; Glaser, Kiecolt-Glaser, Stout, et al., 1985) and Gleeson (Gleeson et al., 
2002)et al. Immune dysregulation similar to that found in astronauts was found in highly 
stressed cohorts. Elite swimmers during intense training have shown EBV reactivation and 
shedding. Medical students during examinations and military cadets have shown signs of 
suppressed cell mediated immunity along with EBV, CMV and HSV-1 shedding.  
 
Antarctica winter-over expeditions: 
Amongst all the human spaceflight simulation analogs, it is probably Antarctica winter-over 
studies that show most immunological similarities to spaceflight. Sever temperatures, 3-
months of complete darkness, high altitudes, isolation and extreme remoteness making 
evacuations impossible make Antarctica winter-over stays psychologically extremely stressful. 
Diminished cell-mediated immunity along with Epstein-Barr virus reactivation were observed 
in Antarctica expeditioners by Mehta et al. (Satish K. Mehta, Pierson, Cooley, Dubow, & Lugg, 
2000). Expeditioners showed reduced delayed-type hypersensitivity (DTH) reaction, a 
measure of cell-mediated immune response. A later study by Feuerecker et al. (Moreels, States, 
Ulrike, Quintens, & Sams, 2019) used a modified ‘new global immunity test’ assay that 
replaced the traditional DTH, also showed reduced cellular immunity. Response of whole 
blood to a mixture of bacterial, viral, and fungal antigens showed lower levels of TNFα, IL2, 
IFNγ, and IL10. This confirmed lower levels of cell-mediated immunity in Antarctica winter-
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over expeditioners. A more recent study by Feuerecker (Feuerecker et al., 2019) showed that 
a 1-year Antarctica stay at the Concordia station showed high levels of immune activation 
evidenced by elevated cytokine responses. This yearlong study might become very relevant in 
expecting what might occur in exploration class missions, as this might be hinting at response 
of immune system to chronic stress. However, genome transcriptional analysis also revealed 
hypoxic pathways being activated, which might be a confounding factor, as this might not 
occur in spaceflight. Chronic stress resulting in overactivation of immune system for long 
periods might also result in ‘immune exhaustion’ and ‘inflammaging’ in astronauts. Humoral 
immunity appears to stay intact during Antarctica winter-over expeditions (Shearer et al., 
2001).  
 
NASA Extreme Environment Mission Operations (NEEMO): 
NASA has a laboratory 3.5 miles offshore the Florida Keys, at 60 feet depth. 14-day undersea 
deployments are supposed to elicit some amount of stress response. Hyperbaric hyperoxia in 
these habitats might not simulate spaceflight environment. However, it could represent extra-
vehicular activities (EVAs) that occur in hyperbaric hyperoxia. Nevertheless, isolation, 
confinement and stress experienced by aquanauts might provide us with some hints about 
spaceflight. Strewe et al. (C. Strewe et al., 2015) found that as the 14-day mission progressed, 
there was evidence of leukocytosis, driven by neutrophilia and monocytosis, but with 
concomitant lymphopenia. No significant differences in cytokine production were observed. 
Innate immune system disturbances were observed with granulocytes showing higher 
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activation levels (β2-integrin CD11b) and shedding of adhesion molecules (CD62L), hinting 
that these stress levels are enough to transform the innate system to a ‘high alert’ status. 
 
Head-down bed rest studies: 
Head down bed rest (HDBR) studies are used as spaceflight analogs to simulate the cephalad-
fluid shift seen in spaceflight. This analog simulates musculoskeletal decrements but does not 
stimulate the effects of microgravity and stress. Therefore, some studies, for example Crucian 
et al. (Sams et al., 2009) have failed to show the latent viral reactivation and immune activation 
deficiencies that occur during spaceflight. There were also no significant cortisol changes 
suggesting microgravity and stress to be possible causes of immune dysregulation in this 90-
day bed rest trial. Contrastingly, another study by Chouker et al. (Choukèr et al., 2001) argued 
that there was a psychic stress component to a 6° head down bed rest showing increases in 
‘current stress test’ questionnaire along with increased urinary dopamine and norepinephrine 
excretion. This study also reported decreased CD4:CD8 ratio and increased IL6 plasma 
concentration. It should be noted that this was a 120-day trial. Therefore, restricted body 
movement for such extended periods might be causing hypokinesia-associated psychological 
stress to some extent. Kelsen et al. (Kelsen et al., 2012) showed suppression in cell-mediated 
immunity following a 21-day head down bed rest. Reduced production of IL2, IFNγ and TNFα 
was observed during bed rest when stimulated with PHA. This study also failed to notice any 
latent viral reactivation. Another study (Stowe, Yetman, Storm, Sams, & Pierson, 2008) by 
Stowe et al. showed spaceflight resembling patterns of urinary epinephrine and cortisol 
excretions in just 14-day head down bed rest. In this study, subjects were exposed to G-forces 
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of launching and landing using a human centrifuge to mimic Shuttle launch and landing 
patterns. Therefore, this could serve as evidence that the high G-forces might be responsible 
for urinary catecholamine excretion. This study also provided evidence for landing stress 
induced neutrophilia usually observed in return samples. Simulation of landing G-forces 
showed similar patterns of leukocytosis mainly driven by neutrophilia. A recent 45-day HDBR 
study by Xu et al. (Xu et al., 2013) showed decreased cell-mediated immunity, increased 
secretion of pro-inflammatory cytokines (IL1β and IL18) by B-cells and myeloid cells and 
reduced secretion of IFNγ and IL17 by activated T-cells. This study also showed increased 
serum cortisol during the bed rest. These studies taken together indicate that if psychic stress 
is a constituent of head down bed rest, it could mildly simulate spaceflight without latent viral 
reactivation. 
 
Hind limb unloading studies: 
Hind limb unloading studies, where rats or mice are hoisted up by their hind limbs to produce 
a 30° head-down tilt is used as a model to simulate the cephalad fluid shift seen in spaceflight 
(Morey-Holton & Globus, 2002). This model elicits similar stress patterns like spaceflight 
since a quadruped prey animal is restrictively hung by a support. Like HDBR studies, this was 
originally intended to study muscle and bone loss, but stress hormones (glucocorticoids and 
catecholamines) released show a hypothalamic oxidative stress (Sarkar et al., 2008). Pro-
inflammatory response (increased IL1β, IL6) coupled with diminished cellular cytokine 
response (reduced IL2 production) (Felix et al., 2004) show similarities with humans upon 
return from spaceflight (R+0) (B. Crucian et al., 2014a). However, the results might be 
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signaling a systemic inflammatory response in the rodents. There is evidence of bacterial 
endotoxin in blood during hind limb unloading (Rivera, Tcharmtchi, Mendoza, & Smith, 
2003). Excessive hydrostatic fluid pressure in the cephalad portion of body results in disruption 
of gut lining causing a ‘leaky gut syndrome’, allowing lipopolysaccharide (LPS) to enter the 
blood stream, which might be causing the systemic inflammation. Therefore, puritanical 
comparisons of hind limb unloading to spaceflight must be done with caution. Other additional 
factors like radiation have been reported to amplify detrimental effect of hind limb unloading 
on the immune system. For example, solar particle event (SPE)-like radiation has been shown 
to decrease bacterial clearance (M. Li et al., 2014). Hind limb unloading has also shown to 
increase tumor growth in mice (Lee, Ding, Kulkarni, & Granstein, 2005). Therefore, this 




Parabolic flight or ‘vomit comet’ is a peculiar flight pattern that involves near vertical nose-
dive and nose-lift of a commercial jet. During the nose-dive, accelerating downwards at 1G 
(9.86m/s2) neutralizes the gravitational vector allowing the flight to experience near 0G for 
approximately 20 seconds during each injection. Therefore, this provides a great opportunity 
for conduction, convection, and signal transduction studies to be performed, although for very 
brief periods. Commencing the experiment at the beginning of injection into the downward 
parabola and fixing the cells at the end of it facilitates observing cellular interactions in real 
microgravity. While gravitational stress of parabolic flights affects human immune system, 
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stress response to altered gravity seems more complex. While some studies like Stervbo et al. 
(Stervbo et al., 2018) showed no changes in cortisol levels, other studies Strewe et al. showed 
a correlation of ‘perceived stress’ and signs of motion sickness with elevations in cortisol 
(Claudia Strewe et al., 2012). Interestingly, participants that did not show signs of motion 
sickness or elevations in cortisol, showed activation of the endocannabinoid system with 
elevations in 2-Arachidonoylglycerol. Similar elevations in another endocannabinoid, 
anandamide (N-arachidonoylethanolamine) were observed in cosmonauts (J. Buchheim et al., 
2019) during ISS missions. Parabolic flights simulating microgravity, showed reduced delayed 
type hypersensitivity reactions and altered cytokine production in mice spleen (Kita, 
Yamamoto, Imanishi, & Fuse, 2004) mirroring spaceflight alterations. Neutrophils showed 
increased cytotoxic capabilities (I. Kaufmann et al., 2009) in humans, but ex vivo 
supplementation of adenosine reduced tissue toxic H2O2 production of the neutrophils via 
A2(A) receptor (Ines Kaufmann et al., 2011). This strategy might be helpful to prevent G-stress 
induced overactivation of immune system when landing on Mars surface. 
 
Simulated microgravity: 
Rotating wall vessels (RWV) and random positioning machines (RPM) have been used for 
decades to study effects of simulated microgravity. This effect was studied on various cells 
and tissues (Goodwin, Prewett, Wolf, & Spaulding, 1993; Goodwin, Schroeder, et al., 1993; 
Hammond & Hammond, 2001; Jessup, Goodwin, & Spaulding, 1993; Klaus, 2001; Monici et 
al., 2006; Schwarz et al., 1992; Tsao, Goodwin, Wolf, & Spaulding, 1992; Wuest, Richard, 
Kopp, Grimm, & Egli, 2015). Initially borrowing from botanists that used similar concepts to 
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study gravitropic effects on plant growth, NASA devised this system to culture cells and tissues 
in the microgravity of space. Soon realizing that these instruments can be used on earth to 
simulate microgravity, they have been used by life scientists to study the effects of simulated 
microgravity on Earth. Now, modeled microgravity is used in a wide variety of applications 
including tissue regeneration, 3D-cell culturing, tissue-cell interactions, host-pathogen 
interactions (Aleshcheva et al., 2016; Grimm et al., 2014; Higginson, Galen, Levine, & 
Tennant, 2016; Manley & Lelkes, 2006; Cheryl A. Nickerson et al., 2003; Wuest et al., 2015). 
Rotating wall vessel operates by suspending cells in a high-aspect (radius-to-depth) ratio vessel 
in a quiescent low-shear stress environment. When rotated on a horizontal axis at enough speed 
while maintaining laminar flow of the fluid, the cells can be subjected to randomization of 
gravity vector and continuous free fall. When this occurs over extended periods, the average 
gravitational vector reaches to a magnitude of 10-2G. The aggregate force experienced by any 
cell in systemic physiology inside a human body —especially a motile cell, like most cells in 
the immune system—is dependent on multiple factors. These include hydrostatic forces of 
blood or extracellular fluid, tissue tensile strength, rigidity of extracellular matrix etc. 
Nevertheless, simulated microgravity machines have been accurately replicating the effect of 
microgravity on cells (Freed et al., 1999; Hammond & Hammond, 2001; Klaus, 2001; Lappa, 
2003; Martinez et al., 2015; Walther, 2001). 
 
In systemic physiology, simulated microgravity has shown effects on humoral responses 
(Fitzgerald et al., 2009), signal transduction (Paulsen et al., 2010), cell cycle (Thiel et al., 
2012), and DNA repair mechanisms (Degan et al., 2005; Kumari, Singh, & DuMond, 2009; 
Moreno-villanueva et al., n.d.). Effect of simulated microgravity on lymphocytes include 
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alterations in proliferation (Martinelli et al., 2009), signaling pathways (Licato & Grimm, 
1999), activation and function (Fitzgerald et al., 2009; Risso et al., 2005), lymphocyte 
locomotion through type 1 collagen (Pellis et al., 1997; Sundaresan, Risin, & Pellis, 2002), 
epigenetics (Singh, Kumari, & DuMond, 2010). Other major effects on the immune system 
include alterations in cytoskeletal structure, (Zheng et al., 2011), function of hematopoietic 
stem cells (D. Cao et al., 2019) and  monocyte function (Yu, Zheng, Xiong, Cai, & Wang, 
2011).  
Buravkova et al. reported that NK cells retained their ability to recognize, maintain contact and 
lyse k562 target cells onboard the ISS compared to ground based controls (Buravkova, Rykova, 
Grigorieva, & Antropova, 2004) but this experiment was only performed twice.  In contrast, 
Li et al. (Q. Li et al., 2013) used expanded NK cells to show 48-hour exposure to SMG impairs 
NK cell cytotoxicity, increases NK cell apoptosis, reduces expression of IFNγ by 
downregulation of NKG2D and NKG2A. However, expanded NK cell functional activity is 
not regulated by its phenotypic markers (Lieberman et al., 2018) and their potency/loss-of-
function cannot be estimated as a consequence of receptor modulation. Our experiments with 
primary, naïve unexpanded NK cells show that even short-term exposure (12 hours) to SMG 
affects primary NK cells. NK cells lysed ~50% fewer cancer cells when tested in 16 subjects 
in four different cancer cell lines (k562, u266, 721.221, and 221.AEH). This reduction in 
function was due to reduced expression of cytotoxic granules, perforin and granzyme B. 
Primary NK cells also showed reduced degranulation (CD107a+), TNFα and IFNγ production 
when encountering target cells. Therefore, it is still not certain whether NK cells retain their 
function in microgravity. We propose to explore if this loss in function will extend to more 
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physiologically relevant in vivo model. Future in vitro and murine experiments onboard the 
space station could help answer this important question.  
 
4. Spaceflight countermeasures 
Countermeasures currently being considered include screening, nutritional, behavioral 
(exercise, positive experiences), and pharmacological interventions (B. E. Crucian et al., 
2018). 
Multiple in vitro remedies/countermeasures to SMG induced suppression of function have 
been successfully reported. These include interleukins (Q. Li et al., 2013), polysaccharides 
(Huyan et al., 2014), nutritional nucleotides (Hales et al., 2002; Kulkarni, Yamauchi, 
Sundaresan, Ramesh, & Pellis, 2005; Yamauchi et al., 2002), PMA stimulation (Simons, 
Gardner, & Lelkes, 2009), morin sulphates/glucuronides (Hsieh, Chao, & Fang, 2005), 
rhodiola rosea (Xu et al., 2016). However, the clinical efficacy, safety and drug interactions of 
these compounds remain untested.  
 
ZOLEDRONIC ACID: 
Zoledronic acid is an amino-bisphosphonate that has multiple clinical therapeutic applications 
including prevention of osteoporosis (Fobelo Lozano & Sanchez-Fidalgo, 2019), bone loss in 
cancer induced osteopenia (Mei, Xiang, Yang, & Xiang, 2019). Since bone mineral density 
loss due to gravity unloading in space is a major complication, life scientists are now 
considering zoledronic acid as a spaceflight therapeutic countermeasure (Cavanagh, Licata, & 
29  
Rice, 2005). Coincidentally, zoledronic acid also has many immunological consequences. One 
of the ways zoledronic acid improves bone mineral density is by inhibiting osteoclastogenesis 
by downregulating nuclear factor kappa-B ligand (RANKL). Zoledronic acid also improves 
anti-tumor immunity through suppression of Tregs which use the same RANKL ligand (Liu et 
al., 2016; Salaroglio et al., 2015). Tumor infiltration by Tregs promotes tumor evasion (Wilke, 
Wu, Zhao, Wang, & Zou, 2010). Suppressing Tregs activity improves anti-tumor activity by 
making the tumor microenvironment more accessible to cytotoxic (CD8+) T-cells, NK cells 
and tumor-associated macrophages (Aldinucci, Borghese, & Casagrande, 2019). Another 
immune cell type that zoledronic acid has an effect on are γδ-T cells. Zoledronic acid sensitizes 
tumors to γδ-T cell killing by increasing phosphoantigen expression on their surface (Caccamo 
et al., 2008; Hamilton, Clay, & Blackwell, 2011). Zoledronic acid is also used to expand γδ-T 
cells in vitro (Kondo et al., 2011). Antigen presenting cells take up zoledronic acid from the 
surrounding media and convert it to isopentenyl pyrophosphate (IPP). When they present this 
IPP to γδ-T cells, they are activated and in presence of IL2 expand to yield highly pure γδ-T 
cell product. This has been used as a strategy to expand γδ-T cells ex vivo for 
immunotherapeutic purposes. Zoledronic acid has also been shown to expand γδ-T cells in vivo 
(Monkkonen et al., 2007). Therefore, we propose to use zoledronic acid to revive anti-tumor 
activity by suppressing Tregs, and activating and expanding (in the presence of IL2) γδ-T cells 





Administration of IL-2 has shown to improve anti-tumor activity in pre-clinical mice models 
(Cheever, Greenberg, Fefer, & Gillis, 1982; Mazumder & Rosenberg, 1984) by activating 
lymphocytes into lymphokine activated killer (LAK) cells. It has also been shown to be an 
effective immune-therapeutic agent against various cancers in clinical trials by improving NK 
cell function (Kimpo, Oh, & Lee, 2019; Muntasell et al., 2017; Rosenberg, 2014). Therefore, 
we propose using IL-2 along with zoledronic acid to improve ‘effector lymphocyte’ function 
in vivo in a NSG-tg(hu-IL15) mice model to revive SMG-induced loss of function. 
 
Another hopeful strategy is to use granulocyte-colony stimulating factor (G-CSF) to counter 
spaceflight induced immune suppression. G-CSF is used to proliferate and mature white blood 
cells in neutropenia patients and hematopoietic stem cell donors. G-CSF has been shown to 
improve immunity against space radiation (M. Li et al., 2015). Therefore, combining G-CSF 
with other immunotherapeutic agents and timing it around heavy radiation exposure periods 
like passing through the Van Allen belts or instances of solar flares could prevent 
tumorigenesis in astronauts. 
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Limitations of spaceflight immunology literature: 
 Post-flight data is confounded by landing G-stress. Therefore, it becomes complicated 
to discern effects of long-term spaceflight with late-mission time points in a 6-month 
mission. Some recent studies have collected samples just before return (R-1, one day 
before return) to circumvent this problem. 
 In-flight samples are confounded by processing delays due to transfer to earth based 
laboratories. 
 Different processing and testing methodology standards showing conflicting results 
between the US, International and Russian crew members. 
 In-flight stress levels are not accurately represented by cortisol levels due to circadian 
misalignment. Cortisol levels in the body follow a diurnal pattern with highest levels 
in the morning. Altered circadian rhythm and sleep patterns might interfere with 
cortisol production. Cortisol:DHEA and ECS metabolite measurements have shown 
ambiguous and sometimes conflicting results. 
 Radiation exposures beyond LEO might alter interactions with immune system. There 
is a lack of data in regards to space radiation effect on immune system. With the new 
GCR simulation equipment at the National space radiation laboratory (NSRL), there 
could be new data  
 20 times higher CO2 levels on ISS (around 2.3-5.3 mm Hg) compared to Earth’s 0.3 
mm Hg has already been implicated in headaches, visual impairment due to intracranial 
pressure (VIIP) (Gibson, Alexander, & Hamilton, 2012). There is some evidence that 
altered CO2 levels affect immune system (Cho et al., n.d.). Future studies could look 
into the systemic effect of high CO2 levels on the immune system. 
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 Altered microbial virulence in confluence with reduced cell mediated immunity might 
compound the effect of immune dysregulation.  
 Most countermeasures to immune dysregulation have been tested in vitro using SMG 
models. How these nutritional/therapeutic countermeasures would fare in vivo remains 
to be tested. This dissertation will involve testing the efficacy of a common in vivo 
countermeasure in a SMG mice model. 
 Partial gravities of the Lunar and Mars surfaces are a novel stimulus to the human body. 
How this affects the immune system remains unknown. 
 Lack of in vivo data is a major limitation to spaceflight data. Almost all immune studies 
involve in vitro testing. While it is unethical to perform human in vivo experiments 
concerning immune dysregulation and tumor development, mice models are beset with 
limitations of extrapolation to human physiology. This dissertation aims to find a 
middle ground using a humanized mice model with human immune cells and SMG. 
 
Aims and Hypotheses 
The planned longer duration spaceflights will result in greater exposure of astronauts to the 
deleterious effects of spaceflight, including immune dysregulation. We have previously shown 
that natural killer (NK) cell function is suppressed after 12-hour exposure to simulated 
microgravity (SMG) using a NASA-validated rotary cell culture system.  
 
Specifically, when compared to NK cells that experienced 1G gravitational force, SMG-
exposed NK cells kill 50% fewer cancer cells, have a reduced expression of cytotoxic granules 
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(perforin and granzyme B), and a reduced production of effector cytokines (TNFα and IFNγ) 
when exposed to cancer cells. Although in vitro models help to estimate the effect of short-
term SMG on immune cells, there is a need to examine if these detrimental effects of SMG 
extend to more physiologically relevant in vivo models such as humanized murine models. 
 
Additionally, clinical countermeasures for long duration exploratory class missions currently 
being considered have known immunological consequences.  For example, zoledronic acid 
(ZOL), a bisphosphonate, may improve bone mineral density loss observed with spaceflight 
and subcutaneous IL2 may improve NK cell and γδ-T-cell function. Coincidentally, ZOL+IL2 
is also used to improve in vivo anti-leukemia activity of γδ T-cell function and hasten immune 
reconstitution after a hematopoietic stem cell transplantation. Hence, it becomes pertinent to 
examine if ZOL+IL2 therapy, routinely used in a stem cell transplantation setting, can be used 
to boost in vivo anti-leukemia activity of human PBMCs after they have been exposed to SMG. 
 
Problem statement 
Therefore, there exists a need to examine the effect of SMG on both in vitro and in vivo 
function of various immune cells and evaluate the efficacy of common clinical therapies as 






We hypothesize that exposure to SMG adversely affects function of various immune cells both 
in vitro and in vivo; while systemic administration of ‘ZOL+IL2’ will boost the in vivo function 




Determine the effect of SMG on in vitro expansion and function of CMV-specific T-
cells and γδ-T cells.  
 
This aim will address the following questions: 
 
Q1. Does SMG impair expansion of CMV-specific T-cells and/or γδ-T cells in vitro? 
Q2. Does SMG impair function of CMV-specific T-cells and/or γδ-T cells in vitro? 
via the following hypotheses: 
 
Hypothesis 1a: Exposure to 12-hour SMG in a RCCS impairs in vitro expansion of CMV-
specific T-cells and/or γδ-T cells. 
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Expected outcome: We expect fewer CMV-specific T-cells and/or γδ-T cells post-expansion 
after exposure to SMG. 
Hypothesis 1b: Exposure to 12-hour SMG in a RCCS impairs in vitro function of CMV-
specific T-cells and/or γδ-T cells.  
Expected outcome: We expect reduced function of CMV-specific T-cells and/or γδ-T cells 
after exposure to SMG. 
 
AIM 2:  
Determine the effect of simulated microgravity on the in vivo anti-leukemia activity of 
human immune cells. 
 
This aim will address the following question: 
 
Q. Does SMG impair anti-leukemia activity of human immune cells in vivo? 
via the following hypothesis: 
Hypothesis 2: Exposure to 12-hour SMG in a RCCS adversely affects anti-leukemia 
activity of human immune cells in vivo by impairing their ability to control tumor 
growth in a NSG-tg(hu-IL15) mice model. 
Expected outcome: We expect reduced anti-leukemia activity of human immune cells 
after exposure to SMG. 
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AIM 3:  
Determine the effect of systemic administration of ZOL+IL-2 on the function of human        
immune cells in vivo and/or in vitro. 
This aim will address the following question: 
Q. Does systemic administration of ZOL+IL-2 boost the impaired anti-leukemia 
capacity of human immune cells in vivo and/or in vitro after exposure to SMG? 
via the following hypothesis: 
Hypothesis 3: Systemic administration of ZOL+IL-2 will boost the in vivo anti-leukemia 
capacity of human immune cells in an NSG-tg(hu-IL15) mice model and/or in an in vitro 
model. 
Expected outcome: We expect that ZOL+IL-2 administration will boost the anti-leukemia 















Healthy adults between ages 18-49 who were willing to volunteer for the study were recruited 
and consent for blood draw was obtained according to Human Subjects Protection Program 
(HSSP) in compliance with the Institutional Review Boards (IRB) at University of Arizona 
and University of Houston. 
 
2. Blood collection and processing 
Blood was collected by a trained phlebotomist via venipuncture. Acid citrate dextrose (ACD) 
tubes or heparin tubes will be utilized for cell culture experiments, while serum-separating 
tubes (SST) were used to isolate serum to perform ELISAs for CMV status. 
 
3. Rotary cell culture system 
This culture system was originally designed by NASA at Johnson Space Center to culture 
tissues during spaceflight and was later licensed by Synthecon Inc., Houston, Texas USA. 
Rotary cell culture system (RCCS) was designed to suspend cells in the culture media to 
simulate the effect of microgravity. Simulation of microgravity is made possible in this system 
due to rotation of the high-aspect ratio vessels (HARV) on a horizontal axis. This rotation 
would facilitate the suspension of cells to coalesce into 3D aggregates and maintain a circular 
orbit within the vessel. This would result in the 3D aggregates to stay in continuous free fall 
while experiencing randomization of gravity vector (g) in a quiescent low-shear stress 
environment. Lymphocytes rotated at 10RPM will stay suspended within the vessel and 
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experience G-force equivalent to 10-2G (RCCS manual, Synthecon Inc.). Two control vessels 
will be used. One vessel remains static allowing the immune cells to experience 1G 
gravitational force while the other vessel rotates on a vertical axis, which allows the cells to 
sediment to the bottom. The rotation of the media exposes the cells to shear stress, which will 
be used as rotational control. While one of the operating principles of RCCS was to expose the 
cells to a low-shear stress model (LSSM), this will account for any changes in function due to 
rotational shear stress while also experiencing 1G gravitational force, however minimal they 
might be. The experimental setup is shown in Figure 3. 
 
Figure 3. RCCS showing orientation of high-aspect ratio vessels (HARVs). Vessel ‘A’ rotates on 
a horizontal axis suspending cells in a circular orbit simulating microgravity (SMG). Vessel ‘B’ 
used as a rotational control (RC), rotates on a vertical axis in which the cells experience shear 
stress while also experiencing 1G gravitational force. Vessel ‘C’ remains static in which the cells 
experience only 1G gravitational force (STATIC) devoid of any shear stress. The suspended 
aggregate particle follows a circular path inside the vessel in a low-shear stress environment. The 
hydrostatic rotational force created by the rotating vessel and the gravitational (1G) force acting 
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on the particle will result in two partial ‘g’ vectors: gCP, a centripetal force towards the center 
and gT, a tangential force towards the momentum of traced particle. 
 
4. Expansion of CMV-specific T-cells  
Expansion protocols previously described (Gerdemann et al., 2009; Spielmann, Bollard, Kunz, 
Hanley, & Simpson, 2016a) using PBMCs from CMV+ subjects, CMV peptides (IE-1 and 
pp65) and cytokines IL-4, IL-7 and IL-15 (Miltenyi, Bergisch Gladbach, Germany) were used 
to expand CMV-specific T-cells in G-rex vessels (WILSONWOLF, Saint Paul, MN). Briefly, 
10 million PBMCs from each condition were exposed to STATIC, rotational control and SMG 
conditions. Later, they were stimulated with CMV peptides, 400ng each of IE-1 and PP-65 
(Miltenyi, Bergisch Gladbach, Germany), for one hour in an incubator (37C, 5% CO2) in 50ml 
conical tubes. After stimulation, 15ml culture media containing 10% FBS+RPMI, 0.3µL/ml 
IL-4 (1666 I.U./ml) and 0.1µL/ml IL-7 (10ng/ml) per condition was added and transferred to 
G-rex vessels. After 5 days, media was replaced with 15ml 10% FBS+RPMI culture media 
that contains 0.3µL/ml IL-15 (5 ng/ml) in addition to 0.3µL/ml IL-4 (1666 I.U./ml) and 
0.1µL/ml IL-7 (10 ng/ml) in each condition. Cell counts and phenotyping were performed at 
the end of expansion period using eight-color flow cytometry (MACS QUANT, Miltenyi, 
Bergisch Gladbach, Germany). CMV-specific T-cells were enumerated either with ELISPOT 
or with IFNγ secretion assay. 
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5. Expansion of γδ-T-cells 
PBMCs from healthy human subjects were used to expand γδ-T cells using zoledronic acid 
along with 100 I.U./ml IL-2 as previously described (Kondo et al., 2011). Briefly, 10 million 
PBMCs from each condition were exposed to 1G (STATIC) control and SMG conditions. 
Later, they were plated in a flat bottom 24-well plate at a concentration of 1million cells per 
well in a culture media that contains zoledronic acid (5µM) and IL-2 (100 I.U./ml). The media 
was changed with culture media containing only IL-2 (100 I.U./ml) on days 3, 7, 10. Finally, 
the cells were harvested on day 14 for subsequent experiments. Cell counts and phenotyping 
were performed at the end of expansion period using eight-color flow cytometry (MACS 
QUANT, Miltenyi, Bergisch Gladbach, Germany). 
 
6. Function of CMV-specific T cells  
CMV-specific T-cell function was measured using a cytotoxicity assay against autologous 
PHA blasts (Spielmann et al., 2016a). CMV-specific T-cell functional assays included SMG 
exposed cells that were later expanded in 1G and conversely 1G expanded cells that were 
exposed to SMG at the end of expansion. Functional differences were compared within the 
three groups: STATIC, rotational control and SMG. 
 
To evaluate the function of CMV-specific T-cells their cytotoxicity against autologous PHA 
blasts was estimated. PHA blasts were generated following manufacturer’s instructions using 
phytohemagglutinin from Thermo Fisher Scientific (10576015). PHA blast generation 
protocol and cytotoxicity assay has been adopted from previous literature (LaVoy et al., 2015; 
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Spielmann et al., 2016a). 2% v/v PHA-M was used to stimulate 10million PBMCs in the 
presence of IL-2 (400IU/ml) for 72hours at 37°C. After blastogenesis, PHA blasts were 
cultured for 72 hours in culture medium (5% human serum+ RPMI). PHA blast cultures were 
unpulsed, pulsed with irrelevant peptide (MOG) or with CMV peptides (IE1, pp65) for 1-hour 
at 37°C. Following that, PHA blasts used as target cells were stained with CD3 (Viogreen) 
(Miltenyi Biotec, Bergisch Gladbach, Germany) to identify them. After two washes with PBS, 
target cells were incubated with CMV-specific T-cells at an effector: target cell ratio of 10:1. 
0:1 effector: target cell ratio was used to estimate spontaneous cell death. Cryopreserved CMV-
specific T-cells were thawed and incubated overnight in 100 IU/ml IL-2 at 37C 5% CO2 before 
being used in the cytotoxicity assay. Specific lysis was used to estimate CMV-specific T-cell 
cytotoxicity. Data was presented as target cells lysed per 100,000 CMV-specific CD3+CD8+ 
T-cells. 
 
7. Function of γδ-T-cells 
γδ-T cell function was measured as specific lysis of cancer cell lines (K562 and U266) (Bigley, 
Spielmann, Agha, O’Connor, & Simpson, 2016). Briefly, target cells were initially stained with 
CD71 FITC (Miltenyi, Bergisch Gladbach, Germany). Later, γδ-T cells and target cells (K652 
or U266) were co-incubated at different E:T ratios (0:1, 1:1, 5:1. 10:1 and 20:1) in u-bottom 
96 well plates with 30,000 target cells in each well and in a final volume of 200µL in an 
incubator at 37C, 5% CO2 for 4 hours. At the end of incubation, the cells were washed twice 
in PBS at 300G for 10 minutes. Cells were analyzed for dead target cells using flow cytometer 
immediately after adding propidium iodide (PI). PI+ target cells in 0:1 condition was 
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considered spontaneous cell death, while ‘specific lysis’1, a measure of γδ-T cell activity, was 
calculated for each E:T ratio. Data was presented at 10:1 Effector: Target cell ratio. 1G 
(STATIC) control and SMG conditions were compared within each experiment. 
 
8. Gas-permeable rapid cell expansion vessels 
Gas permeable rapid expansion (G-rex) vessels (WILSONWOLF, Saint Paul, MN) was used 
to expand CMV-specific T-cells by several folds (Bajgain et al., 2014). The gas permeable 
membrane in the bottom enables convectional exchange of O2 from ambient air in the incubator 
into the vessel and escape of CO2 from the media. This enabled us to perform phenotyping and 
functional assays (cytotoxicity, ELISPOT, and IFN- γ secretion assays).  
 
9. CMV ELISA 
CMV IgG qualitative ELISA kits from Immuno-biological laboratories, Inc. (IBL-America, 
Minneapolis, MN) was used to evaluate CMV status of the participants. Manufacturer’s 
instructions were used to perform the ELISA and optical density of the wells was read using a 
luminescence plate reader at 450nm. 
 
                                                 
1 Specific lysis = Total target cell death – spontaneous target cell death. 
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10. CMV ELISPOT  
To enumerate the number of CMV-specific T-cells we used an enzyme linked immunospot 
assay (ELISPOT). ELISPOT for CMV specific T-cells was performed using the protocol 
previously mentioned (Spielmann, Bollard, Kunz, Hanley, & Simpson, 2016b). 10,000 cells 
per well from the expansion product were stimulated with CMV peptides: IE1 or pp65 for 
12hours at 37 °C. Spot-forming cells (SFCs) were enumerated with Zellnet Consulting Inc. 
(Fort Lee, NJ, USA). Total SFCs were calculated and adjusted for number of CD3+ cells (% 
of cells from expansion product expressing CD3+). Data was presented as IE1 or pp65 reactive 
cells per 1million CD3+cells. 
 
11. IFNγ secretion assay 
To enumerate the number of CMV-specific T-cells we also used an IFNγ secretion assay. We 
followed manufacturer’s instructions for the protocol obtained from Miltenyi Biotec (130-090-
762). CMV-specific T-cells expanded in Aim 1a were reconstituted in culture medium (5% 
human serum+ RPMI) at a concentration of 107 cells/ml and stimulated with CMV peptides 
IE-1 and pp65 (10µg/ml) for 3 hours in an incubator at 37C, 5% CO2. Later, they were washed 
in cold buffer (PBS at pH 7.2+ 0.5% bovine serum albumin+ 2mM EDTA). Followed by 
resuspension in cold culture medium, 15µL IFN-γ catch reagent was added and incubated on 
ice for 5 minutes. Followed by another incubation for 45 minutes at 37C after resuspension in 
1mL warm culture medium. After two washes with cold buffer, 15µL IFN-γ detection antibody 
(APC) and 2µL each of CD8 (VioBlue), CD3 (VioGreen), CD4 (FITC), CD45 (APC-Vio770) 
was added and incubated for 15 minutes in the dark at 4C. After the incubation, and two washes 
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with PBS (300G, 10 minutes), the cells were analyzed on the flow cytometer. All antibodies 
were purchased from Miltenyi (Miltenyi Biotec, Bergisch Gladbach, Germany). 
 
12. NSG-Tg(Hu-IL15) mouse model 
All mouse experiments were done in compliance with Institutional Animal Care and Use 
Committee (IACUC) guidelines at the University of Arizona. Animals were purchased from 
Jackson laboratory (Bar Harbor, ME, USA) and breeding colonies were maintained at the 
Animal Care facility. Animals were housed at the University Animal Care facility. 
Humanized NSG mice are severely immunodeficient mice that do not have a mature immune 
system (Leonard D. Shultz, Ishikawa, & Greiner, 2007). This makes them uniquely suited for 
in vivo models to study human hematopoietic system reconstitution, graft-versus-leukemia 
effect, graft-versus-host disease, in addition to studying chemotherapeutic drug toxicities, 
interactions, and efficacies in a pre-clinical stem cell transplantation setting.  
 
Mutations in NSG-Tg(Hu-IL15) mice:   
Prkdcscid mutation in these mice cause ‘severe combined immune-deficiency’ resulting from 
absence of mature B and T cells (Bosma, Custer, & Bosma, 1983). Il2rgtm1Wjl —a targeted 
mutation— in the common IL-2R gamma chain affecting IL-2, IL-4, IL-7, IL-9, IL-15 and IL-
21 receptors prevents NK cell development, differentiation, and function along with reduced 
spontaneous generation of mature B and T cells (X. Cao et al., 1995; L. D. Shultz et al., 2005; 
Leonard D. Shultz et al., 2007). These mutations are on a NOD (non-obese diabetic) mouse 
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background that originally were intended to study autoimmune (type I) diabetes. These NOD 
mice inherently have several immune-deficiencies which include immature macrophages 
(Serreze, Gaedeke, & Leiter, 1993),  defective antigen-presenting dendritic cells (Pearson et 
al., 2003), reduced NK cell activity (Kataoka et al., 1983) and a completely absent complement 
system (Nilsson & Muller-Eberhard, 1967).  
 
Since all these immune-deficiencies congregate in NSG mice, the mice do not have a capable 
immune system to mount a resistance to xenogeneic transplantation with human CD34+ 
(hematopoietic stem cells) cells or peripheral blood stem cell (PBSC) grafts resulting in 
improved engraftments (L. D. Shultz et al., 2005).  
 
NK cells develop in the bone marrow microenvironment and need IL-15 for their development 
(Fehniger & Caligiuri, 2001; Williams et al., 1998). In vivo survival of NK cells is also 
predicated on the exogenous supply or indigenous production of IL-15 (Cooper et al., 2002). 
Therefore, when a transgenic insertion of humanized IL-15 sequence (Tg(IL15)1Sz/SzJ) is 
added onto the NSG mouse background, this resulted in enhanced development and survival 
of human NK cells from the stem cell graft in the NSG mice (Brehm et al., 2018).     
 
Since we propose to study the effect SMG on in vivo anti-leukemic activity of human PBMCs, 
which is largely driven by NK cells, we will utilize this NSG-Tg(Hu-IL15) mice model which 
enhances in vivo survival of human NK cells. Our experiments suggested that acute GVHD 
starts occurring around 14 days after PBMC injection and severe GVHD occurs around day 
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28. Therefore, we chose to evaluate graft-versus-tumor effect before severe GVHD starts 
setting in to prevent GVHD associated immune modulation from eclipsing the graft-versus-
tumor effect of human PBMCs. Acute GVHD scoring will be based on previously published 
grading (Lai, Chou, Tzeng, & Lee, 2012; Naserian et al., 2018).  
 
GVHD scoring: GVHD will be scored on 6 parameters:  
1. Activity: normal=0, mild to moderately inactive=1, severely inactive=2. 
2. Diarrhea: absent=0, present=1. 
3. Fur: normal texture=0, mild to moderate ruffling=1, severe ruffling=2. 
4. Posture: normal=0, hunching at rest=1, severely hunching=2. 
5. Skin integrity: normal=0, scaling of paws and tail=1, obviously denuded=2. 
6. Weight loss: 0-9.99%=0, 10-19.99%=1, ≥20%= sacrifice criteria met. 
 
An acute GVHD score of 4 or more will be considered termination point of the experimental 
data collection. NSG-Tg(Hu-IL15) mice will be obtained from Jackson labs and breeding 
colonies will be maintained at the University of Arizona Animal Care Facility.  
 
Zoledronic acid+IL-2 therapy: 
Administration of zoledronic acid and interleukin-2 has been shown to improve in vivo γδ T 
cell activity against various tumors in both human trials and murine models (Ottewell et al., 
2008; Pressey, Adams, Kelly, & Lamb, 2013). Low doses of subcutaneous IL-2 has shown to 
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expand NK cells in vivo (Meropol et al., 1996), improve function of NK-cells, γδ-T-cells, T-
cells and B-cells (Gaffen & Liu, 2004; Mahmoudpour et al., 2019). Therefore, we propose to 
test the efficacy of ‘ZOL+IL-2’ therapy as a potential countermeasure to SMG induced loss-
of-function in vivo. All mouse care and experimental procedures were performed in accordance 
with the guidelines of Institutional Animal Care and Use Committee (IACUC) at the animal 
care facility at the University of Arizona. 
 
13. Bioluminescent imaging 
K-562-luc2 (strain: ATCC® CCL-243-LUC2™) (American Type Culture Collection, 
Manassas, VA, USA), which is a K562 (chronic myeloid leukemia) cell line that has been 
tagged with luciferase will be used for in vivo experiments. When cells bearing luciferase 
encounter luciferin, catalytic oxidation of luciferin will result in emission of photons. This 
combined with negligible auto fluorescence of regular cells and tissues will result in high 
signal-to-noise ratio which can be used for in vivo imaging applications (Duda, Karimi, Negrin, 
& Contag, 2007; Paley & Prescher, 2014). After K-562-luc2 has engrafted in the mice, tumor 
burden can be measured when D-luciferin (GoldBio, St Louis, MO) is injected 
intraperitoneally. A LagoX spectral imager (Spectral Instruments Imaging, Tucson, AZ) will 
be used to obtain bioluminescent intensity (BLI) scores.  
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14. Statistical analysis 
Statistical analysis was performed on Graphpad Prism 8.4.3 software (Graphpad, San Diego, 
CA). Statistical significance level was set at p<0.05. 
CMV-specific T-cell expansion numbers and IFNγ secretion assay results met normality 
(Shapiro-Wilk test), equality of variances (Brown-Forsythe test), and normality of residuals 
assumptions. Therefore, a one-way RM ANOVA was used to analyze the data without 
assuming sphericity and Geisser-Greenhouse correction was applied. PHA blast cytotoxicity 
data for CMV-specific T-cells was analyzed using RM ANOVA (for day 14) or Friedman test 
(for day 15) in compliance with normality assumption. CMV ELISPOT enumeration data met 
normality assumption (Shapiro-Wilk test). So, a paired t-test was used to analyze the data since 
there were only two groups (1G control and SMG).    
 
Γδ-T cell expansion numbers failed normality test. Therefore, a two-tailed Wilcoxon matched-
pairs signed rank test was performed to evaluate differences between the groups. Γδ-T cell 
phenotyping: paired t-test was used when normality assumption was met. When normality test 
failed, Wilcoxon matched-pairs signed rank test was used. Day14 Γδ-T cell numbers, day 14 
and 15 vγ9vδ2 and vγ9vδ1 proportions, day 15 NKG2D+ proportions, day 14 and day 15 
NKp30+ proportions, day 14 CD3- CD56+, day 15 NKG2D+ CD158b- proportions failed 
normality tests. All Γδ-T cell cytotoxicity data passed normality tests, so a two-tailed paired t-
test was used since there were two groups (1G control and SMG). 
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For AIMS 2 and 3, for tumor progression bioluminescent intensity data was log-transformed 
for normality as previously done for BLI data (Stokes, Hoffman, Zeng, Larmonier, & Katsanis, 
2016). A mixed effects model was used to analyze differences between tumor growth with 
‘condition’, ‘time’ main effects and ‘condition*time’ interaction effect in the model. When 
‘condition*time’ interaction effect was significant in the whole model (suggesting that tumor 
growth varied between conditions as the experiment progressed), systematic pairwise 
comparisons were conducted to identify which conditions were significantly different from 
each other as time progressed. Peak BLI was analyzed using Friedman test for paired 
comparisons. For GVHD scores and engraftment data were analyzed using a linear mixed 
model or a two-way RM ANOVA with main effects of condition and time as well as an 
interaction term condition*time was added into the model. A log-rank (Mantel-Cox) test was 
used for survival analysis.  
 
15. Rationale for 12-hour SMG exposure 
Exposure to SMG was limited to 12 hours. This ensured optimal viability of PBMCs after 
exposure to SMG, enabling functional analysis without viability being a confounding factor. 
While various groups have used extended exposure to SMG with the help of cytokines that 
extend viability ex vivo, this will invariably affect functionality. This could mask any effect of 
a novel stimulus like SMG on uninitiated effector immune cells.  
 
Piloting experiments in our lab showed that while human lymphocytes retained >90% viability 
up to 12 hours in SMG. Extending exposure to SMG beyond 12-hours increased the proportion 
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of lymphocytes entering early apoptosis—identified by annexin V+ve staining—indicating 
decrements in viability. Extending SMG exposure beyond 12-hours also increased proportion 
of lymphocytes entering late apoptosis/necrotic stage—identified by annexin V +ve and 
propidium iodide +ve— indicating increased plasma membrane permeability, a sign of cell 
entering the apoptotic cycle. Figure 4 shows representative flow cytometry plots of 1G control 
and SMG exposed lymphocytes after various (0, 6, 12 and 18 hours) time-periods along with 
viability graphs. Viable lymphocytes were identified within the forward and side scatter of 
lymphocyte gate within the PBMC sample and later gated on CD45+ve to exclude any large 
debris. Viability at zero hour was 98.4±0.4 (Mean±SE). After 6-hours, viability was stable in 
both 1G-control (97.4±0.27) and SMG (96.9±0.42) conditions and at 12-hours; viability was 
still comparable between 1G-control (93.4±0.63) and SMG (91.6±0.98). When exposure to 
SMG was extended to 18-hours, the viability dropped to 85.87±2.45 while 1G-control retained 
viability above 90% at 90.34±1.23. Therefore, we restricted exposure to SMG for 12-hours.   
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Figure 4 4a. Representative flow cytometry plots showing lymphocytes with annexin V/PI 
staining after exposure to 1G control (top row) and SMG (bottom row). Lower left quadrant of 
the plot shows viable cell population (annexin V –ve and PI -ve), upper left quadrant shows early 
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apoptotic cells (annexin V +ve and PI -ve), upper right quadrant shows late apoptotic cells 
(annexin V +ve and PI +ve). Figure 4b. shows average proportions of viable (left), early apoptotic 
(center) and late apoptotic (right) lymphocytes after 0, 6, 12 and 18 hours of exposure to 1G 
control (blue line) and SMG (red line).  
 
16. Preservation of PBMC subsets and NK cell proportions 
after 12-hour SMG exposure 
Proportions of major lymphocyte subsets were not altered due to differential attrition from 
exposure to SMG. Especially, the effector lymphocytes of the innate immune system crucial 
to MHC-unrestricted killing (NK cells) were not depleted in the population. T-cells appear to 
be more susceptible to entering apoptotic phase due to SMG exposure with CD3+CD4-CD8- 
(presumptive γδ-T cells) showing 9.84±4.57% Annexin V+ staining and CD3+CD4+ T-cells 
showing 2.42±1.32% entering late apoptotic phase (figure 5e. and 5f.). Viable NK cells 
(figure.5d.) after exposure to SMG (98.46±0.67, MEAN±SE) remained at levels comparable 
to both STATIC-1G (99.21±0.28) and rotational-1G (99.33±0.22) controls. While more NK 
cells entered early (1.1±0.44) and late apoptotic (0.16±0.11) stages in SMG condition 
compared to both 1G controls, the levels 1.1% and 0.16% respectively (figures 5g. and 5h.), 
are not significant enough to account for functional differences observed between the 
conditions in both in vitro and in vivo experiments. Furthermore, NK cells that have been 
exposed to SMG successfully engrafted and have undergone an in vivo expansion in NSG-
tg(hu-IL15) mice corroborating their viability.  
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Limitations of 12-hour SMG exposure 
 Short-term exposure might only reveal initial effects of SMG exposure. 
 Limited extrapolation to long-term effect of SMG in vivo. 




Figure 5. Viable total T-cells (4a.), T-helper cells (4b.), cytotoxic T-cells (4c.) and natural killer 
cells (4d.) were comparable in both 1G controls (static and rotational control) with SMG exposed 
lymphocytes. Less than 5% total T-cells entered early apoptosis and 2% of total T-cells entered 
late apoptosis (4e. and 4f.). 1.1% and 0.16% of NK cells have entered early and late apoptosis 






Effect of Simulated microgravity on expansion potential and 
function of γδ-T cells and CMV-specific T-cells. 
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1. Introduction 
Latent viral reactivation is a consistently observed phenomenon during spaceflight. 53% of 
astronauts on shuttle missions and 61% of ISS crew members have shown shedding of at least 
one latent herpes virus (Rooney et al., 2019). 61% of the ISS crew shed CMV at detectable 
levels during the mission. CMV seroprevalence in the United States is around 50% (Bate, 
Dollard, & Cannon, 2010). CMV reactivation symptoms include CMV retinitis (Port et al., 
2017), pneumonitis (Balthesen, Messerle, & Reddehase, 1993) and ulcerative colitis (Sager, 
Alam, Bond, Chinnappan, & Probert, 2015) in immune-compromised individuals. While CMV 
causes significant comorbidity in immune-compromised individuals, it does not seem to 
clinically burden immune-competent individuals (Cook, 2007).  
 
Therapeutic interventions for CMV reactivation might be ineffective at reducing morbidities 
in critically ill immune-competent individuals (Heininger et al., 2001; Jaber et al., 2005).  This 
is true in terrestrial settings. However, immune dysregulation observed during spaceflight 
combined with CMV reactivation might further incapacitate or reduce efficiency of 
crewmembers during long-duration missions. Severe CMV reactivation and its associated 
clinical symptoms could be a major medical emergency during an exploratory class mission 
with limited exploration medical capabilities (B. Crucian, Kunz, & Sams, n.d.).  
 
Control of latency of CMV infection is achieved when there is a balance between viral load 
and CMV-specific T-cells (van der Heiden, Marijt, Falkenburg, & Jedema, 2018). Successful 
control of CMV infection has been correlated with CD4+ and CD8+ CMV-specific T-cells in 
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the memory compartment (Sylwester et al., 2005). Maintenance of the CMV-specific 
repertoire in the CD8+ effector memory compartment also is needed to control CMV latency  
(Klarenbeek et al., 2012).  
Older populations show a dominance of CMV-specific T-cells in the CD8+ T-cell 
compartment underscoring the impact latent CMV infection has on the immune system (Hosie 
et al., 2017). Average age of astronaut population is 44.5 years for men and 42.5 years for 
women (Goel et al., 2014) making it pertinent to examine the effects of spaceflight on CMV-
specific T-cell compartment. Additionally, NK cell function is also important to maintain 
latency  and control CMV reactivation (Biron, Byron, & Sullivan, 1989; Polić et al., 1998). 
We have previously shown that NK cell function might be impaired in astronauts (Bigley et 
al., 2018).  
 
These concerns make CMV-specific T-cell function crucial to maintaining immune health 
during long-duration exploration class missions. However, there is lack of data on how 
microgravity affects CMV-specific T-cell expansion potential and function.  
 
Γδ-T cells possess γ and δ chains in their heterodimeric T-cell receptor, distinguishing them 
from the conventional T-cells that possess α and β chains. Γδ- T cells account for 0.5-5% of 
total T lymphocytes (Zhao, Niu, & Cui, 2018). This makes them a much smaller subpopulation 
of the lymphocytes compared to NK cells, which boast a strong contingent of 5-15% of all 
lymphocytes. However, their role in tumor transformation, especially in the early stages, is 
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being recognized owing to their tissue heterogeneity and multiple alternative pathways to 
activation (Pauza et al., 2018).  
While they can be activated through the conventional TCR-peptide-MHC interaction, they also 
possess natural killer receptors (NKRs) including activating receptors NKG2D, NKG2C, 
DNAM-1, NKp30 and NKp44 and killer inhibitory receptors (KIRs) like NKG2A, KIR2DL3 
etc. (Correia, Lopes, & Silva-Santos, 2013). The unconventional TCR’s ability to recognize 
stressed cells via pathogen associated molecular proteins (PAMPs) and the innate-like ability 
to recognize “stressed cells” without relying on MHC molecules (like NK cells) make them a 
cell population that possess features of both innate and adaptive immune system.  
 
Two major subsets of γδ-T cells: Vδ1 and Vδ2, exhibit high degree of tissue heterogeneity. 
Vδ1 γδ-T cells are mostly restricted to intra-epithelial layers, where they recognize various 
tissue stress signals like heat shock proteins and viral proteins. This makes them important to 
maintain epithelial health (Nielsen, Witherden, & Havran, 2017). Vδ2 γδ-T cells are the 
dominant subset in the peripheral blood compartment, with ability to recognize 
phosphoantigens.  Phosphoantigens are a major by-product of mevalonate pathway, which is 
considerably upregulated after malignant transformation. This makes the circulating Vδ2 γδ-T 
cells ideal to control leukemias (Pistoia et al., 2018). Subsets of γδ-T cells that possess 
immunosuppressive properties that might promote tumor progression in tumor 
microenvironment have also been studied (Fleming, Morrissey, Cai, & Yan, 2017). Their 
possession of a broad cytokine profile can also be used to compound immune responses 
(Lawand, Déchanet-Merville, & Dieu-Nosjean, 2017). All these features make γδ-T cells an 
important subset in the immune system. However, the effect of microgravity on these cells has 
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not been explored. In this dissertation, effect of simulated microgravity on CMV-specific T-




2. Experimental Design 
Hypothesis 1a2:  
To evaluate the effect of exposure to SMG on CMV-specific T-cell expansion: PBMCs from 
CMV+ve subjects—identified with CMV ELISA— were exposed to 1G-control or SMG and 
later exposed to CMV peptides and expanded using the protocol detailed earlier. The expansion 
potential of CMV-specific T-cells from being a tiny portion of the T-cells to functionally 
significant proportion of the effector-memory compartment would dictate how well a latent 
viral reactivation—like those seen in astronauts on an ISS mission—could be curtailed from 
becoming a clinical manifestation. Hence, it is pertinent to examine if a modeled short-term 
exposure to SMG might impair the expansion potential of CMV-specific cells.  Using a paired-
sampling in vitro expansion model (Figure 6) controlled for any differences in subsets and the 
maturation stages of the subsets.  The culture media was devoid of IL-15 until the first media 
change (day5) preventing growth of unwanted PBMC subsets; especially NK cells. This is to 
prevent NK-cell contamination from over-estimating killing capacity in functional assays. 
CMV-specific T-cells were enumerated using either ELISPOT or flow cytometry using IFNγ 
secretion assay.  
 
                                                 
2 “Exposure to 12-hour SMG in a RCCS impairs in vitro expansion of CMV-specific T-cells and/or γδ-T cells.” 
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Enumeration of CMV-specific T-cells: 
CMV-specific T-cells were enumerated with an ELISPOT or using the IFNγ secretion assay. 
ELISPOT was used to enumerate CMV-specific T-cells from total VST expansion product as 
well as to test the ability of immune cells exposed to SMG to recognize their cognate antigen. 
This was done a priori to performing secretion and functional assays to prevent structural 
inability of CMV-specific T-cells to recognize their antigen from confounding later analyses. 
The data is presented as CMV-specific T-cells per million T-cells. IFNγ secretion assay gating 
strategy is detailed in Figure 7. CD8 (Vioblue), CD3 (Viogreen), CD4 (FITC), propidium 
iodide (PerCP), IFNγ (APC), CD45 (APC Vio770) were used in the phenotyping panel for the 









Figure 7. Interferon-gamma secretion assay. 7a. Identification of viable lymphocytes. 7b. 
Identification of CD3+ T-cells. 10c. Identifying CD4+ and CD8+ T-cells. 7d-f. Identifying IFNγ+ 
cells in total CD3+ and CD4+, CD8+ subsets. 7g-h. Histogram overlays showing negative control, 
positive control and irrelevant peptide (MOG) stimulation control. 
 
To evaluate the effect of exposure to SMG on γδ-T cell expansion: PBMCs from healthy 
human subjects were exposed to 1G-control or SMG for 12-hours and later expanded using 
previously described ex vivo expansion protocol (Kondo et al., 2011) (Figure 8). At the end of 
the 14-day expansion, the number of γδ-T cells were enumerated on the flow cytometer. 
Phenotypic differences for major subsets of γδ-T cells (vγ9 vδ2 and vγ9 vδ1) along with 
differences in major activating and inhibitory receptors were measured on flow cytometer 
using the phenotyping panel in Table 1. Detailed expansion protocol is mentioned earlier.  
Table 1. γδ-T cell phenotyping panel. 




Panel 1 CD8 CD3 vγ9 vδ2 CD4 CD45 - vγ9 vδ1 CD56 
Panel 2 CD16 CD3 - NKG2D PD-1 CD158b NKG2A TCR-γδ 





To evaluate the immediate effect of exposure to SMG on CMV-specific T-cell function: cells 
that were expanded in 1G and were later exposed to SMG at the end of expansion were used 
in a 4-hour PHA blast cytotoxicity assay detailed earlier. Conversely, to evaluate the residual 
effects of exposure to SMG on CMV-specific T-cells, much akin to the design mentioned in 
γδ-T cell experiments, CMV-specific T-cells that were exposed to SMG and later expanded in 
1G were stimulated with CMV peptides and their cytotoxicity against autologous PHA blasts 
was measured. 
To evaluate the immediate effect of  exposure to SMG on cytotoxicity of γδ-T cells: cells that 
were expanded in 1G and were later exposed to SMG at the end of the 14-day expansion, were 
co-incubated with chronic myeloid leukemia (K562) and multiple myeloma (U266) cell lines 
in a 4-hour killing assay. Conversely, to evaluate the residual effects of exposure to SMG on 
γδ-T cell function: γδ-T cells that were exposed to SMG and later expanded in 1G for 14-days 
were co-incubated with K562 and U266 in a 4-hour killing assay detailed earlier. The latter 
would identify any long-term residual effects of exposure to SMG, since the 14-day expansion 
in 1G would accommodate for any reparative cellular processes. Therefore, functional 
differences would be representative of any residual detrimental effects of SMG that were 
sustained after the 14-day expansion. 
                                                 
3 “Exposure to 12-hour SMG in a RCCS impairs in vitro function of CMV-specific T-cells and/or γδ-T cells.” 
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3a. Exposure to 12-hour SMG in a RCCS impaired in vitro expansion of 
CMV-specific T-cells 
Exposure to SMG impaired the ability of CMV-specific T-cells to expand compared to both 
1G-exposed controls (RM ANOVA, F(1.571, 6.283)= 8.367, p=0.0198). 10-million PBMCs 
at day1 of the expansion in SMG-exposed condition yielded 17.63±3.75 million 
(MEAN±SEM, N=5) CMV-specific T-cells at the end of the expansion. In comparison, 
STATIC-1G control cells expanded to 33.8±7.57 million, while 1G-rotational control exposed 
cells expanded to 28.32±7.21 million cells (Figure 9).  
 
ELISPOT enumeration of the number of CMV-specific T-cells per million T-cells using 
ELISPOT also showed that SMG-exposure did not impair their ability to later expand and 
detect antigens compared to 1G-control (paired t test, t(3)=1.543, p=0.22). SMG exposed 
PBMCs contained 4654±2397 (N=4, MEAN±SEM) CMV-peptide detecting VSTs per 1 
million CD3+ T-cells while 1G-control PBMCs contained 1062±465 CMV-peptide detecting 
VSTs (Figure 10).  
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Figure 9.  Exposure to SMG suppressed CMV-specific T-cell ability to expand in a 14-day 
expansion. N=5, MEAN±SEM, RM ANOVA, p=0.0198. 
 
Figure 10. Exposure to SMG did not hinder CMV-specific T-cells’ ability to detect CMV peptides 
later.  N=4, MEAN±SEM, paired t test, p=0.22. 
71  
3b. Exposure to 12-hour SMG in a RCCS impaired in vitro expansion of 
γδ-T cells. 
Exposure to SMG impaired the ability of γδ-T cells to expand compared to 1G-control 
(Wilcoxon signed ranks test, p=0.039). 10 million PBMCs at day 1 of the expansion in SMG-
exposed condition yielded 102.3±23.07 million (MEAN±SEM, N=9) γδ-T cells at the end of 
the expansion. In comparison, 1G-control PBMCs yielded 113.7±23.91 million γδ-T cells 
(Figure 11). 
                               
Figure 11. Exposure to SMG suppressed naïve γδ-T cell ability to expand in a 14-day expansion. 




3c. Exposure to 12-hour SMG in a RCCS did not impair in vitro function 
of CMV-specific T-cells. 
In vitro function of CMV-specific T-cells was measured as cytotoxicity against autologous 
PHA blasts generated from the donor’s PBMCs (Figure 12). 
 
Exposure to SMG did not impair CMV-specific T-cell ability to kill target cells compared to 
1G and 1G-rotational control (RM ANOVA, F(1.357,12.21)=0.7434, p=0.4457). 100,000 
cytotoxic (CD8+) CMV-specific T-cells exposed to SMG at the end of expansion killed 
804.6±166.3 (MEAN±SEM, N=10) autologous PHA blasts pulsed with CMV peptides. In 
comparison, 1G-control and 1G-rotational control killed 909.2±160.6 and 669.7±125 PHA 
blasts respectively (fig. 12d). 
 
To examine the residual effects of exposure to SMG on CMV-specific T-cell function, PBMCs 
were exposed to SMG and CMV-specific T-cells were later expanded in 1G. Cytotoxic activity 
was measured in the expanded product. Exposure to SMG did not impair CMV-specific T-cell 
ability to later expand and kill target cells in 1G (RM ANOVA, F(1.976,17.78)=3.875, 
p=0.04). While the overall model was significant, post-hoc analysis using Tukey’s multiple 
comparisons test, showed SMG exposed CMV-specific T-cells that were later expanded in 1G 
killed more target cells compared to 1G-rotational control (p=0.039) but not 1G-control 
(p=0.36). 100,000 cytotoxic (CD8+) CMV-specific T-cells exposed to SMG and later 
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expanded in 1G killed 948.3±154.1 (MEAN±SEM, N=10) autologous PHA blasts pulsed with 
CMV peptides. In comparison, 1G-control and 1G-rotational control killed 770.5±152.8 and 
616.5±135.1 PHA blasts respectively (fig. 12c). 
 
Figure 12. CMV-specific T-cell cytotoxicity assay. 12a-b. shows CMV-specific T-cells’ 
cytotoxicity against autologous PHA blasts when left unpulsed, pulsed with irrelevant peptide 
(MOG), or pulsed with CMV peptides (IE1+pp65). 12c. shows CMV-specific T-cells’ cytotoxicity 
after being exposed to SMG and later expanded in 1G. SMG>1G-rotational control, p=0.039, 
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N=10, MEAN±SEM. 12d. Shows CMV-specific T-cells’ cytotoxicity after being expanded in 1G 
and later exposed to SMG. N=10, MEAN±SEM. 
 
3d. Exposure to 12-hour SMG in a RCCS did not impair in vitro function 
of γδ-T cells. 
Γδ-T cell function was measured against two target cell lines: chronic myeloid leukemia 
(K562) and multiple myeloma (U266) (Figure 13).  
 
To estimate the effect of exposure to SMG, γδ-T cells that were expanded in 1G were exposed 
to SMG at the end of the 14-day expansion. SMG exposed γδ-T cells lysed 18.9±4.25% 
(MEAN±SEM, N=9) of k562 target cells while 1G-control γδ-T cells lysed 19.44±4.5% of 
them (paired t-test, t(8) =0.5032, p=0.628) (fig. 13f). SMG exposed γδ-T cells lysed 
21.41±1.92% (MEAN±SEM, N=9) of U266 target cells while 1G-control γδ-T cells lysed 
21.08±2.76% of them (paired t-test, t(8) =0.1479, p=0.886) (fig. 13g).  
 
To estimate the residual effect of exposure to SMG, γδ-T cells that were exposed to SMG and 
later expanded in 1G for 14-days were used in the killing assays. SMG exposed γδ-T cells 
lysed 16.44±2.67% (MEAN±SEM, N=9) of k562 target cells while 1G-control γδ-T cells lysed 
13.11±2.23% of them (paired t-test, t(8) =1.489, p=0.174) (fig. 13d). SMG exposed γδ-T cells 
lysed more U266 cells than 1G-control γδ-T cells. Interestingly, SMG-exposed γδ-T cells 
killed more U266 cells than 1G-exposed γδ-T cells. While SMG-exposed γδ-T cells lysed 
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23.06±2.86% (MEAN±SEM, N=9) of U266 target cells, 1G-control γδ-T cells lysed only 
18.09±2.26% of them (paired t-test, t(8) =2.405, p=0.042) (fig. 13e).  
 
3e. Exposure to 12-hour SMG preserved major subset proportions during a 
γδ-T cell expansion but induced minor phenotypic changes. 
Both conditions showed high purity of γδ-T cells in the expansion product with 96.48±0.67% 
(MEAN±SEM, N=8) of SMG condition and 95.16±1.5% of the 1G-control condition were 
identified as γδ-T cells (CD3+ γδ+). Majority of the γδ-T cells were Vγ9Vδ2+ with 
87.83±3.16% in the SMG condition and 86.45±3.93% in 1G-control staining +ve for it. NK 
cell contamination remained low with 2.72±1.49% in the SMG condition and 2.26±0.76% in 
1G staining +ve for NK cells (CD3-CD56+). Marginal downregulation of inhibitory receptor 
CD158b+ (KIR2DL2+) with 27.38±4.36% in 1G-control and 25.81±4.18% in SMG was the 
only significant phenotypic difference between the conditions (paired t-test, t(7)=2.693, 
p=0.03).  Complete phenotyping shifts are shown in Figure 14.  
 
To estimate the effects of exposure to SMG on γδ-T cells that were expanded in 1G, γδ-T cells 
that were expanded in 1G were exposed to SMG at the end of the expansion. Further 
downregulation of inhibitory receptor CD158b+ (KIR2DL2+) was evidenced with only 
22.37±3.97% expressing it after exposure to SMG compared to 23.59±4.06% in 1G-control. 
This downregulation trended towards significance (paired t-test, p=0.05). Upregulation of 
activating receptor NKG2D was observed with 37.89±7.76% in 1G-control to 48.87±7.15% in 
SMG condition expressing it (Wilcoxon matched-pairs signed rank test, p=0.0078). Similar 
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upregulation of Vγ9Vδ1+ γδ-T cells from 1.26±0.59 to 2.51±1.09% was observed (Wilcoxon 




Figure 13. Effect to SMG did not suppress γδ-T cell function. Flow cytometry based killing assay 
was used to evaluate the function of γδ-T cells (13a-c). Exposure to SMG did not suppress γδ-T 
cell ability to kill target cells (13f and 13g). N=9, MEAN±SEM, paired t-test, p=0.63 (K562), 
p=0.88 (U266). Exposure to SMG and later expanding in 1G did not suppress γδ-T cell ability to 
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kill target cells (13d and 13e). N=9, MEAN±SEM, paired t-test, p=0.17 (K562), p=0.04 (U266). 






Figure 14. Exposure to SMG did not alter γδ-T cell phenotype in the expanded product at the 
end of 14-day expansion. γδ-T cell (14a), vγ9vδ2 (14b.), vγ9vδ1 (14c.), NKG2D+ (14d.), NKG2A 
(14e.), NKp30 (14g.) proportions did not change significantly. Inhibitory receptor CD158b+ 
(14h.) was significantly downregulated in the expanded product after exposure to SMG (paired 






Figure 15. Exposure to SMG induced minor γδ-T cell phenotype changes when 1G-expanded 
product was exposed to SMG at the end of 14-day expansion. γδ-T cell (15a), vγ9vδ2 (15b.), 
NKG2A (14e.), NKp30 (14g.) proportions did not change significantly. Activating receptor 
NKG2D+ (15d.) was upregulated (Wilcoxon matched-pairs signed rank test, p=0.0078). Vγ9vδ1 
(15c.) subset showed higher proportions after exposure to SMG (Wilcoxon matched-pairs signed 




A significant proportion of effector memory CMV-specific T-cells in CD8+ T-cell 
compartment has been shown to be beneficial and necessary to control CMV latency. In 
addition, expanding from smaller proportions to occupy significant portions of the T-cell 
compartment is vital to control reactivation. This ability becomes important in spaceflight 
where increased psychological and physiological stress in confluence with various other 
detrimental factors might threaten a full-blown CMV reactivation in crewmembers on an 
exploratory mission. Therefore, we examined the effect of exposure to short-term SMG on the 
expansion potential of CMV-specific T-cells.  
 
The expansion potential of SMG exposed CMV-specific T-cells was suppressed compared to 
both 1G-controls. At day 14 after exposure to SMG, 10million PBMCs yielded 16 and 10 
million fewer CMV-specific T-cells compared to 1G and 1G-rotational controls respectively. 
This suggests viral specific T-cells are susceptible to the dampening effects of SMG on 
immune cells. 
Hypothesis 1a regarding CMV-specific T cells holds true that exposure to 12-hour SMG in a 
RCCS impaired in vitro expansion of CMV-specific T cells. 
 
There exists wide variation in subsets and maturation phenotypes specific to CMV in the 
circulating blood of individuals. This could vary by age, and other characteristics including 
general immune health and stress levels of the individual during the time of blood draw.   This 
undoubtedly affected the total number of cells in the final expansion product between subjects. 
Normalization to total CMV-specific viral T-cells was possible due to IFNγ secretion assay 
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performed at the end of the expansion facilitating enumeration of CMV-specific T-cells in the 
expansion product. Additionally, using a paired sample experimental design from the same 
subject controlled for inter-subject variability. Enumeration of CMV-specific T-cells was not 
performed on PBMCs collected from the subjects at Day 0. The underlying assumption being 
that there would be similar proportions of CMV-specific T-cells in 1G-control and SMG-
exposed PBMCs at the beginning of the expansion. However, this remains a limitation of these 
experiments. Furthermore, it is unlikely that SMG exposure preferentially depletes viral-
specific T-cells from the PBMCs. 
CMV-specific T-cells appear to retain their ability to recognize CMV-peptides when presented 
by antigen presenting cells and then proceed to lyse the cells. Hence, hypothesis 1b. regarding 
CMV-specific T-cells is disproved. 
 
There was also high variability in both peptide recognition per 106 T-cells in ELISPOT data 
and number of target cells killed per 105 CMV-specific CD8 T-cells in the cytotoxicity data. 
This can also be attributed to variability in various effector and secretory phenotypes of the 
CMV-specific T-cell repertoire in the peripheral compartment of the individuals. 
 
Short-term immune health also influences the proportion and type of CMV specific T-cells 
deployed in the peripheral blood compartment. Therefore, further studies on physiological 
responses of immune system to the stress and stimulus of spaceflight in the CMV T-cell 
repertoire would benefit the understanding of the magnitude of risk posed by latent viruses 
during long duration spaceflight.  
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Past evidence shows spaceflight alters secretory profile of CD4 T-cells towards a TH2-cytokine 
shift. There was also a reduction in levels of IL-2 and IFNγ-secreting CD4+ and CD8+ T-cells 
upon return from both Shuttle and ISS missions (B. E. Crucian, Stowe, Pierson, & Sams, 
2008a).  Functional assays in this dissertation focused on cytotoxic (CD8+) CMV-specific T-
cells. How SMG effects secretory profile of CMV-specific CD4 T-cells remains to be explored 
in future studies.  
 
In summary, SMG impairs expansion of CMV-specific T-cells while not affecting their ability 
to recognize and lyse target cells. Future studies should evaluate the effect of SMG on CD4+ 
T-cell function while also estimating the systemic effect of spaceflight on CMV immune-
surveillance and latency control. 
 
Γδ-T cells’ ability to expand from a small proportion of T-cells to relatively large numbers 
when detecting phosphoantigens remains an early design in the adaptive immune system to 
curtail hematological malignancies at early stages. This function is crucial during spaceflight, 
since tumor transformation in hematopoietic system is a known risk due to space radiation. Γδ-
T cells can work in conjunction with NK cells to curtail any tumor transformation in early 
stages before adaptive immune system could be geared up. Therefore, we examined the 
expansion potential of γδ-T cells after being exposed to SMG. 
 
The expansion potential of SMG exposed γδ-T cells appears to be lagging behind 1G-control. 
At day 14 after exposure to SMG, there were 11million more γδ-T cells in 1G-control 
condition. This accounted for 10% fewer γδ-T cells in SMG condition. Hypothesis 1a 
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regarding γδ-T cells holds true that exposure to 12-hour SMG in a RCCS impaired in vitro 
expansion of γδ-T cells. 
 
Their ability to expand could be recovering over a 14-day expansion in our experimental 
design. This might be due to the exposure to SMG being limited to 12-hours while the rest of 
the 14-day expansion occurs in 1G. It would be worthwhile to investigate whether they expand 
as well when the expansion occurs in microgravity over extended periods. While the expansion 
potential of SMG exposed cells appears to be lagging behind 1G-control; their ability to expand 
seems to recover over a 14-day expansion. An interesting question would be to investigate 
whether they expand as well when the expansion occurs in microgravity. 
 
Another major risk with space radiation are epithelial tumors due to high turnover rates in 
epithelial cells. Vγ9Vδ1 subset of γδ-T cells reside in the intraepithelial chambers of gut 
mucosa, and skin and detect stress ligands (PAMPs). This expansion protocol was primed to 
expand Vγ9Vδ2 subset of γδ-T cells, which primarily exist in the vascular compartment.  
Future studies could look at the specific effect of SMG exposure on tissue vigilance of Vγ9Vδ1 
cells. 
 
Γδ-T cell function appears to be sustained after exposure to SMG. Their alternative activation 
mechanisms might be the reason behind their resistance to SMG-induced suppression in 
functionality. While immediate exposure to SMG did not appear to affect γδ-T cell function 
(figures 13f. and 13g.), pre-expansion exposure to SMG appears to have increased γδ-T cell 
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function. While there was non-significant increase in specific lysis against chronic myeloid 
leukemia (K562) cells (fig.13d), there was a significant increase in killing against multiple 
myeloma (U266) cells (fig. 13e). This could be explained by minor downregulation of 
inhibitory receptor CD158b+ expressing γδ-T cells (fig.14h). 
Immediate changes in γδ-T cell receptor phenotype included upregulation of activating 
receptor NKG2D (fig.15e) and a trend towards further downregulation of inhibitory receptor 
CD158b+ (fig.15h). However, these changes did not translate to any functional differences in 
killing assays possibly due to the minute effect sizes of these changes and their resultant effect 
on γδ-T cell function. It is also possible that there was a saturation of NK receptor signaling 
that determines γδ-T cell response. Further increase in function might need alternative 
activating and killing mechanisms. In summary, single exposure to 12-hour SMG in a RCCS 
does not impair in vitro function of γδ-T cells disproving hypothesis 1b regarding γδ-T cells. 
 
NK cells appear to be more susceptible to SMG-induced suppression in function as previously 
reported (Mylabathula et al., 2020). NK cell killing is restricted by the balance between 
activating/inhibitory signals from the NK-cell receptors. This determines the outcome of an 
interaction with a suspicious cell. Fortunately, γδ-T cells have alternative γδ-TCR-peptide-
MHC interaction in addition to NK-cell receptor signaling, which supplements the decision-
making.  
In summary, SMG impairs γδ-T cell expansion while not hindering γδ-T cell function. Future 
studies should evaluate the effect of Vγ9Vδ1 subset of γδ-T cell function along with their 









NK cells are crucial subset of innate immune system that specialize in identifying tumor 
transformed cells and virus-infected cells. They rely on their activating and inhibitory signals 
and their interaction with MHC class Ⅰ molecules to identify erratic cells in our body (Orr & 
Lanier, 2010; Topham & Hewitt, 2009). MHC receptor signal perturbations are one of the early 
signs of tumor transformation or viral infection of a cell (Garcia-Lora, Algarra, & Garrido, 
2003; Hewitt, 2003). Therefore, NK cells have been ascribed the role of preventing tumor 
transformation and controlling tumor growth in early stages. We have previously shown that 
NK cells kill 50% fewer target cells in vitro after exposure to SMG for 12-hours (Mylabathula 
et al., 2020). Fewer NK cells expressed perforin and granzyme B. They also showed lower 
levels of degranulation and effector cytokines (TNFα and IFNγ) production when encountering 
target cells. Furthermore, cancer cells (K562) did not show any changes in susceptibility to 
NK cell killing. This suggests that while innate immune cells might be disarmed by 
microgravity, tumor cells might exhibit a certain level of resistance to the detrimental effects 
of microgravity. This might tip the scale in favor of tumorigenesis in spaceflight, especially 
when increased exposure to stimuli like space radiation is taken into account.  
 
While in vitro experiments help us to evaluate immune cell function in a strictly controlled 
environment, translating this to an in vivo setting will help us to estimate the effect of any 
stimulus in a physiologically more relevant environment. Additionally, the true magnitude of 
impairment of immune cell’s efficacy after exposure to microgravity will be better estimated 
in an in vivo model. In addition to function, these models could test an immune cell’s 
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surveillance, homing, extravasation, tumor-infiltration properties which are all crucial to 
prevent disease and prolong health. 
 
Therefore, this dissertation examined if the impairment of in vitro NK cell function after 
exposure to SMG will also extend to an in vivo model. We used immunocompromised NSG-
tg(hu-IL15) mice engrafted with chronic myeloid leukemia (K562) and evaluated the 
differences in tumor growth control between human immune cells that have been exposed to 
either 1G or simulated microgravity. 
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2. Experimental Design 
To evaluate tumor growth control of primary human NK cells, we optimized the model to 
prevent the effect of other immune cells from modulating the tumor growth. Most of the anti-
tumor activity in naïve PBMCs can be approximated to NK cells (Kandarian, Sunga, Arango-
Saenz, & Rossetti, 2017). Moreover, using PBMCs for in vitro cytotoxicity assays provides 
better estimation of in vivo activity since NK cells do not act as an isolated group of cells in 
the body (Park et al., 2013; Sierich & Eiermann, 2013).  
 
Initial experiments showed that around day 28 (4weeks) after injection with 10 million 
PBMCs, the mice showed signs of moderate GVHD. The signs commonly included hunched 
posture indicating intestinal distress, ruffled fur and naked/scaly skin indicating distress of 
skin, reduced activity indicating general malaise, and occasional diarrhea. Another sign 
included weight loss. Weight loss of more than 10% initial weight was evaluated as a 
GVHD/morbidity score of 1. Weight loss greater than 20% indicated that the mouse has 
reached sacrificial criteria in accordance with our IACUC guidelines. Since GVHD has known 
immune-modulatory effects, we stopped estimating anti-leukemia activity after moderate 
GVHD set in. This was a GVHD score of 4 or 5 within a total possible score of 10.  
 
‘TUMOR control’ mice, which did not receive human immune cells, were piloted to study 
unrestrained tumor growth dynamics. Using 1 million K562 cells tagged with luciferase 
initially showed luminescence levels at 1-8e6 photons/sec during the first week. After some 
minor fluctuations, there was a steady exponential growth in tumor burden represented by in 
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vivo bioluminescence intensity (BLI) (measured in photons/second). Tumor bioluminescence 
reached saturation levels of 1e10 to 1e11 around 6 weeks after tumor cells injection. 
 
Therefore, the experiment was designed for a duration of 6 weeks, with human PBMCs 
injected one week after tumor cells injection. This allowed time for the tumor cells to be 
established in the animal’s body. Their growth, in the presence of human immune cells, was 
monitored via bioluminescent imaging. Any reduction in bioluminescence compared to 
‘TUMOR control’ can be attributed to anti-leukemia activity of effector cells in the PBMCs. 
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Figure 16. Experimental design for AIM 2. 
Hypothesis 24: NSG-tg(hu-IL15) mice were injected with 1 million luciferase-labelled human 
leukemia cells (K562) and one week later 1 million human PBMCs exposed to SMG, rotational 
control and STATIC conditions were engrafted into the mice. Anti-leukemia activity was 
measured as reduction in bioluminescent intensity (BLI) score in comparison to ‘TUMOR 
control’ mice. 1G-control and SMG conditions were compared within each experiment that 
had PBMCs from the same human participant controlling for differences in immune cell 
subsets. They also received same batch of K562 controlling for differences in tumor growth 
                                                 
4 Exposure to 12-hour SMG in a RCCS adversely affects anti-leukemia activity of human immune cells in vivo 
by impairing their ability to control tumor growth in a NSG-tg(hu-IL15) mice model. 
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due to viability and number of passages in cell culture. Experiment was ended when severe 
GVHD starts setting in (composite GVHD score≥4). This was done to prevent 
immunomodulatory effects of GVHD from making it complicated to evaluate the in vivo anti-
leukemia activity of effector lymphocytes. Separate mice with PBMCs only and without k-
562-luc2 tumor were used to check for engraftment levels amongst the conditions to prevent 
different levels of lymphocyte engraftment being a confounding factor. This enabled us to 
determine if SMG exposed lymphocytes have diminished survival in vivo. Timeline of tumor 
and PBMC injections (figure 16): One million K-562-luc2 cell were administered 
intravenously via a tail vein injection after irradiating the mice with 100cGY using a cesium-
32 irradiator on the previous day. One week later, normal saline (TUMOR control) or 
10million PBMCs from respective conditions (1G-CONTROL or SMG) were injected into the 
mice. Progression of tumor was monitored after injecting 200μl of luciferin (15mg/ml) intra-
peritoneally. Mice were anesthetized with 2% isoflurane and BLI scores (photons/second) 
were obtained using LagoX spectral imager. 
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Figure 17 Experimental design for AIM 3. 
Hypothesis 35: In an attempt to improve immune-function in SMG-exposed PBMC group, 
ZOL (50µg/kg) intraperitoneally (Ottewell et al., 2008) and IL-2 (40,000 I.U.) subcutaneous 
(Himizu, Ields, & Iedlin, 1999) were administered once/week (figure 17).  
                                                 
5 Systemic administration of ZOL+IL-2 will boost the in vivo anti-leukemia capacity of human immune cells in 
an NSG-tg(hu-IL15) mice model and/or in an in vitro model. 
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For hypotheses 2 and 3, Bioluminescent imaging (BLI) score (photons/second) which is a 
measure of tumor burden was used as dependent variable with onset of severe GVHD and 





3a. Exposure to SMG impaired anti-leukemia activity of human immune 
cells in vivo. 
Tumor growth control was compared between mice that were injected with PBMCs exposed 
to SMG (TUMOR+SMG PBMCs) or 1G-control (TUMOR+1G PBMCs) to evaluate the effect 
of SMG on anti-leukemia activity of human immune cells in vivo. TUMOR control was used 
as a reference for unrestrained tumor growth. Representative BLI images showing tumor 
dynamics in vivo are shown in Figure 18. A mixed effects model was used to analyze BLI 
scores with ‘condition’ (TUMOR control, TUMOR+SMG PBMCs, TUMOR+1G PBMCs) 
and ‘time’ as main effects and an interaction term ‘condition*time’ in the model.  
 
Time, condition and time*condition effects were all statistically significant (p<0.0001) 
(fig.19a). Significant interaction effect suggested that ‘tumor burden’ grew differentially over 
time in different conditions. A pairwise comparison indicated that there was significant 
interaction (p<0.0001) between TUMOR+1G PBMCs and TUMOR+SMG PBMCs revealing 
that 1G-exposed PBMCs controlled tumor growth better than SMG-exposed PBMCs. There 
was also significant interaction  (p<0.0001) between TUMOR+1G PBMCs and TUMOR 
control conditions as expected showing 1G-exposed PBMCs ability to control tumor growth. 
Interestingly, there was no interaction (p=0.082) between TUMOR+SMG PBMCs and 
TUMOR control, showing that while SMG-exposed PBMCs might have shown some anti-
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leukemia activity, the tumor burden in mice with SMG-exposed PBMCs was not curtailed 
significantly compared to mice that only received tumor. 
 
Peak BLI reached during the experiment was also compared between the conditions using 
matched pairs non-parametric Friedman test (fig.19b). After a significant effect in the model 
(p=0.0018), a post-hoc comparison was performed. Dunn’s multiple comparison test revealed 
that TUMOR+1G PBMCs reached a significantly lower BLI score during the experiment 
compared to both TUMOR control (p=0.003) and TUMOR+SMG PBMCs (p=0.013). 
TUMOR+SMG PBMCs did not show a lower peak BLI during the experiment compared to 
TUMOR control (p>0.99) further emphasizing SMG-exposed PBMCs inability to control 
tumor growth.  
 
3b. Exposure to SMG did not alter survival in mice injected with SMG 
PBMCs. 
To ensure differential survival was not a confounding factor between the conditions over time, 
a survival analysis was done.  . A log-rank (Mantel-Cox) test was used for survival analysis. 
As expected, survival did not significantly differ between conditions (χ2=2.934, p=0.231) (fig. 
19c). 
 
During the 6 weeks duration of the experiment, there were more deaths in TUMOR control 
(deaths=4) compared to both TUMOR+SMG PBMCs (deaths=3) and TUMOR+1G PBMCs 
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(deaths=1) among 12 mice in each group. Most of the deaths occurred in the later part of the 
experiment in correspondence with tumor burden.  
 
3c. Exposure to SMG did not alter GVHD/morbidity severity. 
The duration of the experiment was limited to 6 weeks to prevent differential survival and 
GVHD from confounding the analysis. GVHD/morbidity onset, progression, and severity were 
monitored between both conditions that received PBMCs. A linear mixed model was used to 
analyze GVHD scores overtime with ‘condition’ (TUMOR control, TUMOR+SMG PBMCs, 
TUMOR+1G PBMCs) and ‘time’ as main effects. An interaction term ‘condition*time’ was 
also introduced into the model. 
 
Significant time effect was observed as GVHD/morbidity scores grew overtime (p<0.0001). 
Neither ‘condition’ (p=0.764) nor ‘condition*time’ (p=0.981) were significant showing that 
onset, progression and severity between the groups did not differ over time (fig. 19d).  
 
3d. Exposure to SMG did not impair human immune cell engraftment in 
vivo. 
To verify that exposure to SMG did not impair PBMCs’ ability to thrive later in a xenograft; 
mice were injected only with PBMCs without tumor. Engraftment was measured as a 
proportion of CD45human+ (CD45h+) cells in total immune cells in mice blood. SMG did not 
alter engraftment dynamics of PBMCs (figure 21).  
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A linear mixed model was used to analyze engraftment overtime with ‘condition’ (TUMOR 
control, TUMOR+SMG PBMCs, TUMOR+1G PBMCs) and ‘time’ as main effects. An 
interaction term ‘condition*time’ was also introduced into the model. No significant 
differences were observed between groups in engraftment of human immune cells (CD45h+%, 
p=0.175) (CD45h+ cells/uL, p=0.628) (fig. 21a, 21c.) and NK cells (CD45h+ CD3- CD56+%, 
p=0.219) (CD45h+ CD3- CD56+ cells/μl, p=0.478) (fig. 21b, 21d.). Initial weeks showed high 
NK cell proportions in blood, with 25.85% in SMG-exposed PBMCs and 23.86% in 1G-
exposed PBMCs of the CD45h+ cells being NK cells. Engraftment rose steadily as the 
experiment progressed with NK cell proportions decreasing as a total proportion of CD45h+ 
cells. NK cell proportions reached 3.94% in SMG-exposed PBMCs and 1.49% in 1G-exposed 
PBMCs at week 5. Similar human immune cell engraftment dynamics were observed in mice 
that had tumor (figure 20).  
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Figure 18.  Bioluminescent intensity (BLI) images. Days 1, 12, 19, 22 and 28 of the experiment. 





Figure 19. Effect of SMG on effector immune cell function in vivo. Exposure to SMG impaired 
effector immune cell ability to control tumor growth in an in vivo model (19a.) (****=p<0.0001). 
Exposure to SMG also significantly increased peak BLI score during the experiment (19b.) 
(* denotes p<0.05, ** denotes p<0.01). Exposure to SMG did not affect survival (19c.) and GVHD 




Figure 20. Effect of exposure to SMG on human cell engraftment dynamics in vivo in the presence 
of tumor. Exposure to SMG did not impair human PBMCs’ (20a., 20c.) and NK cells’ (20b., 20d.) 






Figure 21. Effect of SMG on human cells engraftment in vivo in the absence of tumor. Exposure 
to SMG did not impair human PBMCs’ (21a., 21c.) and NK cells’ (21b., 21d.) ability to thrive in 





3e. Zoledronic acid and IL-2 therapy improved anti-leukemia activity of 
human immune cells in vivo. 
In an attempt to boost anti-leukemia activity, ZOL+IL2 therapy was administered to a group 
of mice that were injected with TUMOR+SMG PBMCs. A mixed effects model was used to 
analyze BLI scores with ‘condition’ (TUMOR control, TUMOR+ZOL+IL2 control, 
TUMOR+1G PBMCs, TUMOR+SMG PBMCs, TUMOR+SMG PBMCs+ZOL+IL2) and 
‘time’ as main effects and an interaction term ‘condition*time’ in the model. 
 
Time (p<0.0001), condition (p=0.0006) and time*condition (p<0.0001) effects were all 
significant (fig. 22a) in the complete model. A pairwise comparison indicated that there was 
significant interaction (p=0.0004) between TUMOR+SMG PBMCs and TUMOR+SMG 
PBMCs+ZOL+IL2 revealing that administration of ZOL+IL2 improved control of tumor 
growth rate in PBMCs exposed to SMG.  TUMOR+SMG PBMCs+ZOL+IL2 did not show an 
interaction effect with TUMOR+1G PBMCs (p=0.567) revealing that ZOL+IL2 
administration enabled SMG-exposed PBMCs to control tumor growth rate as efficiently as 
1G-exposed PBMCs. There were no significant differences in condition (p=0.947) or time 
(p=0.221) between these groups further showing that tumor control patterns were similar 
between the groups. 
TUMOR+1G PBMCs, TUMOR+SMG PBMCs+ZOL+IL2 showed significant interaction with 
TUMOR control (both p<0.0001) showing they effectively controlled tumor growth, while 
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TUMOR+SMG PBMCs did not show significant interaction with TUMOR control (p=0.381) 
following the pattern seen in previous experiment, showing SMG-exposure impaired anti-
leukemia activity of human immune cells. TUMOR+SMG PBMCs also showed significant 
interaction (p<0.0001) with TUMOR+1G PBMCs, also following the pattern seen in previous 
experiment. TUMOR control and TUMOR+ZOL+IL2 showed no differences between groups. 
Neither condition (p=0.635) nor interaction (p=0.924) were significant between the groups, 
showing that administration of ZOL+IL2 did not alter tumor growth pattern in the absence of 
human PBMCs. 
 
Peak BLI reached during the experiment was also compared between the conditions using 
matched pairs non-parametric Friedman test (fig.22b). After a significant effect in the model 
(p=0.0076), a post-hoc comparison was performed. Dunn’s multiple comparison test revealed 
that TUMOR+1G PBMCs reached a significantly lower BLI score during the experiment 
compared to TUMOR+ZOL+IL2 (p=0.027). No other post-hoc comparisons were significantly 
different from each other. 
 
3f. Zoledronic acid and IL-2 therapy did not alter survival. 
ZOL+IL2 therapy did not alter survival (χ2=2.429, p=0.6575) (fig. 22b). TUMOR control had 
one death (1/4) during the experiment. ‘TUMOR+SMG PBMCs+ZOL+IL2’ group had one 
death (1/5) during the experiment compared to TUMOR+1G PBMCs and TUMOR+SMG 
PBMCs groups, which had no deaths.  
 
107  
3g. Zoledronic acid and IL-2 therapy did not alter GVHD/morbidity 
severity. 
Administration of ZOL+IL2 therapy did not alter the onset, severity, and progression of 
GVHD/morbidity (p>0.999) (fig. 22c). 
 
3h. Zoledronic acid and IL-2 therapy did not alter levels of NK and γδ-T 
cells in blood. 
To examine if ZOL+IL2 therapy increased blood levels of NK cells and γδ-T cells, engraftment 
checks were done weekly similar to the previous experiment. ZOL+IL2 therapy did not alter 
engraftment dynamics of PBMCs (figure 23). A mixed effects model was used to analyze 
engraftment overtime with ‘condition’ (TUMOR control, TUMOR+SMG PBMCs, 
TUMOR+1G PBMCs) and ‘time’ as main effects. An interaction term ‘condition*time’ was 
also introduced into the model. ZOL+IL2 therapy did not alter engraftment dynamics of total 
human immune cells (CD45h+%, p=0.713) (CD45h+ cells/uL, p=0.419) (fig. 23a, 23b), NK 
cells (CD45h+ CD3- CD56+%, p=0.99) (CD45h+ CD3- CD56+ cells/uL, p=0.941) (fig. 23c, 
23d), or γδ-T cells (CD45h+ CD3+ γδ-TCR+%, p=0.915) (CD45h+ CD3+ γδ-TCR+ cells/uL, 
p=0.40.937)  (fig. 23e, 23f). ZOL+IL2 therapy showed non-significant increase in NK cells 
and γδ-T cell proportions and absolute counts throughout the experiment hinting at improved 






Figure 22. Effect of zoledronic acid+IL2 (ZOL+IL2) therapy on SMG induced suppression of in 
vivo anti-leukemia activity. ZOL+IL2 therapy abrogated SMG induced loss of anti-leukemia 






Figure 23. Effect of SMG and ZOL+IL2 therapy on human cells engraftment in vivo in the 
presence of tumor. ZOL+IL2 therapy did not alter human PBMCs’ (23a., 23b.) and NK cells’ 





The main aim of this dissertation was to examine if suppression in NK cell function due to 
SMG exposure (previously observed in vitro) would translate into an in vivo setting. In a 6-
week experimental model to estimate in vivo function, anti-leukemia activity was evaluated as 
reduction in bioluminescence intensity compared to mice that have been injected with only 
tumor cells. The main result reported here is that impairments in effector lymphocyte anti-
leukemia activity extend to in vivo setting. 
 
SMG-exposed PBMCs showed impaired anti-leukemia activity in vivo, as evidenced by poor 
control of tumor growth rate compared to SMG-exposed PBMCs. TUMOR+SMG PBMCs 
mice showed tumor burden increase at the same rate as TUMOR control resulting in same 
aggregate tumor levels (1e10-1e11) at the end of the experiment. TUMOR+1G PBMCs mice 
had much better control over tumor growth. Their BLI scores were consistently lower; with 
their tumor burden at 6 weeks not rising above 1e8-1e9.  Peak BLI scores were also significantly 
lower in TUMOR+1G PBMCs group compared to TUMOR+SMG PBMCs group. These 
experiments show that exposure to SMG impaired immune cell ability to control tumor growth 
rate in vivo. While tumor lysis in a 4-hour in vitro killing assay with PBMCs might be majorly 
attributed to NK cells, tumor growth control in vivo in a 6-week experiment might be a 
composite effect of ‘effector lymphocytes’. It remains unanswered if the difference observed 
in tumor growth control was exclusively due to suppression in NK-cell activity. Contributions 
of other effector lymphocytes like CD8+ cytotoxic T-cells could have very well played a role, 
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however minute, in tumor control. Future experiments involving depletion of cells of interest 
could answer these questions. 
Survivability was comparable between groups. While 3/8 mice died in TUMOR control group 
due to tumor burden, only 2/8 mice in TUMOR+SMG PBMCs group and 1/8 TUMOR+1G 
PBMCs died during the experiment (fig. 19c). These events reflect the tumor burden observed 
in these groups validating the tumor control capacity reflected with general health of the 
animals, at least during the span of the experiment.  
 
Clinical evaluation of GVHD also showed similar onset, progression and severity patterns 
between the groups. Animals started showing signs of GVHD around 2 weeks with ruffled fur 
and hunched posture at rest usually being the initial signs (fig. 19d). Over the duration of the 
experiment, progression to moderate GVHD showed clinical signs of reduced activity, ruffling 
of fur, extremely hunched posture during movement, and some signs of skin distress with loss 
of hair and scaling. Weight loss was also considered a sign of GVHD or general morbidity due 
to both tumor and pathophysiology of GVHD causing loss of weight and reduced food intake 
in the animal. GVHD did not progress to severe GVHD (>7) during the span of the experiment 
to estimate if it induced any graft-versus-leukemia (GVL) effects. While αβ-T cell activity is 
crucial to GVHD pathophysiology, this does not seem to be affected in our current model. Past 
evidence shows in vitro T-cell activity is suppressed after exposure to SMG (Hauschild et al., 
2014). However, in our in vivo model, there might be a recovery of the lost function over the 
duration of the experiment. Since GVHD does not start showing clinical symptoms until 3-4 
weeks into the experiment, this might reflect in similar GVHD onset patterns between the 
groups. While similar recovery is possible in NK cells too, failure to control tumor growth in 
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the initial weeks might be contributing to tumor burden reaching an uncontrollable level before 
NK cells regain their activity. The more efficient 1G-exposed PBMCs could be more adept at 
killing K562 tumor cells in vivo during the initial weeks, which might have resulted in stunted 
growth of the tumor in the later weeks. 
 
Exposure to SMG did not impair immune cell ability to engraft in vivo. CD45h+ cells engrafted 
successfully after exposure to SMG with their engraftment dynamics mirroring that of immune 
cells exposed to 1G-control (fig. 21). NK cell proportions and absolute numbers did not differ 
between the groups. These findings alleviated concerns that exposure to SMG might hinder 
immune cells’ ability to thrive in vivo which might have confounded our BLI findings. Initial 
weeks showed low CD45h+%s averaging around 1-5%, with most of the human cells in the 
peripheral blood being NK cells. Engraftment rose to higher levels reaching 20-30% at the end 
of the experiment (5 weeks after PBMCs injection) with drop in overall NK cell proportions. 
This coincided with onset and progression of GVHD since αβ-T cells are the main contributors 
to GVHD. Engraftment levels in mice that had tumor were also measured. There were no 
differences between the two groups with SMG-exposed PBMCs showing consistently 
comparable levels of CD45h+ and CD45h+CD3-CD56+ proportions. While blood levels of 
immune cells might not be reflective of engraftment levels in mice with tumor, this showed 
that human immune cells and NK cells thrived similarly in mice after exposure to 1G and 
SMG. In vivo expansion of (CD45h+CD3-CD56+) human NK cells in the initial weeks was to 
be expected in a NSG-tg(hu-IL15) mouse model. NSG-tg(hu-IL15) mice sustain  IL-15 blood 
levels of 7.1 +/- 0.3 pg/ml (https://www.jax.org/strain/030890). These levels are considerably 
higher than the usual undetectable levels in human blood (≈1 pg/ml) (Bergamaschi et al., 
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2012). This mouse model was precisely chosen to sustain and expand NK cells, since 
estimation of NK cell function in vivo was the underpinning question. NK cell levels drop in 
the later weeks when the differences in BLI between the groups start to be accentuated. It 
remains unclear if NK cells are exhausted in the later weeks or they traffic away from the 
peripheral blood.  
 
In summary, hypothesis 26 holds true that exposure to SMG impaired anti-leukemia activity of 
human effector immune cells in an in vivo model. 
 
In the third aim of this dissertation, subcutaneous IL2, a common immunotherapeutic strategy 
to enhance graft-versus-leukemia effect along with intra-peritoneal zoledronic acid, an amino-
bisphosphonate were tested as countermeasures. IL-2 has been shown to accelerate NK cell 
reconstitution in T-cell depleted stem cell grafts, increase GVL without increasing GVHD, and 
improve outcomes in various cancer therapies. Additionally, zoledronic acid, an amino-
bisphosphonate, already being considered as a spaceflight countermeasure (to prevent 
decreases in bone mineral density) has also been shown to increase γδ-T cell proportion and 
function. Here we report that systemic administration of ZOL+IL2 therapy improved anti-
leukemia activity of SMG-exposed PBMCs in vivo. 
                                                 
6 Exposure to 12-hour SMG in a RCCS adversely affects anti-leukemia activity of human immune cells in vivo 
by impairing their ability to control tumor growth in a NSG-tg(hu-IL15) mice model. 
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While tumor growth rate of TUMOR+SMG PBMCs+ZOL+IL2 group was not different from 
TUMOR+1G PBMCs group, it was significantly lower than TUMOR+SMG PBMCs group 
(figure 23). When taken in context with the previous experiment showing significantly higher 
tumor growth rate after SMG exposure, these results suggest that ZOL+IL2 therapy improved 
anti-leukemia activity after SMG exposure. The peak BLI scores did not reach significance in 
this aim but there was a clear trend towards reduced peak BLI score in 
TUMOR+SMG+ZOL+IL2 group compared to TUMOR+SMG PBMCs group. There also 
appears to be a downward trend in BLI score for the TUMOR+SMG PBMCs+ZOL+IL2 group 
towards the end of the experiment, suggesting an improved and sustained anti-leukemia 
activity after ZOL+IL2 therapy.  
 
Survivability was not altered because of ZOL+IL2 therapy. Only 1/6 mice died after ZOL+IL2 
therapy in the duration of the experiment. This was due to the animal reaching sacrificial 
criteria for morbidity score due to weight loss and general malaise since the tumor translocated 
to the brain. Overall survivability was comparable to other PBMC groups suggesting that 
ZOL+IL2 therapy did not cause systemic toxic effect in the animals. 
 
Engraftment levels did not change due to ZOL+IL2 therapy (figure 23). Non-significant 
increases in NK cell and γδ-T cell proportions were observed after ZOL+IL2 therapy as 
expected. Since NK cells and γδ-T cells do not contribute to GVHD pathophysiology, there 




In summary, Hypothesis 37 holds true that ZOL+IL2 therapy improved anti-leukemia activity 
of human effector immune cells after exposure to SMG. 
 
 
                                                 
7 Systemic administration of ZOL+IL-2 will boost the in vivo anti-leukemia capacity of human immune cells in 


















Immune dysregulation observed in spaceflight is a composite effect of plethora of hazardous 
stimuli to the human body. These include psychological and physiological stress, microgravity, 
radiation exposure, isolation and confinement, circadian disruption, sleep disturbances, to 
name a few. Understanding of the precise effect of each of these perturbations could help to 
devise appropriate countermeasures to preserve health, prevent disease and sustain human 
performance. 
 
Due to paucity of previous research, we examined the effect of simulated microgravity on NK 
cells. We reported that NK cell function is suppressed after short-term exposure to SMG. NK 
cells exposed to SMG kill 50% fewer cancer cells. NK cells showed lower levels of cytotoxic 
granule expression, degranulation, and cytokine production after SMG exposure. 
Contrastingly, cancer cells exposed to SMG did not show increased susceptibility to NK cell 
lysis (Mylabathula et al., 2020). Continuing the work, in this dissertation we further examined 
if this in vitro loss of function will extend into a physiologically more relevant in vivo setting. 
Furthermore, we also explored the effect of SMG on other immune cells—namely γδ-T cells 





Main findings in this dissertation 
Chapter 4: 
1. Exposure to 12-hour SMG in a RCCS impaired in vitro expansion of CMV-specific T-
cells. Exposure to expansion impaired their ability to later expand when stimulated with 
CMV peptides compared to 1G-control and 1G-rotational control but did not impair 
their ability to recognize CMV peptides.  
 
2. Exposure to 12-hour SMG in a RCCS impaired in vitro expansion of γδ-T cells. 
Exposure to SMG lowered the yield of γδ-T cells at the end of expansion while not 
significantly altering the phenotype of the expansion product. Vγ9vδ2 and vγ9vδ2 
proportions along with major activating receptors like NKG2D, NKp30 were similar 
to 1G-control while significant downregulation of inhibitory receptor CD158b was 
observed in the expansion product, after exposure to SMG. This downregulation of 
CD158b might have played a role in increased killing observed in the functional assays. 
When 1G-expanded γδ-T cells were exposed to SMG at the end of the expansion, there 
was significant upregulation of activating receptor NKG2D and a trend towards further 
downregulation of CD158b without concomitant increase in function. This might be 
due to saturation of NK receptor signaling that governs γδ-T cell response.  
 
3. Exposure to 12-hour SMG in a RCCS did not impair function of CMV-specific T-cells. 
1G-expanded cytotoxic CMV-specific T-cells killed comparable number of target cells 
(autologous PHA blasts pulsed with CMV-peptides) when exposed to 1G-control or 
SMG. Interestingly, SMG-exposed PBMCs that were later expanded in 1G to yield 
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CMV-specific T-cells killed more target cells compared to 1G-rotational control. It is 
possible that this increase in function was a result of altered cytotoxic capabilities in 
the expanded product, warranting further investigation.  
 
4. Exposure to 12-hour SMG in a RCCS did not impair in vitro function of γδ-T cells. 
1G-expanded γδ-T cells killed comparable number of K562 and U266 target cells after 
exposure to SMG. Significant upregulation of NKG2D and trending downregulation of 
CD158b after exposure to SMG did not result in increased killing capacity possibly due 
to NK receptor signaling saturation. Similar to viral specific T-cells, SMG-exposed 
PBMCs that were later expanded in 1G to yield γδ-T cells killed more U266 target cells 
but not more K562 target cells. Differential downregulation of inhibitory receptor 
CD158b in the expanded product might be responsible for increased activating signal 
resulting in increased killing.  
 
Chapter 5: 
1. Exposure to SMG impaired anti-leukemia activity of human immune cells in vivo. 
Human PBMCs exposed to SMG showed reduced capacity to control tumor growth 
rate in vivo compared to 1G-exposed PBMCs. While SMG exposed PBMCs 
showed some anti-leukemia activity, they did not significantly curtail tumor burden 
resulting in a growth rate that was comparable to TUMOR control. In contrast, 1G-
exposed PBMCs significantly corralled tumor growth resulting in relatively stunted 
growth rate. Mice that received SMG exposed PBMCs also showed similar peak 
BLI scores to mice that received tumor cells only further underscoring their 
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inability to restrict tumor growth.   
 
2. Exposure to SMG did not impair human immune cell ability to thrive in vivo. 
Human immune cell (CD45h+) engraftment levels were comparable in 1G and 
SMG exposed conditions. NK cell engraftment  (CD45h+CD3-CD56+%) showed 
high proportions in initial weeks, as expected in a NSG-tg(hu-IL15) mouse model 
and steadily declined thereafter as prevalence of other subsets increased in 
peripheral circulation.  
 
3. Onset, progression and severity of graft-versus-host disease was similar between 
the groups of mice that received 1G and SMG exposed PBMCs suggesting that αβ-
T cells retained their ability to attack the host in a xenograft. GVHD was not 
allowed to progress beyond moderate levels to prevent resultant 
immunomodulatory effects and morbidity from confounding the graft-versus-
leukemia effect.  
 
4. Survival of mice did not differ between the groups that received 1G or SMG 
exposed PBMCs. Most of the mice that received PBMCs survived the duration of 
the experiment alleviating concerns that differential survival might confound graft-
versus-leukemia results. GVHD and resulting morbidity also did not reach 
sacrificial criteria for the animals. As expected, TUMOR control mice showed 
higher mortality rate in the duration of experiment in accordance with their tumor 
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burden.   
 
5. ZOL+IL2 therapy improved anti-leukemia activity of human immune cells in vivo. 
Mice that received SMG-exposed PBMCs and weekly ZOL+IL2 therapy showed 
improved control of tumor growth. At the end of the experiment, tumor burden in 
the group that received SMG PBMCs and ZOL+IL2 therapy was at levels 
comparable to mice that received 1G PBMCs. This suggested that the 
countermeasure effectively abrogated SMG induced suppression of function in 
vivo.  These mice also showed similar peak BLI levels to mice that received 1G 
exposed PBMCs.  Mice that received SMG exposed PBMCs but did not receive 
ZOL+IL2 therapy showed poorer control of tumor growth and higher peak BLI 
scores compared to both TUMOR+SMG PBMCs+ZOL+IL2 and TUMOR+1G 
PBMCs groups.   
 
6. While ZOL+IL2 therapy did not show significant improvements in overall 
engraftment dynamics, there were trending increases in NK cell and γδ-T cell 
proportions in the peripheral blood suggesting that the improved tumor growth 
control to be driven by NK cells and γδ-T cells.   
 
7. ZOL+IL2 therapy did not affect survival of the mice. The treatment also did not 
influence the onset, progression and severity of GVHD. This suggested that the 
ZOL+IL2 therapy did not collaterally increase αβ-T cell activity. 
  
123  
Limitations of new knowledge obtained and suggestions for 
future directions 
1. In vitro exposure to SMG might not accurately reflect in vivo physiology. Our model 
improved the understanding of the effects of microgravity on immune cells after short-
term exposure. How continued exposure to microgravity over a period of months, if 
not years, affects immune cells remains to be explored.   
 
2. While NK cells remain crucial to containing systemic and localized tumor 
transformation, their function in controlling tumor depends on their ability to expand 
when receiving accurate stimulus, homing to the site of interest and tumor infiltration 
(in case of solid tumors). These functions need to be accurately modeled in vivo using 
solid tumor models.   
 
3. There is also evidence that microgravity alters pathogen virulence (C A Nickerson et 
al., 2000). A conglomerate model that evaluates pathogen-immune cell interaction and 
their perturbations in microgravity will improve our understanding of the magnitude of 
this effect. 3D organoids could be used in models to examine changes in tumor 
infiltration by effector cells like NK cells (Barrila et al., 2010).   
 
4. Lowered γδ-T cell and CMV-specific T-cell expansion potential was observed in these 
experiments. While microgravity did not affect the function of these cells in vitro, if 
lowered their ability to expand  translates to in vivo remains to be explored in future 
studies. Their ability to expand in vivo will be crucial when the host is challenged with 
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a latent viral reactivation or a tumor transformation. Current ISS data suggests that 
spaceflight induced latent viral reactivation is not controlled. Our in vivo experiments 
showed non-significant increases in γδ-T cell proportions in response to systemic 
zoledronic acid administration. This suggests that γδ-T cell expansion due to zoledronic 
administration in crewmembers to preserve bone mineral density might have some 
collateral immune benefits.   
 
5. Our in vivo experiments showed that exposure to SMG impaired anti-leukemia activity 
of human effector immune cells. This loss of function was regained after systemic 
ZOL+IL2 administration. We believe this to be an NK-cell mediated mechanism, 
drawing the conclusion from a combination of experiments showing in vitro loss of 
function of NK cells after SMG exposure, while no such loss was observed in other 
immune subsets like γδ-T cells. Regaining lost anti-leukemia activity after ZOL+IL2 
therapy could be a combined effect of improved NK cell and γδ-T cell function. NK-
cell or γδ-T cell depletion experiments, which would remove cells of interest from the 
PBMC inoculum and observe differences in anti-leukemia activity, would provide 
definitive answers to these questions.   
 
6. It is unclear how much of the in vivo anti-leukemia activity observed in these 
experiments could be attributed to other effector cells like CD8+ T-cells. There is 
substantial amount of evidence connecting GVHD with GVL. Moderate to severe 
GVHD provides some GVL effect in allogeneic stem cell transplant recipients. 
Therefore, some of the anti-leukemia activity (at least in later weeks) in our in vivo 
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experiments could be attributed to allogeneic αβ-T cells that are sensitized against host 
antigens. Similar GVHD scores were observed between conditions (TUMOR+SMG 
PBMCs and TUMOR+1G PBMCs) in our experiments. This would mean that any GVL 
effect afforded by GVHD could also be similar between the groups, alleviating 
concerns of this GVL effect being a confounder. Additionally, general trends of tumor 
growth in our experiments do not show reduction of tumor burden after it reaches levels 
of 1e8-1e9 photons/second, which is around week 4 of our experiment. This is when 
GVHD scores reach 4-5, contributing to some GVL effect. Therefore, this additional 
GVL effect might be insignificant to the general trend of tumor growth. One strategy 
to control this would be to administer anti-GVHD drugs like alemtuzumab (anti-CD52 





Exposure to microgravity detrimentally affects anti-leukemia activity of human immune cells 
in vivo. Natural killer cell function and expansion potential of other effector cells—namely γδ-
T cells, CMV-specific T cells—appear to be detrimentally affected by microgravity. While 
exposure to SMG in a bioreactor vessel affords a glimpse into the effect of microgravity on 
immune cells, the overall effect of microgravity or spaceflight on the human immune system 
will also depend on other perturbations of spaceflight on the human body. Immune system will 
be a responder to the detrimental effect of various factors like exposure to galactic cosmic 
radiation, physiological and psychological stress of the mission, demands of the body during 
spaceflight and the coping mechanisms to altered nutrition, microbiome and circadian rhythms. 
While it is important to know various effects of SMG on several immune subsets, how these 
cells behave when exposed to a myriad of factors remains to be explored. In the words of 
neuroscientist, V. S. Ramachandran, “nature is not a linear phenomenon”. Exposure to 
microgravity for prolonged periods might exponentially worsen human physiology or hasten 
their evolution to adapt. Predictive models that simultaneously include multiple hazardous 
stimuli and employ a systems physiology approach to study various organ systems would 
greatly benefit space life sciences research in the future. Future spacefarers should include 
scientists and physicians that could bring back invaluable data collected from zero gravity and 





Acharya, M. M., Baulch, J. E., Klein, P. M., Baddour, A. A. D., Apodaca, L. A., Kramár, E. 
A., … Limoli, C. L. (2019). New concerns for neurocognitive function during deep 
space exposures to chronic, low dose-rate, neutron radiation. ENeuro, 6(4), 1–15. 
https://doi.org/10.1523/ENEURO.0094-19.2019 
Ade, C. J., Broxterman, R. M., & Barstow, T. J. (2015). VO(2max) and Microgravity 
Exposure: Convective versus Diffusive O(2) Transport. Medicine and Science in Sports 
and Exercise, 47(7), 1351–1361. https://doi.org/10.1249/MSS.0000000000000557 
Agha, N. H., Baker, F. L., Kunz, H. E., Spielmann, G., Mylabathula, P. L., Rooney, B. V., … 
Simpson, R. J. (2020). Salivary antimicrobial proteins and stress biomarkers are 
elevated during a 6-month mission to the International Space Station. Journal of Applied 
Physiology, 128(2), 264–275. https://doi.org/10.1152/japplphysiol.00560.2019 
Agha, N. H., Mehta, S. K., Rooney, B. V., Laughlin, M. S., Markofski, M. M., Pierson, D. 
L., … Simpson, R. J. (2020). Exercise as a countermeasure for latent viral reactivation 
during long duration space flight. FASEB Journal, 34(2), 2869–2881. 
https://doi.org/10.1096/fj.201902327R 
Aldinucci, D., Borghese, C., & Casagrande, N. (2019). Formation of the immunosuppressive 
microenvironment of classic hodgkin lymphoma and therapeutic approaches to counter 
it. International Journal of Molecular Sciences, 20(10), 1–23. 
https://doi.org/10.3390/ijms20102416 
Aleshcheva, G., Bauer, J., Hemmersbach, R., Slumstrup, L., Wehland, M., Infanger, M., & 
Grimm, D. (2016). Scaffold-free Tissue Formation Under Real and Simulated 
128  
Microgravity Conditions. Basic & Clinical Pharmacology & Toxicology, 119 Suppl, 
26–33. https://doi.org/10.1111/bcpt.12561 
Antonsen, E, Bayuse, T,  et al (NASA). (2017). Risk of Adverse Health Outcomes 
performance Decrements in Performance due to In-Flight Medical Conditions. NASA 
Human Research Programme, Exploration Medical Capabilities Element, 1–80. 
Retrieved from https://humanresearchroadmap.nasa.gov/evidence/reports/Medical.PDF 
Bajgain, P., Mucharla, R., Wilson, J., Welch, D., Anurathapan, U., Liang, B., … Vera, J. F. 
(2014). Optimizing the production of suspension cells using the G-Rex “M” series. 
Molecular Therapy. Methods & Clinical Development, 1, 14015. 
https://doi.org/10.1038/mtm.2014.15 
Balthesen, M., Messerle, M., & Reddehase, M. J. (1993). Lungs are a major organ site of 
cytomegalovirus latency and recurrence. Journal of Virology, 67(9), 5360–5366. 
https://doi.org/10.1128/jvi.67.9.5360-5366.1993 
Barrila, J., Radtke, A. L., Crabbé, A., Sarker, S. F., Herbst-Kralovetz, M. M., Ott, C. M., & 
Nickerson, C. A. (2010). Organotypic 3D cell culture models: using the rotating wall 
vessel to study  host-pathogen interactions. Nature Reviews. Microbiology, 8(11), 791–
801. https://doi.org/10.1038/nrmicro2423 
Bate, S. L., Dollard, S. C., & Cannon, M. J. (2010). Cytomegalovirus Seroprevalence in the 
United States: The National Health and Nutrition Examination Surveys, 1988–2004. 
Clinical Infectious Diseases, 50(11), 1439–1447. https://doi.org/10.1086/652438 
Bergamaschi, C., Bear, J., Rosati, M., Beach, R. K., Alicea, C., Sowder, R., … Pavlakis, G. 
N. (2012). Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in 
129  
human and mouse serum. Blood, 120(1), e1–e8. https://doi.org/10.1182/blood-2011-10-
384362 
Bigley, A. B., Agha, N. H., Baker, F. L., Spielmann, G., Kunz, H. E., Mylabathula, P. L., … 
Simpson, R. J. (2018). NK-cell function is impaired during long-duration spaceflight. 
Journal of Applied Physiology (Bethesda, Md. : 1985). 
https://doi.org/10.1152/japplphysiol.00761.2018 
Bigley, A. B., Agha, N. H., Baker, F. L., Spielmann, G., Kunz, H. E., Mylabathula, P. L., … 
Simpson, R. J. (2019). NK cell function is impaired during long-duration spaceflight, 
842–853. https://doi.org/10.1152/japplphysiol.00761.2018 
Bigley, A. B., Spielmann, G., Agha, N., O’Connor, D. P., & Simpson, R. J. (2016). 
Dichotomous effects of latent CMV infection on the phenotype and functional 
properties of CD8+ T-cells and NK-cells. Cellular Immunology, 300, 26–32. 
https://doi.org/10.1016/j.cellimm.2015.11.005 
BIOMEDICAL RESULTS OF SKYLAB. (2013). 
Biron, C. A., Byron, K. S., & Sullivan, J. L. (1989). Severe Herpesvirus Infections in an 
Adolescent without Natural Killer Cells. New England Journal of Medicine, 320(26), 
1731–1735. https://doi.org/10.1056/NEJM198906293202605 
Blue, R. S., Chancellor, J. C., Suresh, R., Carnell, L. S., Reyes, D. P., Nowadly, C. D., & 
Antonsen, E. L. (2019). Challenges in Clinical Management of Radiation-Induced 
Illnesses During Exploration Spaceflight. Aerospace Medicine and Human 
Performance, 90(11), 966–977. https://doi.org/10.3357/AMHP.5370.2019 
130  
Bosma, G. C., Custer, R. P., & Bosma, M. J. (1983). A severe combined immunodeficiency 
mutation in the mouse. Nature, 301(5900), 527–530. https://doi.org/10.1038/301527a0 
Brainard, G. C., Barger, L. K., Soler, R. R., & Hanifin, J. P. (2016). The development of 
lighting countermeasures for sleep disruption and circadian misalignment during 
spaceflight. Current Opinion in Pulmonary Medicine, 22(6), 535–544. 
https://doi.org/10.1097/MCP.0000000000000329 
Brehm, M. A., Aryee, K.-E., Bruzenksi, L., Greiner, D. L., Shultz, L. D., & Keck, J. (2018). 
Transgenic expression of human IL15 in NOD-scid IL2rgnull (NSG) mice enhances the 
development and survival of functional human NK cells. The Journal of Immunology, 
200(1 Supplement), 103.20 LP-103.20. Retrieved from 
http://www.jimmunol.org/content/200/1_Supplement/103.20.abstract 
Britten, R. A., Davis, L. K., Jewell, J. S., Miller, V. D., Hadley, M. M., Sanford, L. D., … 
Lonart, G. (2014). Exposure to mission relevant doses of 1 GeV/Nucleon (56)Fe 
particles leads to impairment of attentional set-shifting performance in socially mature 
rats. Radiation Research, 182(3), 292–298. https://doi.org/10.1667/RR3766.1 
Buchheim, J. I., Hoskyns, S., Moser, D., Han, B., Deindl, E., Hörl, M., … Choukèr, A. 
(2018). Oxidative burst and Dectin-1-triggered phagocytosis affected by norepinephrine 
and endocannabinoids: Implications for fungal clearance under stress. International 
Immunology, 30(2), 79–89. https://doi.org/10.1093/intimm/dxy001 
Buchheim, J., Matzel, S., Rykova, M., Vassilieva, G., Ponomarev, S., Nichiporuk, I., … 
Choukèr, A. (2019). Stress Related Shift Toward Inflammaging in Cosmonauts After 
Long-Duration Space Flight, 10(February), 1–13. 
131  
https://doi.org/10.3389/fphys.2019.00085 
Buravkova, L. B., Rykova, M. P., Grigorieva, V., & Antropova, E. (2004). Cell interactions 
in microgravity: cytotoxic effects of natural killer cells in vitro. Journal of Gravitational 
Physiology Vol 11 (2). 
Caccamo, N., Meraviglia, S., Scarpa, F., La Mendola, C., Santini, D., Bonanno, C. T., … 
Salerno, A. (2008). Aminobisphosphonate-activated gammadelta T cells in 
immunotherapy of cancer: doubts no more. Expert Opinion on Biological Therapy, 8(7), 
875–883. https://doi.org/10.1517/14712598.8.7.875 
Cao, D., Song, J., Ling, S., Niu, S., Lu, L., Cui, Z., … Li, Y. (2019). Hematopoietic stem 
cells and lineage cells undergo dynamic alterations under microgravity and recovery 
conditions. FASEB Journal : Official Publication of the Federation of American 
Societies for  Experimental Biology, 33(6), 6904–6918. 
https://doi.org/10.1096/fj.201802421RR 
Cao, X., Shores, E. W., Hu-Li, J., Anver, M. R., Kelsail, B. L., Russell, S. M., … Leonard, 
W. J. (1995). Defective lymphoid development in mice lacking expression of the 
common cytokine receptor γ chain. Immunity, 2(3), 223–238. 
https://doi.org/10.1016/1074-7613(95)90047-0 
Cavanagh, P. R., Licata, A. A., & Rice, A. J. (2005). Exercise and pharmacological 
countermeasures for bone loss during long-duration space flight. Gravitational and 
Space Biology Bulletin : Publication of the American Society for Gravitational and 
Space Biology, 18(2), 39–58. 
Cekanaviciute, E., Rosi, S., & Costes, S. V. (2018). Central Nervous System Responses to 
132  
Simulated Galactic Cosmic Rays. International Journal of Molecular Sciences, 19(11). 
https://doi.org/10.3390/ijms19113669 
Chancellor, J. C., Scott, G. B. I., & Sutton, J. P. (2014). Space Radiation: The Number One 
Risk to Astronaut Health beyond Low Earth Orbit. Life (Basel, Switzerland), 4(3), 491–
510. https://doi.org/10.3390/life4030491 
Cheever, M. A., Greenberg, P. D., Fefer, A., & Gillis, S. (1982). Augmentation of the anti-
tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo 
administration of purified interleukin 2. The Journal of Experimental Medicine, 155(4), 
968–980. https://doi.org/10.1084/jem.155.4.968 
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018). Natural killer cells and other 
innate lymphoid cells in cancer. Nature Reviews. Immunology, 18(11), 671–688. 
https://doi.org/10.1038/s41577-018-0061-z 
Cho, B., Spratford, C. M., Yoon, S., Cha, N., Banerjee, U., & Shim, J. (n.d.). chemosensation 
in Drosophila. Nature Communications, (2018), 1–12. https://doi.org/10.1038/s41467-
018-04990-3 
Choukèr,  a, Thiel, M., Baranov, V., Meshkov, D., Kotov,  a, Peter, K., … Christ, F. (2001). 
Simulated microgravity, psychic stress, and immune cells in men: observations during 
120-day 6 degrees HDT. Journal of Applied Physiology (Bethesda, Md. : 1985), 90(5), 
1736–1743. 
Cook, C. H. (2007). Cytomegalovirus Reactivation in “Immunocompetent” Patients: A Call 
for Scientific Prophylaxis. The Journal of Infectious Diseases, 196(9), 1273–1275. 
https://doi.org/10.1086/522433 
133  
Cooper, M. A., Bush, J. E., Fehniger, T. A., VanDeusen, J. B., Waite, R. E., Liu, Y., … 
Caligiuri, M. A. (2002). In vivo evidence for a dependence on interleukin 15 for 
survival of natural killer cells. Blood, 100(10), 3633–3638. 
https://doi.org/10.1182/blood-2001-12-0293 
Correia, D. V, Lopes, A., & Silva-Santos, B. (2013). Tumor cell recognition by γδ T 
lymphocytes: T-cell receptor vs. NK-cell receptors. Oncoimmunology, 2(1), e22892–
e22892. https://doi.org/10.4161/onci.22892 
Crucian, B. E., Choukèr, A., Simpson, R. J., Mehta, S., Marshall, G., Smith, S. M., … Sams, 
C. (2018). Immune system dysregulation during spaceflight: Potential countermeasures 
for deep space exploration missions. Frontiers in Immunology, 9(JUN), 1–21. 
https://doi.org/10.3389/fimmu.2018.01437 
Crucian, B. E., Stowe, R. P., Pierson, D. L., & Sams, C. F. (2008a). Immune system 
dysregulation following short- vs long-duration spaceflight. Aviation, Space, and 
Environmental Medicine, 79(9), 835–843. https://doi.org/10.3357/asem.2276.2008 
Crucian, B. E., Stowe, R. P., Pierson, D. L., & Sams, C. F. (2008b). Immune system 
dysregulation following short- vs long-duration spaceflight. Aviation Space and 
Environmental Medicine, 79(9), 835–843. https://doi.org/10.3357/ASEM.2276.2008 
Crucian, B., Kunz, H., & Sams, C. F. (n.d.). Risk of Crew Adverse Health Event Due to 
Altered Immune Response Human Research Program Human Health Countermeasures 
Element. Retrieved from https://ntrs.nasa.gov/search.jsp?R=20150008177 
Crucian, B., & Sams, C. (2009). Immune system dysregulation during spaceflight: clinical 
risk for exploration-class missions. Journal of Leukocyte Biology, 86(5), 1017–1018. 
134  
https://doi.org/10.1189/jlb.0709500 
Crucian, B., Simpson, R. J., Mehta, S., Stowe, R., Chouker, A., Hwang, S. A., … Sams, C. 
(2014a). Terrestrial stress analogs for spaceflight associated immune system 
dysregulation. Brain, Behavior, and Immunity, 39, 23–32. 
https://doi.org/10.1016/j.bbi.2014.01.011 
Crucian, B., Simpson, R. J., Mehta, S., Stowe, R., Chouker, A., Hwang, S., … Sams, C. 
(2014b). Brain , Behavior , and Immunity Terrestrial stress analogs for spaceflight 
associated immune system dysregulation. Brain Behavior and Immunity, 39, 23–32. 
https://doi.org/10.1016/j.bbi.2014.01.011 
Crucian, B., Stowe, R., Mehta, S., Uchakin, P., Quiriarte, H., Pierson, D., & Sams, C. (2013). 
Immune system dysregulation occurs during short duration spaceflight on board the 
space shuttle. Journal of Clinical Immunology, 33(2), 456–465. 
https://doi.org/10.1007/s10875-012-9824-7 
Crucian, B., Stowe, R. P., Mehta, S., Quiriarte, H., Pierson, D., & Sams, C. (2015). 
Alterations in adaptive immunity persist during long-duration space fl ight, (January), 
1–10. https://doi.org/10.1038/npjmgrav.2015.13 
Crucian, B., Stowe, R., Quiriarte, H., Pierson, D., & Sams, C. (2011). Monocyte phenotype 
and cytokine production profiles are dysregulated by short-duration spaceflight. 
Aviation, Space, and Environmental Medicine, 82(9), 857–862. 
https://doi.org/10.3357/asem.3047.2011 
Cucinotta, F. A. (2014). Space radiation risks for astronauts on multiple International Space 
Station missions. PloS One, 9(4), e96099. https://doi.org/10.1371/journal.pone.0096099 
135  
Cucinotta, F. A., To, K., & Cacao, E. (2017). Predictions of space radiation fatality risk for 
exploration missions. Life Sciences in Space Research, 13, 1–11. 
https://doi.org/10.1016/j.lssr.2017.01.005 
Degan, P., Sancandi, M., Zunino, A., Ottaggio, L., Viaggi, S., Cesarone, F., … 
Abbondandolo, A. (2005). Exposure of human lymphocytes and lymphoblastoid cells to 
simulated microgravity strongly affects energy metabolism and DNA repair. Journal of 
Cellular Biochemistry, 94(3), 460–469. https://doi.org/10.1002/jcb.20302 
Duda, J., Karimi, M., Negrin, R. S., & Contag, C. H. (2007). Methods for imaging cell fates 
in hematopoiesis. Methods in Molecular Medicine, 134, 17–34. 
https://doi.org/10.1007/978-1-59745-223-6_2 
Fehniger, T. A., & Caligiuri, M. A. (2001). Interleukin 15: biology and relevance to human 
disease. Blood, 97(1), 14–32. https://doi.org/10.1182/blood.V97.1.14 
Felix, K., Wise, K., Manna, S., Yamauchi, K., Wilson, B. L., Thomas, R. L., … Ramesh, G. 
T. (2004). Altered cytokine expression in tissues of mice subjected to simulated 
microgravity. Molecular and Cellular Biochemistry, 266(1–2), 79–85. 
https://doi.org/10.1023/B:MCBI.0000049136.55611.dd 
Feuerecker, M., Crucian, B. E., Quintens, R., Buchheim, J. I., Salam, A. P., Rybka, A., … 
Choukèr, A. (2019). Immune sensitization during 1 year in the Antarctic high-altitude 
Concordia Environment. Allergy: European Journal of Allergy and Clinical 
Immunology, 74(1), 64–77. https://doi.org/10.1111/all.13545 
Fischer, C. L., Daniels, J. C., Levin, W. C., Kimzey, S. L., Cobb, E. K., & Ritzmann, S. E. 
(1972). Effects of the space flight environment on man’s immune system. II. 
136  
Lymphocyte counts and reactivity. Aerospace Medicine, 43(10), 1122–1125. 
Fischer, C. L., Gill, C., Daniels, J. C., Cobb, E. K., Berry, C. A., & Ritzmann, S. E. (1972). 
Effects of the space flight environment on man’s immune system. I. Serum proteins and 
immunoglobulins. Aerospace Medicine, 43(8), 856–859. Retrieved from 
https://www.ncbi.nlm.nih.gov/pubmed/5056037 
Fitzgerald, W., Chen, S., Walz, C., Zimmerberg, J., Margolis, L., & Grivel, J.-C. (2009). 
Immune suppression of human lymphoid tissues and cells  in rotating suspension culture 
and onboard the International  Space Station. In Vitro Cellular & Developmental 
Biology. Animal, 45(10), 622–632. https://doi.org/10.1007/s11626-009-9225-2 
Fleming, C., Morrissey, S., Cai, Y., & Yan, J. (2017). γδ T Cells: Unexpected Regulators of 
Cancer Development and Progression. Trends in Cancer, 3(8), 561–570. 
https://doi.org/10.1016/j.trecan.2017.06.003 
Fobelo Lozano, M. J., & Sanchez-Fidalgo, S. (2019). Adherence and preference of 
intravenous zoledronic acid for osteoporosis versus other bisphosphonates. European 
Journal of Hospital Pharmacy : Science and Practice, 26(1), 4–9. 
https://doi.org/10.1136/ejhpharm-2017-001258 
Foster, J. S., Wheeler, R. M., & Pamphile, R. (2014). Host-microbe interactions in 
microgravity: assessment and implications. Life (Basel, Switzerland), 4(2), 250–266. 
https://doi.org/10.3390/life4020250 
Freed, L. E., Pellis, N., Searby, N., de Luis, J., Preda, C., Bordonaro, J., & Vunjak-
Novakovic, G. (1999). Microgravity cultivation of cells and tissues. Gravitational and 
Space Biology Bulletin : Publication of the American Society for Gravitational and 
137  
Space Biology, 12(2), 57–66. Retrieved from 
https://www.ncbi.nlm.nih.gov/pubmed/11541784 
Gaffen, S. L., & Liu, K. D. (2004). Overview of interleukin-2 function , production and 
clinical applications, 28. https://doi.org/10.1016/j.cyto.2004.06.010 
Garcia-Lora, A., Algarra, I., & Garrido, F. (2003). MHC class I antigens, immune 
surveillance, and tumor immune escape. Journal of Cellular Physiology, 195(3), 346–
355. https://doi.org/10.1002/jcp.10290 
Gerdemann, U., Keirnan, J. M., Katari, U. L., Yanagisawa, R., Christin, A. S., Huye, L. E., 
… Leen, A. M. (2009). Rapidly Generated Multivirus-specific Cytotoxic T 
Lymphocytes for the Prophylaxis and Treatment of Viral Infections. Molecular 
Therapy, 20(8), 1622–1632. https://doi.org/10.1038/mt.2012.130 
Gibson, C. R., Alexander, D. J., & Hamilton, D. R. (2012). Human Health Countermeasures 
Element Evidence Report Risk of Spaceflight-Induced Intracranial Hypertension and 
Vision Alterations. Evidence Report. 
Glaser, R., Kiecolt-Glaser, J. K., Speicher, C. E., & Holliday, J. E. (1985). Stress, loneliness, 
and changes in herpesvirus latency. Journal of Behavioral Medicine, 8(3), 249–260. 
https://doi.org/10.1007/bf00870312 
Glaser, R., Kiecolt-Glaser, J. K., Stout, J. C., Tarr, K. L., Speicher, C. E., & Holliday, J. E. 
(1985). Stress-related impairments in cellular immunity. Psychiatry Research, 16(3), 
233–239. https://doi.org/10.1016/0165-1781(85)90111-8 
Gleeson, M., Pyne, D. B., Austin, J. P., Lynn Francis, J., Clancy, R. L., McDonald, W. A., & 
138  
Fricker, P. A. (2002). Epstein-Barr virus reactivation and upper-respiratory illness in 
elite swimmers. Medicine and Science in Sports and Exercise, 34(3), 411–417. 
https://doi.org/10.1097/00005768-200203000-00005 
Goel, N., Bale, T. L., Epperson, C. N., Kornstein, S. G., Leon, G. R., Palinkas, L. A., … 
Dinges, D. F. (2014). Effects of sex and gender on adaptation to space: Behavioral 
health. Journal of Women’s Health, 23(11), 975–986. 
https://doi.org/10.1089/jwh.2014.4911 
Goodwin, T. J., Prewett, T. L., Wolf, D. A., & Spaulding, G. F. (1993). Reduced shear-stress 
- A major component in the ability of mammalian-tissues to form 3-dimensional 
assemblies in simulated microgravity. Journal of Cellular Biochemistry, 51(3), 301–
311. 
Goodwin, T. J., Schroeder, W. F., Wolf, D. A., & Moyer, M. P. (1993). Rotating-wall vessel 
coculture of small intestine as a prelude to tissue modeling: aspects of simulated 
microgravity. Proceedings of the Society for Experimental Biology and Medicine. 
Society for Experimental Biology and Medicine (New York, N.Y.), 202(2), 181–192. 
https://doi.org/10.3181/00379727-202-43525 
Grimm, D., Wehland, M., Pietsch, J., Aleshcheva, G., Wise, P., Van Loon, J., … Bauer, J. 
(2014). Growing tissues in real and simulated microgravity: New methods for tissue 
engineering. Tissue Engineering - Part B: Reviews, 20(6), 555–566. 
https://doi.org/10.1089/ten.teb.2013.0704 
Guéguinou, N., Huin-Schohn, C., Bascove, M., Bueb, J.-L., Tschirhart, E., Legrand-Frossi, 
C., & Frippiat, J.-P. (2009). Could spaceflight-associated immune system weakening 
139  
preclude the expansion of human presence beyond Earth’s orbit? Journal of Leukocyte 
Biology, 86(5), 1027–1038. https://doi.org/10.1189/jlb.0309167 
Hales, N. W., Yamauchi, K., Alicea,  a, Sundaresan,  a, Pellis, N. R., & Kulkarni,  a D. 
(2002). A countermeasure to ameliorate immune dysfunction in in vitro simulated 
microgravity environment: role of cellularnucleotide nutrition. In Vitro Cellular & 
Developmental Biology. Animal, 38(4), 213–217. https://doi.org/10.1290/1071-
2690(2002)038<0213:ACTAID>2.0.CO;2 
Hamilton, E., Clay, T. M., & Blackwell, K. L. (2011). New perspectives on zoledronic acid 
in breast cancer: potential augmentation of anticancer immune response. Cancer 
Investigation, 29(8), 533–541. https://doi.org/10.3109/07357907.2011.605413 
Hammond, T. G., & Hammond, J. M. (2001). Optimized suspension culture: The rotating-
wall vessel. American Journal of Physiology - Renal Physiology, 281(1 50-1), 12–25. 
https://doi.org/10.1152/ajprenal.2001.281.1.f12 
Hauschild, S., Tauber, S., Lauber, B., Thiel, C. S., Layer, L. E., & Ullrich, O. (2014). T cell 
regulation in microgravity - The current knowledge from in vitro experiments conducted 
in space, parabolic flights and ground-based facilities. Acta Astronautica, 104(1), 365–
377. https://doi.org/10.1016/j.actaastro.2014.05.019 
Heininger, A., Jahn, G., Engel, C., Notheisen, T., Unertl, K., & Hamprecht, K. (2001). 
Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. 
Critical Care Medicine, 29(3), 541–547. 
Hewitt, E. W. (2003). The MHC class I antigen presentation pathway: strategies for viral 
immune evasion. Immunology, 110(2), 163–169. https://doi.org/10.1046/j.1365-
140  
2567.2003.01738.x 
Higginson, E. E., Galen, J. E., Levine, M. M., & Tennant, S. M. (2016). Microgravity as a 
biological tool to examine host–pathogen interactions and to guide development of 
therapeutics and preventatives that target pathogenic bacteria. Pathogens and Disease, 
74(8). https://doi.org/10.1093/femspd/ftw095 
Himizu, K. S., Ields, R. C. F., & Iedlin, M. G. (1999). Systemic administration of interleukin 
2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines, 96(March), 
2268–2273. 
Hosie, L., Pachnio, A., Zuo, J., Pearce, H., Riddell, S., & Moss, P. (2017). Cytomegalovirus-
Specific T Cells Restricted by HLA-Cw*0702 Increase Markedly with Age and 
Dominate the CD8+ T-Cell Repertoire in Older People   . Frontiers in Immunology  . 
Retrieved from https://www.frontiersin.org/article/10.3389/fimmu.2017.01776 
Hsieh, C. L., Chao, P. D. L., & Fang, S. H. (2005). Morin sulphates/glucuronides enhance 
macrophage function in microgravity culture system. European Journal of Clinical 
Investigation, 35(9), 591–596. https://doi.org/10.1111/j.1365-2362.2005.01551.x 
Huyan, T., Li, Q., Yang, H., Jin, M. L., Zhang, M. J., Ye, L. J., … Yin, D. C. (2014). 
Protective effect of polysaccharides on simulated microgravity-induced functional 
inhibition of human NK cells. Carbohydrate Polymers, 101(1), 819–827. 
https://doi.org/10.1016/j.carbpol.2013.10.021 
Jaber, S., Chanques, G., Borry, J., Souche, B., Verdier, R., Perrigault, P.-F., & Eledjam, J.-J. 
(2005). Cytomegalovirus infection in critically ill patients: associated factors and  
consequences. Chest, 127(1), 233–241. https://doi.org/10.1378/chest.127.1.233 
141  
Jessup, J. M., Goodwin, T. J., & Spaulding, G. (1993). Prospects For Use Of Microgravity-
Based Bioreactors To Study 3- Dimensional Host Tumor Interactions In Human 
Neoplasia. Journal Of Cellular Biochemistry, 51(3), 290–300. 
Johnston, R. S., Dietlein, L. F., Berry, C. A., Parker, F., Vernon, J., & Larry, E. (1975). 
Biomedical Results of Apollo. 
Joye, A., & Gonzales, J. A. (2018). Ocular manifestations of cytomegalovirus in 
immunocompetent hosts. Current Opinion in Ophthalmology, 29(6), 535–542. 
https://doi.org/10.1097/ICU.0000000000000521 
Kamin, H. S., & Kertes, D. A. (2017). Cortisol and DHEA in development and 
psychopathology. Hormones and Behavior, 89, 69–85. 
https://doi.org/10.1016/j.yhbeh.2016.11.018 
Kandarian, F., Sunga, G. M., Arango-Saenz, D., & Rossetti, M. (2017). A flow cytometry-
based cytotoxicity assay for the assessment of human NK cell activity. Journal of 
Visualized Experiments, 2017(126), 1–8. https://doi.org/10.3791/56191 
Kast, J., Yu, Y., Seubert, C. N., Wotring, V. E., & Derendorf, H. (2017). Drugs in space: 
Pharmacokinetics and pharmacodynamics in astronauts. European Journal of 
Pharmaceutical Sciences, 109(May), S2–S8. https://doi.org/10.1016/j.ejps.2017.05.025 
Kataoka, S., Satoh, J., Fujiya, H., Toyota, T., Suzuki, R., Itoh, K., & Kumagai, K. (1983). 
Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular 
immunity. Diabetes, 32(3), 247–253. https://doi.org/10.2337/diab.32.3.247 
Kaufmann, I., Schachtner, T., Feuerecker, M., Schelling, G., Thiel, M., & Choukèr,  a. 
142  
(2009). Parabolic flight primes cytotoxic capabilities of polymorphonuclear leucocytes 
in humans. European Journal of Clinical Investigation. https://doi.org/10.1111/j.1365-
2362.2009.02136.x 
Kaufmann, Ines, Feuerecker, M., Salam, A., Schelling, G., Thiel, M., & Choukèr, A. (2011). 
Adenosine A2A receptor modulates the oxidative stress response of primed 
polymorphonuclear leukocytes after parabolic flight. Human Immunology, 72(7), 547–
552. https://doi.org/10.1016/j.humimm.2011.03.021 
Kaur, I., Simons, E. R., Castro, V. a., Mark Ott, C., & Pierson, D. L. (2004). Changes in 
neutrophil functions in astronauts. Brain, Behavior, and Immunity, 18(5), 443–450. 
https://doi.org/10.1016/j.bbi.2003.10.005 
Kaur, I., Simons, E. R., Castro, V. a., Ott, C. M., & Pierson, D. L. (2005). Changes in 
monocyte functions of astronauts. Brain, Behavior, and Immunity, 19(6), 547–554. 
https://doi.org/10.1016/j.bbi.2004.12.006 
Kelsen, J., Bartels, L. E., Dige, A., Hvas, C. L., Frings-Meuthen, P., Boehme, G., … 
Dahlerup, J. F. (2012). 21 Days head-down bed rest induces weakening of cell-mediated 
immunity - Some spaceflight findings confirmed in a ground-based analog. Cytokine, 
59(2), 403–409. https://doi.org/10.1016/j.cyto.2012.04.032 
Kimpo, M. S., Oh, B., & Lee, S. (2019). The Role of Natural Killer Cells as a Platform for 
Immunotherapy in Pediatric Cancers. Current Oncology Reports, 21(10), 93. 
https://doi.org/10.1007/s11912-019-0837-8 
Kita, M., Yamamoto, T., Imanishi, J., & Fuse, A. (2004). Influence of gravity changes 
induced by parabolic flight on cytokine production in mouse spleen. Journal of 
143  
Gravitational Physiology : A Journal of the International Society for Gravitational 
Physiology, 11(2), P67—8. Retrieved from 
http://europepmc.org/abstract/MED/16235419 
Klarenbeek, P. L., Remmerswaal, E. B. M., ten Berge, I. J. M., Doorenspleet, M. E., van 
Schaik, B. D. C., Esveldt, R. E. E., … van Lier, R. A. W. (2012). Deep Sequencing of 
Antiviral T-Cell Responses to HCMV and EBV in Humans Reveals a Stable Repertoire 
That Is Maintained for Many Years. PLoS Pathogens, 8(9). 
https://doi.org/10.1371/journal.ppat.1002889 
Klaus, D. M. (2001). Clinostats and bioreactors. Gravitational and Space Biology Bulletin : 
Publication of the American Society for Gravitational and Space Biology, 14(2), 55–64. 
Kondo, M., Izumi, T., Fujieda, N., Kondo, A., Morishita, T., Matsushita, H., & Kakimi, K. 
(2011). Expansion of human peripheral blood γδ T cells using zoledronate. Journal of 
Visualized Experiments, 2(55), 6–11. https://doi.org/10.3791/3182 
Kulkarni, A. D., Yamauchi, K., Sundaresan, A., Ramesh, G. T., & Pellis, N. R. (2005). 
Countermeasure for space flight effects on immune system: nutritional nucleotides. 
Gravitational and Space Biology Bulletin : Publication of the American Society for 
Gravitational and Space Biology, 18(2), 101–102. 
Kumari, R., Singh, K. P., & DuMond, J. W. (2009). Simulated microgravity decreases DNA 
repair capacity and induces DNA damage in human lymphocytes. Journal of Cellular 
Biochemistry, 107(4), 723–731. https://doi.org/10.1002/jcb.22171 
Lai, H. Y., Chou, T. Y., Tzeng, C. H., & Lee, O. K. S. (2012). Cytokine profiles in various 
graft-versus-host disease target organs following hematopoietic stem cell 
144  
transplantation. Cell Transplantation, 21(9), 2033–2045. 
https://doi.org/10.3727/096368912X653110 
Lappa, M. (2003). Organic tissues in rotating bioreactors: fluid-mechanical aspects, dynamic 
growth models, and morphological evolution. Biotechnology and Bioengineering, 84(5), 
518–532. https://doi.org/10.1002/bit.10821 
LaVoy, E. C. P., Bollard, C. M., Hanley, P. J., Blaney, J. W., O’Connor, D. P., Bosch, J. A., 
& Simpson, R. J. (2015). A single bout of dynamic exercise enhances the expansion of 
MAGE-A4 and  PRAME-specific cytotoxic T-cells from healthy adults. Exercise 
Immunology Review, 21, 144–153. 
Lawand, M., Déchanet-Merville, J., & Dieu-Nosjean, M. C. (2017). Key features of gamma-
delta T-cell subsets in human diseases and their immunotherapeutic implications. 
Frontiers in Immunology, 8(JUN). https://doi.org/10.3389/fimmu.2017.00761 
Lee, E. H., Ding, W., Kulkarni, A. D., & Granstein, R. D. (2005). Tumor growth and 
immune function in mice during hind-limb unloading. Aviation, Space, and 
Environmental Medicine, 76(6), 536–540. 
Li, M., Holmes, V., Ni, H., Sanzari, J. K., Romero-Weaver, A. L., Lin, L., … Weissman, D. 
(2015). Broad-spectrum antibiotic or G-CSF as potential countermeasures for impaired 
control of bacterial infection associated with an SPE Exposure during spaceflight. PLoS 
ONE, 10(3), 1–15. https://doi.org/10.1371/journal.pone.0120126 
Li, M., Holmes, V., Zhou, Y., Ni, H., Sanzari, J. K., Kennedy, A. R., & Weissman, D. 
(2014). Hindlimb suspension and SPE-like radiation impairs clearance of bacterial 
infections. PLoS ONE, 9(1). https://doi.org/10.1371/journal.pone.0085665 
145  
Li, Q., Mei, Q., Huyan, T., Xie, L., Che, S., Yang, H., … Huang, Q. (2013). Effects of 
Simulated Microgravity on Primary Human NK Cells. Astrobiology, 13(8), 703–714. 
https://doi.org/10.1089/ast.2013.0981 
Liakopoulos, V., Leivaditis, K., Eleftheriadis, T., & Dombros, N. (2012). The kidney in 
space. International Urology and Nephrology, 44(6), 1893–1901. 
https://doi.org/10.1007/s11255-012-0289-7 
Licato, L. L., & Grimm, E. a. (1999). Multiple interleukin-2 signaling pathways differentially 
regulated by microgravity. Immunopharmacology, 44(3), 273–279. 
https://doi.org/10.1016/S0162-3109(99)00123-X 
Lieberman, N. A. P., DeGolier, K., Haberthur, K., Chinn, H., Moyes, K. W., Bouchlaka, M. 
N., … Crane, C. A. (2018). An uncoupling of canonical phenotypic markers and 
functional potency of Ex vivo-expanded natural killer cells. Frontiers in Immunology, 
9(FEB), 1–15. https://doi.org/10.3389/fimmu.2018.00150 
Liu, H., Wang, S.-H., Chen, S.-C., Chen, C.-Y., Lo, J.-L., & Lin, T.-M. (2016). Immune 
modulation of CD4(+)CD25(+) regulatory T cells by zoledronic acid. BMC 
Immunology, 17(1), 45. https://doi.org/10.1186/s12865-016-0183-7 
Maffiuletti, N. A., Green, D. A., Vaz, M. A., & Dirks, M. L. (2019). Neuromuscular 
Electrical Stimulation as a Potential Countermeasure for Skeletal Muscle Atrophy and 
Weakness During Human Spaceflight. Frontiers in Physiology, 10, 1031. 
https://doi.org/10.3389/fphys.2019.01031 
Mahmoudpour, S. H., Jankowski, M., Valerio, L., Becker, C., Espinola-klein, C., 
Konstantinides, S., … Barco, S. (2019). Safety of low-dose subcutaneous recombinant 
146  
interleukin-2 : systematic review and meta- analysis of randomized controlled trials. 
Scientific Reports, (March), 1–9. https://doi.org/10.1038/s41598-019-43530-x 
Manley, P., & Lelkes, P. I. (2006). A novel real-time system to monitor cell aggregation and 
trajectories in rotating wall vessel bioreactors. Journal of Biotechnology, 125(3), 416–
424. https://doi.org/10.1016/j.jbiotec.2006.03.030 
Martinelli, L., Russomano, T., Dos Santos, M., Falcao, F., Bauer, M., MacHado, A., & 
Sundaresan, A. (2009). Effect of microgravity on immune cell viability and 
proliferation. IEEE Engineering in Medicine and Biology Magazine, 28(4), 85–90. 
https://doi.org/10.1109/MEMB.2009.933572 
Martinez, E. M., Yoshida, M. C., Candelario, T. L. T., Hughes-Fulford, M., Baqai, F., 
Gridley, D., … Beg, A. (2015). Spaceflight and simulated microgravity cause a 
significant reduction of key gene expression in early T-cell activation. American 
Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 308(6), 
R480-8. https://doi.org/10.1152/ajpregu.00449.2014 
Mazumder, A., & Rosenberg, S. A. (1984). Successful immunotherapy of natural killer-
resistant established pulmonary melanoma metastases by the intravenous adoptive 
transfer of syngeneic lymphocytes activated in vitro by interleukin 2. The Journal of 
Experimental Medicine, 159(2), 495–507. https://doi.org/10.1084/jem.159.2.495 
Mehta, S. K., Crucian, B. E., Stowe, R. P., Simpson, R. J., Ott, C. M., Sams, C. F., & 
Pierson, D. L. (2013). Reactivation of latent viruses is associated with increased plasma 
cytokines in astronauts. Cytokine, 61(1), 205–209. 
https://doi.org/10.1016/j.cyto.2012.09.019 
147  
Mehta, S. K., Laudenslager, M. L., Stowe, R. P., Crucian, B. E., Sams, C. F., & Pierson, D. 
L. (2014). Multiple latent viruses reactivate in astronauts during Space Shuttle missions. 
Brain, Behavior, and Immunity, 41(1), 210–217. 
https://doi.org/10.1016/j.bbi.2014.05.014 
Mehta, Satish K., Laudenslager, M. L., Stowe, R. P., Crucian, B. E., Feiveson, A. H., Sams, 
C. F., & Pierson, D. L. (2017). Latent virus reactivation in astronauts on the 
international space station. Npj Microgravity, 3(1), 1–7. https://doi.org/10.1038/s41526-
017-0015-y 
Mehta, Satish K., Pierson, D. L., Cooley, H., Dubow, R., & Lugg, D. (2000). Epstein-Barr 
virus reactivation associated with diminished cell-mediated immunity in antarctic 
expeditioners. Journal of Medical Virology, 61(2), 235–240. 
https://doi.org/10.1002/(SICI)1096-9071(200006)61:2<235::AID-JMV10>3.0.CO;2-4 
Mei, M., Xiang, Z., Yang, J., & Xiang, R. (2019). Efficacy of zoledronic acid for prevention 
of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-
analysis of 13 randomized controlled trials. Current Problems in Cancer, 100507. 
https://doi.org/10.1016/j.currproblcancer.2019.100507 
Meropol, N. J., Porter, M., Blumenson, L. E., Lindemann, M. J., Perez, R. P., Vaickus, L., … 
Caligiuri, M. A. (1996). Daily subcutaneous injection of low-dose interleukin 2 expands 
natural killer cells in vivo without significant toxicity. Clinical Cancer Research : An 
Official Journal of the American Association for Cancer Research, 2(4), 669–677. 
Monici, M., Fusi, F., Paglierani, M., Marziliano, N., Cogoli, A., Pratesi, R., & Bernabei, P. 
A. (2006). Modeled gravitational unloading triggers differentiation and apoptosis in 
148  
preosteoclastic cells. Journal of Cellular Biochemistry, 98(1), 65–80. 
https://doi.org/10.1002/jcb.20747 
Monkkonen, H., Ottewell, P. D., Kuokkanen, J., Monkkonen, J., Auriola, S., & Holen, I. 
(2007). Zoledronic acid-induced IPP/ApppI production in vivo. Life Sciences, 81(13), 
1066–1070. https://doi.org/10.1016/j.lfs.2007.08.007 
Moreels, M., States, U., Ulrike, T., Quintens, R., & Sams, C. F. (2019). Paper ID : 12410 
From Earth Missions to Deep Space Exploration ( 05 ) ( session not specified ) Author : 
Dr . Matthias Feuerecker University of Munich , Germany , 
matthias.feuerecker@med.uni-muenchen.de Dr . Ines Kaufmann Dr . Alex Paddy Salam 
United King, (05), 5–6. 
Moreno-villanueva, M., Feiveson, A. H., Krieger, S., Brinda, A. K., Scheven, G. Von, 
Bürkle, A., … Wu, H. (n.d.). Synergistic Effects of Weightlessness , Isoproterenol , and 
Radiation on DNA Damage Response and Cytokine Production in Immune Cells, 1–23. 
https://doi.org/10.3390/ijms19113689 
Morey-Holton, E. R., & Globus, R. K. (2002). Hindlimb unloading rodent model: technical 
aspects. Journal of Applied Physiology (Bethesda, Md. : 1985), 92(4), 1367–1377. 
https://doi.org/10.1152/japplphysiol.00969.2001 
Mulavara, A. P., Peters, B. T., Miller, C. A., Kofman, I. S., Reschke, M. F., Taylor, L. C., … 
Bloomberg, J. J. (2018). Physiological and Functional Alterations after Spaceflight and 
Bed Rest. Medicine and Science in Sports and Exercise, 50(9), 1961–1980. 
https://doi.org/10.1249/MSS.0000000000001615 
Muntasell, A., Ochoa, M. C., Cordeiro, L., Berraondo, P., Lopez-Diaz de Cerio, A., Cabo, 
149  
M., … Melero, I. (2017). Targeting NK-cell checkpoints for cancer immunotherapy. 
Current Opinion in Immunology, 45, 73–81. https://doi.org/10.1016/j.coi.2017.01.003 
Mylabathula, P. L., Li, L., Bigley, A. B., Markofski, M. M., Crucian, B. E., Mehta, S. K., … 
Simpson, R. J. (2020). Simulated microgravity disarms human NK-cells and inhibits 
anti-tumor cytotoxicity in vitro. Acta Astronautica, 174(March), 32–40. 
https://doi.org/10.1016/j.actaastro.2020.03.023 
Narici, M. V, & de Boer, M. D. (2011). Disuse of the musculo-skeletal system in space and 
on earth. European Journal of Applied Physiology, 111(3), 403–420. 
https://doi.org/10.1007/s00421-010-1556-x 
Naserian, S., Leclerc, M., Thiolat, A., Pilon, C., Le Bret, C., Belkacemi, Y., … Cohen, J. L. 
(2018). Simple, reproducible, and efficient clinical grading system for murine models of 
acute graft-versus-host disease. Frontiers in Immunology, 9(JAN), 1–9. 
https://doi.org/10.3389/fimmu.2018.00010 
Nickerson, C A, Ott, C. M., Mister, S. J., Morrow, B. J., Burns-Keliher, L., & Pierson, D. L. 
(2000). Microgravity as a novel environmental signal affecting Salmonella enterica 
serovar  Typhimurium virulence. Infection and Immunity, 68(6), 3147–3152. 
https://doi.org/10.1128/iai.68.6.3147-3152.2000 
Nickerson, Cheryl A., Ott, C. M., Wilson, J. W., Ramamurthy, R., LeBlanc, C. L., Höner zu 
Bentrup, K., … Pierson, D. L. (2003). Low-shear modeled microgravity: A global 
environmental regulatory signal affecting bacterial gene expression, physiology, and 
pathogenesis. Journal of Microbiological Methods, 54(1), 1–11. 
https://doi.org/10.1016/S0167-7012(03)00018-6 
150  
Nielsen, M. M., Witherden, D. A., & Havran, W. L. (2017). γδ T cells in homeostasis and 
host defence of epithelial barrier tissues. Nature Reviews. Immunology, 17(12), 733–
745. https://doi.org/10.1038/nri.2017.101 
Nilsson, U. R., & Muller-Eberhard, H. J. (1967). Deficiency of the fifth component of 
complement in mice with an inherited complement defect. The Journal of Experimental 
Medicine, 125(1), 1–16. https://doi.org/10.1084/jem.125.1.1 
Orr, M. T., & Lanier, L. L. (2010). Natural killer cell education and tolerance. Cell, 142(6), 
847–856. https://doi.org/10.1016/j.cell.2010.08.031 
Ottewell, P. D., Mönkkönen, H., Jones, M., Lefley, D. V, Coleman, R. E., & Holen, I. 
(2008). Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse 
Model of Breast Cancer, 1167–1178. https://doi.org/10.1093/jnci/djn240 
Paley, M. A., & Prescher, J. A. (2014). Bioluminescence: a versatile technique for imaging 
cellular and molecular features. MedChemComm, 5(3), 255–267. 
https://doi.org/10.1039/C3MD00288H 
Parihar, V. K., Allen, B. D., Caressi, C., Kwok, S., Chu, E., Tran, K. K., … Limoli, C. L. 
(2016). Cosmic radiation exposure and persistent cognitive dysfunction. Scientific 
Reports, 6, 34774. https://doi.org/10.1038/srep34774 
Park, K.-H., Park, H., Kim, M., Kim, Y., Han, K., & Oh, E.-J. (2013). Evaluation of NK Cell 
Function by Flowcytometric Measurement and Impedance Based Assay Using Real-
Time Cell Electronic Sensing System. BioMed Research International, 2013, 210726. 
https://doi.org/10.1155/2013/210726 
151  
Paulsen, K., Thiel, C., Timm, J., Schmidt, P. M., Huber, K., Tauber, S., … Ullrich, O. 
(2010). Microgravity-induced alterations in signal transduction in cells of the immune 
system. Acta Astronautica, 67(9–10), 1116–1125. 
https://doi.org/10.1016/j.actaastro.2010.06.053 
Pauza, C. D., Liou, M.-L., Lahusen, T., Xiao, L., Lapidus, R. G., Cairo, C., & Li, H. (2018). 
Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local. Frontiers in 
Immunology, 9, 1305. https://doi.org/10.3389/fimmu.2018.01305 
Pearson, T., Markees, T. G., Serreze, D. V., Pierce, M. A., Marron, M. P., Wicker, L. S., … 
Greiner, D. L. (2003). Genetic Disassociation of Autoimmunity and Resistance to 
Costimulation Blockade-Induced Transplantation Tolerance in Nonobese Diabetic Mice. 
The Journal of Immunology, 171(1), 185–195. 
https://doi.org/10.4049/jimmunol.171.1.185 
Pellis, N. R., Goodwin, T. J., Risin, D., Mcintyre, B. W., Pizzini, R. P., Cooper, D., … 
Spaulding, G. F. (1997). Changes in gravity inhibit lymphocyte locomotion through 
type I collagen. In Vitro Cellular and Developmental Biology - Animal, 33(5), 398–405. 
https://doi.org/10.1007/s11626-997-0012-7 
Pistoia, V., Tumino, N., Vacca, P., Veneziani, I., Moretta, A., Locatelli, F., & Moretta, L. 
(2018). Human γδ T-Cells: From surface receptors to the therapy of high-risk 
leukemias. Frontiers in Immunology, 9(MAY). 
https://doi.org/10.3389/fimmu.2018.00984 
Polić, B., Hengel, H., Krmpotić, A., Trgovcich, J., Pavić, I., Lučin, P., … Koszinowski, U. H. 
(1998). Hierarchical and redundant lymphocyte subset control precludes 
152  
cytomegalovirus replication during latent infection. Journal of Experimental Medicine, 
188(6), 1047–1054. https://doi.org/10.1084/jem.188.6.1047 
Port, A. D., Orlin, A., Kiss, S., Patel, S., D’Amico, D. J., & Gupta, M. P. (2017). 
Cytomegalovirus Retinitis: A Review. Journal of Ocular Pharmacology and 
Therapeutics : The Official Journal of the  Association for Ocular Pharmacology and 
Therapeutics, 33(4), 224–234. https://doi.org/10.1089/jop.2016.0140 
Pressey, J. G., Adams, J. M., Kelly, D. R., & Lamb, L. S. (2013). Trial of zoledronic acid and 
interleukin-2 to expand tumoricidal γδ T cells in vivo in patients with refractory 
neuroblastoma. Journal of Clinical Oncology, 31(15_suppl), TPS10073–TPS10073. 
https://doi.org/10.1200/jco.2013.31.15_suppl.tps10073 
Risso, A., Tell, G., Vascotto, C., Costessi, A., Arena, S., Scaloni, A., & Cosulich, M. E. 
(2005). Activation of human T lymphocytes under conditions similar to those that occur 
during exposure to microgravity: A proteomics study. Proteomics, 5(7), 1827–1837. 
https://doi.org/10.1002/pmic.200401082 
Rivera, C. A., Tcharmtchi, M. H., Mendoza, L., & Smith, C. W. (2003). Endotoxemia and 
hepatic injury in a rodent model of hindlimb unloading. Journal of Applied Physiology, 
95(4), 1656–1663. https://doi.org/10.1152/japplphysiol.00302.2003 
Roberts, D. R., Albrecht, M. H., Collins, H. R., Asemani, D., Chatterjee, A. R., Spampinato, 
M. V., … Antonucci, M. U. (2017). Effects of spaceflight on astronaut brain structure as 
indicated on MRI. New England Journal of Medicine, 377(18), 1746–1753. 
https://doi.org/10.1056/NEJMoa1705129 
Rooney, B. V, Crucian, B. E., Pierson, D. L., Laudenslager, M. L., Mehta, S. K., Graham, P., 
153  
& Kennedy, E. (2019). Herpes Virus Reactivation in Astronauts During Spaceflight and 
Its Application on Earth, 10(February), 1–9. https://doi.org/10.3389/fmicb.2019.00016 
Rosenberg, S. A. (2014). IL-2: the first effective immunotherapy for human cancer. Journal 
of Immunology (Baltimore, Md. : 1950), 192(12), 5451–5458. 
https://doi.org/10.4049/jimmunol.1490019 
Sager, K., Alam, S., Bond, A., Chinnappan, L., & Probert, C. S. (2015). Review article: 
cytomegalovirus and inflammatory bowel disease. Alimentary Pharmacology & 
Therapeutics, 41(8), 725–733. https://doi.org/10.1111/apt.13124 
Salaroglio, I. C., Campia, I., Kopecka, J., Gazzano, E., Orecchia, S., Ghigo, D., & Riganti, C. 
(2015). Zoledronic acid overcomes chemoresistance and immunosuppression of 
malignant mesothelioma. Oncotarget, 6(2), 1128–1142. 
https://doi.org/10.18632/oncotarget.2731 
Sams, C. F., Crucian, B. E., Stowe, R. P., Mehta, S. K., Yetman, D. L., Leal, M. J., … 
Pierson, D. L. (2009). Immune status, latent viral reactivation, and stress during long-
duration head-down bed rest. Aviation Space and Environmental Medicine, 80(5 PART 
2), 37–44. https://doi.org/10.3357/ASEM.BR05.2009 
Sarkar, P., Sarkar, S., Ramesh, V., Kim, H., Barnes, S., Kulkarni, A., … Ramesh, G. T. 
(2008). Proteomic analysis of mouse hypothalamus under simulated microgravity. 
Neurochemical Research, 33(11), 2335–2341. https://doi.org/10.1007/s11064-008-
9738-1 
Schwarz, R. P., Goodwin, T. J., & Wolf, D. A. (1992). Cell culture for three-dimensional 
modeling in rotating-wall vessels: An application of simulated microgravity. Journal of 
154  
Tissue Culture Methods, 14(2), 51–57. https://doi.org/10.1007/BF01404744 
Senatore, G., Mastroleo, F., Leys, N., & Mauriello, G. (2018). Effect of microgravity & 
space radiation on microbes. Future Microbiology, 13, 831–847. 
https://doi.org/10.2217/fmb-2017-0251 
Serreze, D. V., Gaedeke, J. W., & Leiter, E. H. (1993). Hematopoietic stem-cell defects 
underlying abnormal macrophage development and maturation in NOD/Lt mice: 
Defective regulation of cytokine receptors and protein kinase C. Proceedings of the 
National Academy of Sciences of the United States of America, 90(20), 9625–9629. 
https://doi.org/10.1073/pnas.90.20.9625 
Shearer, W. T., Lugg, D. J., Rosenblatt, H. M., Nickolls, P. M., Sharp, R. M., Reuben, J. M., 
& Ochs, H. D. (2001). Antibody responses to bacteriophage φX-174 in human subjects 
exposed to the Antarctic winter-over model of spaceflight. Journal of Allergy and 
Clinical Immunology, 107(1), 160–164. https://doi.org/10.1067/mai.2001.112269 
Shen, M., & Frishman, W. H. (2019). Effects of Spaceflight on Cardiovascular Physiology 
and Health. Cardiology in Review, 27(3), 122–126. 
https://doi.org/10.1097/CRD.0000000000000236 
Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., … 
Handgretinger, R. (2005). Human Lymphoid and Myeloid Cell Development in 
NOD/LtSz-scid IL2R null Mice Engrafted with Mobilized Human Hemopoietic Stem 
Cells. The Journal of Immunology, 174(10), 6477–6489. 
https://doi.org/10.4049/jimmunol.174.10.6477 
Shultz, Leonard D., Ishikawa, F., & Greiner, D. L. (2007). Humanized mice in translational 
155  
biomedical research. Nature Reviews Immunology, 7(2), 118–130. 
https://doi.org/10.1038/nri2017 
Siddiqi  1966-, A. A. (2000). Challenge to Apollo : the Soviet Union and the space race, 
1945-1974. Washington, D.C. : National Aeronautics and Space Administration, NASA 
History Div., Office of Policy and Plans, 2000. Retrieved from 
https://search.library.wisc.edu/catalog/999949792102121 
Sierich, H., & Eiermann, T. (2013). Comparing Individual NK Cell Activity In Vitro. 
Current Protocols in Immunology, 100(1), 14.32.1-14.32.11. 
https://doi.org/10.1002/0471142735.im1432s100 
Simons, D. M., Gardner, E. M., & Lelkes, P. I. (2009). Sub-mitogenic phorbol myristate 
acetate co-stimulation rescues the PHA-induced activation of both na??ve and memory 
T cells cultured in the rotating-wall vessel bioreactor. Cell Biology International, 33(8), 
882–886. https://doi.org/10.1016/j.cellbi.2009.04.024 
Singh, K. P., Kumari, R., & DuMond, J. W. (2010). Simulated microgravity-induced 
epigenetic changes in human lymphocytes. Journal of Cellular Biochemistry, 111(1), 
123–129. https://doi.org/10.1002/jcb.22674 
Smith, S. M., Heer, M., Shackelford, L. C., Sibonga, J. D., Spatz, J., Pietrzyk, R. A., … 
Zwart, S. R. (2015). Bone metabolism and renal stone risk during International Space 
Station missions. Bone, 81, 712–720. https://doi.org/10.1016/j.bone.2015.10.002 
Spielmann, G., Agha, N., Kunz, H., Simpson, R. J., Crucian, B., Mehta, S., … Campbell, J. 
(2019). B cell homeostasis is maintained during long-duration spaceflight. Journal of 
Applied Physiology, 126(2), 469–476. https://doi.org/10.1152/japplphysiol.00789.2018 
156  
Spielmann, G., Bollard, C. M., Kunz, H., Hanley, P. J., & Simpson, R. J. (2016a). A single 
exercise bout enhances the manufacture of viral-specific T-cells from healthy donors : 
implications for allogeneic adoptive transfer immunotherapy. Nature Publishing Group, 
(January), 1–13. https://doi.org/10.1038/srep25852 
Spielmann, G., Bollard, C. M., Kunz, H., Hanley, P. J., & Simpson, R. J. (2016b). A single 
exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: 
Implications for allogeneic adoptive transfer immunotherapy. Scientific Reports, 
6(January), 1–13. https://doi.org/10.1038/srep25852 
Stervbo, U., Roch, T., Kornprobst, T., Sawitzki, B., Grutz, G., Wilhelm, A., … Babel, N. 
(2018). Gravitational stress during parabolic flights reduces the number of circulating 
innate and adaptive leukocyte subsets in human blood. PloS One, 13(11), e0206272. 
https://doi.org/10.1371/journal.pone.0206272 
Stokes, J., Hoffman, E. A., Zeng, Y., Larmonier, N., & Katsanis, E. (2016). Post-transplant 
bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone 
marrow transplantation. British Journal of Haematology. 
https://doi.org/10.1111/bjh.14034 
Stowe, R. P., Pierson, D. L., & Barrett, A. D. T. (2001). Elevated stress hormone levels relate 
to Epstein-Barr virus reactivation in astronauts. Psychosomatic Medicine, 63(6), 891–
895. https://doi.org/10.1097/00006842-200111000-00007 
Stowe, R. P., Sams, C. F., Mehta, S. K., Kaur, I., Jones, M. L., Feeback, D. L., & Pierson, D. 
L. (1999). Leukocyte subsets and neutrophil function after short-term spaceflight 
Abstract : Changes in leukocyte subpopulations and function after spaceflight have been 
157  
observed, 65(February), 179–186. https://doi.org/10.1002/jlb.65.2.179 
Stowe, R. P., Yetman, D. L., Storm, W. F., Sams, C. F., & Pierson, D. L. (2008). 
Neuroendocrine and immune responses to 16-day bed rest with realistic launch and  
landing G profiles. Aviation, Space, and Environmental Medicine, 79(2), 117–122. 
https://doi.org/10.3357/asem.2205.2008 
Strewe, C., Crucian, B. E., Sams, C. F., Feuerecker, B., Stowe, R. P., Choukèr, A., & 
Feuerecker, M. (2015). Hyperbaric hyperoxia alters innate immune functional properties 
during NASA Extreme Environment Mission Operation (NEEMO). Brain, Behavior, 
and Immunity, 50, 52–57. https://doi.org/10.1016/j.bbi.2015.06.017 
Strewe, Claudia, Feuerecker, M., Nichiporuk, I., Kaufmann, I., Hauer, D., Morukov, B., … 
Choukèr, A. (2012). Effects of parabolic flight and spaceflight on the endocannabinoid 
system in humans. Reviews in the Neurosciences, 23(5–6), 673–680. 
https://doi.org/10.1515/revneuro-2012-0057 
Sundaresan, A., Risin, D., & Pellis, N. R. (2002). Loss of signal transduction and inhibition 
of lymphocyte locomotion in a ground-based model of microgravity. In Vitro Cellular 
& Developmental Biology. Animal, 38(2), 118–122. https://doi.org/10.1290/1071-
2690(2002)038<0118:LOSTAI>2.0.CO;2 
Swaffield, T. P., Neviaser, A. S., & Lehnhardt, K. (2018). Fracture Risk in Spaceflight and 
Potential Treatment Options. Aerospace Medicine and Human Performance, 89(12), 
1060–1067. https://doi.org/10.3357/AMHP.5007.2018 
Sylvester, C. B., Abe, J.-I., Patel, Z. S., & Grande-Allen, K. J. (2018). Radiation-Induced 
Cardiovascular Disease: Mechanisms and Importance of Linear Energy Transfer. 
158  
Frontiers in Cardiovascular Medicine, 5, 5. https://doi.org/10.3389/fcvm.2018.00005 
Sylwester, A. W., Mitchell, B. L., Edgar, J. B., Taormina, C., Pelte, C., Ruchti, F., … Picker, 
L. J. (2005). Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells 
dominate the memory compartments of exposed subjects. Journal of Experimental 
Medicine, 202(5), 673–685. https://doi.org/10.1084/jem.20050882 
Thiel, C. S., Paulsen, K., Bradacs, G., Lust, K., Tauber, S., Dumrese, C., … Ullrich, O. 
(2012). Rapid alterations of cell cycle control proteins in human T lymphocytes in 
microgravity. Cell Communication and Signaling, 10(1), 1. 
https://doi.org/10.1186/1478-811x-10-1 
Topham, N. J., & Hewitt, E. W. (2009). Natural killer cell cytotoxicity: how do they pull the 
trigger? Immunology, 128(1), 7–15. https://doi.org/10.1111/j.1365-2567.2009.03123.x 
Tsao, Y. D., Goodwin, T. L., Wolf, D. A., & Spaulding, G. F. (1992). Responses of Gravity 
Level Variations on the NASA/JSC Bioreactor System. Physiologist, (March 1992). 
Retrieved from file:///C:/Users/mikep/Downloads/Tsao Goodwin Wolf Spaulding 
1992.pdf 
van der Heiden, P., Marijt, E., Falkenburg, F., & Jedema, I. (2018). Control of 
Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on 
CMV-Specific T Cell Reconstitution. Biology of Blood and Marrow Transplantation, 
24(9), 1776–1782. https://doi.org/10.1016/j.bbmt.2018.03.028 
Van Ombergen, A., Jillings, S., Jeurissen, B., Tomilovskaya, E., Rühl, R. M., Rumshiskaya, 
A., … Wuyts, F. L. (2018, October). Brain Tissue-Volume Changes in Cosmonauts. The 
New England Journal of Medicine. United States. 
159  
https://doi.org/10.1056/NEJMc1809011 
Van Ombergen, A., Jillings, S., Jeurissen, B., Tomilovskaya, E., Rumshiskaya, A., Litvinova, 
L., … Wuyts, F. L. (2019). Brain ventricular volume changes induced by long-duration 
spaceflight. Proceedings of the National Academy of Sciences of the United States of 
America, 116(21), 10531–10536. https://doi.org/10.1073/pnas.1820354116 
Walther, I. (2001). Space bioreactors: their use, their future. Journal of Gravitational 
Physiology : A Journal of the International Society for Gravitational Physiology, 8(1), 
P13–P16. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12638605 
Wilke, C. M., Wu, K., Zhao, E., Wang, G., & Zou, W. (2010). Prognostic significance of 
regulatory T cells in tumor. International Journal of Cancer, 127(4), 748–758. 
https://doi.org/10.1002/ijc.25464 
Williams, N. S., Klem, J., Puzanov, I. J., Sivakumar, P. V, Schatzle, J. D., Bennett, M., & 
Kumar, V. (1998). Natural killer cell differentiation: insights from knockout and 
transgenic mouse models and in vitro systems. Immunological Reviews, 165(1), 47–61. 
https://doi.org/10.1111/j.1600-065X.1998.tb01229.x 
Wood, S. J., Loehr, J. A., & Guilliams, M. E. (2011). Sensorimotor reconditioning during 
and after spaceflight. NeuroRehabilitation, 29(2), 185–195. 
https://doi.org/10.3233/NRE-2011-0694 
Wu, B., Wang, Y., Wu, X., Liu, D., Xu, D., & Wang, F. (2018). On-orbit sleep problems of 
astronauts and countermeasures. Military Medical Research, 5(1), 17. 
https://doi.org/10.1186/s40779-018-0165-6 
160  
Wuest, S. L., Richard, S., Kopp, S., Grimm, D., & Egli, M. (2015). Simulated microgravity: 
Critical review on the use of random positioning machines for mammalian cell culture. 
BioMed Research International, 2015. https://doi.org/10.1155/2015/971474 
Xu, X., Li, P., Zhang, P., Chu, M., Liu, H., Chen, X., & Ge, Q. (2016). Differential effects of 
Rhodiola rosea on regulatory T cell differentiation and interferongamma production in 
vitro and in vivo. Molecular Medicine Reports, 14(1), 529–536. 
https://doi.org/10.3892/mmr.2016.5278 
Xu, X., Tan, C., Li, P., Zhang, S., Pang, X., Liu, H., … Ge, Q. (2013). Changes of Cytokines 
during a Spaceflight Analog - a 45-Day Head-Down Bed Rest. PLoS ONE, 8(10), 1–12. 
https://doi.org/10.1371/journal.pone.0077401 
Yamauchi, K., Hales, N. W., Robinson, S. M., Niehoff, M. L., Ramesh, V., Pellis, N. R., & 
Kulkarni, A. D. (2002). Dietary nucleotides prevent decrease in cellular immunity in 
ground-based microgravity analog. Journal of Applied Physiology (Bethesda, Md. : 
1985), 93(1), 161–166. https://doi.org/10.1152/japplphysiol.01084.2001 
Yu, X., Zheng, L., Xiong, S., Cai, Z., & Wang, Q. (2011). [Effect of simulated microgravity 
on human monocytic cell proliferation and tissue factor mRNA expression]. Nan fang yi 
ke da xue xue bao = Journal of Southern Medical University, 31(6), 1020–1022. 
Zhang, L.-F., & Hargens, A. R. (2018). Spaceflight-Induced Intracranial Hypertension and 
Visual Impairment: Pathophysiology and Countermeasures. Physiological Reviews, 
98(1), 59–87. https://doi.org/10.1152/physrev.00017.2016 
Zhao, Y., Niu, C., & Cui, J. (2018). Gamma-delta (γδ) T Cells: Friend or Foe in Cancer 
Development. Journal of Translational Medicine, 16(1), 1–13. 
161  
https://doi.org/10.1186/s12967-017-1378-2 
Zheng, L., Liu, J.-Z., Hu, Y.-W., Zhong, T.-Y., Xiong, S.-L., Wang, W., & Wang, Q. (2011). 
Simulated microgravity, erythroid differentiation, and the expression of transcription 
factor GATA-1 in CD34+ cells. Aviation, Space, and Environmental Medicine, 82(5), 
513–517. https://doi.org/10.3357/asem.2838.2011 
Zwart, S. R., Mehta, S. K., Ploutz-Snyder, R., Bourbeau, Y., Locke, J. P., Pierson, D. L., & 
Smith, S. M. (2011). Response to Vitamin D Supplementation during Antarctic Winter 
Is Related to BMI, and Supplementation Can Mitigate Epstein-Barr Virus Reactivation. 
The Journal of Nutrition, 141(4), 692–697. https://doi.org/10.3945/jn.110.134742 
 
